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PREFACE
The purpose of this work is to further the understanding of how Manuka honey, a
common anti-bacterial and anti-inflammatory wound treatment and tissue engineering additive,
affects neutrophil behavior. While the effectiveness of Manuka honey in promoting wound
closure has been demonstrated in vivo, less is known about how Manuka honey affects the
various cell types integral to the inflammation and wound healing processes. This work was
undertaken to further the understanding of Manuka honey’s effects on neutrophils, the firstresponding white blood cells which orchestrate the initial inflammation response within a
wound. This dissertation contains several chapters which have been previously published as
journal articles in peer-reviewed publications. Chapter 2 was published as an article entitled
“Honey-Based Templates in Wound Healing and Tissue Engineering” in Bioengineering (2018).
Chapter 3 was published as “Manuka Honey Modulates the Inflammatory Behavior of a dHL60
Neutrophil Model under the Cytotoxic Limit” in International Journal of Biomaterials (2019).
Chapter 4 was published as an article entitled “The Effect of Manuka Honey on dHL-60
Cytokine, Chemokine, and Matrix-Degrading Enzyme Release under Inflammatory Conditions”
in Med One (2019). Chapter 5 was published as an article entitled “Manuka Honey Modulates
the Release Profile of a dHL-60 Neutrophil Model Under Anti-Inflammatory Stimulation” in
Journal of Tissue Viability (2020). The work in this dissertation was supported through the Van
Vleet Memorial Doctoral Award and the Steven Slack Fellowship. Research reported in this
dissertation was supported by the National Institute of Biomedical Imaging and Bioengineering
of the National Institutes of Health under Award Number R15EB022345. This content is solely
the responsibility of the authors and does not necessarily represent the official views of the
National Institute of Health.

iv

ABSTRACT
The overall goal of tissue engineering research is to develop resorbable templates
that induce functional regeneration in damaged tissues within the body. The insertion of these
templates into the body requires the creation of a wound, triggering the tissue response
continuum that occurs with any injury to vascularized tissue. Integral to this tissue response is
the activity of neutrophils, the predominant immune cells which flood any wound site soon after
injury and power the initial inflammatory response. While neutrophil inflammatory behavior is
key to creating the acute inflammation response necessary to begin the healing process,
excessive neutrophil inflammatory activity has been implicated in creating a state of chronic
inflammation which impairs wound healing. In such environments, the neutrophil release of antibacterial superoxide and proteases causes excessive tissue degradation which prevents the wound
from closing. Excessive neutrophil NETosis, a response in which a mixture of DNA and
degradative proteases is ejected to trap and kill bacteria, can also lead to fibrotic capsule
formation surrounding a tissue engineering template which prevents tissue-template integration.
Discovering ways to mitigate this neutrophil inflammatory response will enable the design of
more effective tissue engineering templates and treatments for chronic wounds and other
inflammatory diseases.
Manuka honey is a honey variety produced by bees from the nectar of the Leptospermum
scoparium shrub of New Zealand which has potent wound healing properties. When applied to a
wound, Manuka honey’s high solute concentration creates an osmotic gradient which draws fluid
and nutrients up from the subcutaneous tissue into the wound site and pulls debris and bacteria
out of the wound. The low pH of the honey creates a favorable environment for fibroblast and
macrophage activity, while floral-derived flavonoids scavenge reactive oxygen species to reduce
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tissue damage. Manuka honey’s unique methylglyoxal content is a potent weapon against
bacterial infection, including antibiotic-resistant bacteria. For these reasons, Manuka honey has
become an increasingly predominant wound treatment, and has also become the subject of
research as a tissue engineering bioactive additive to reduce inflammation and eliminate bacterial
infection. However, the effect of Manuka honey on neutrophil inflammatory behavior has yet to
be examined. As this phenomenon is a crucial determinant of the success or failure of tissue
engineering templates, it is imperative that the response of neutrophils to Manuka honey be
observed and characterized.
The work contained in this dissertation characterizes the effect of Manuka honey on a
variety of neutrophil activities. Chapter 1 contains an introduction into the role of neutrophils in
inflammation and wound healing, and Chapter 2 gives a background explanation of the various
mechanisms of Manuka honey in wound healing and a literature review of honey in tissue
engineering research. Chapters 3, 4, and 5 utilize a dHL-60 cell line model of a neutrophil, which
allows for more experimental reproducibility than primary human neutrophils. Chapter 3
examines the cytotoxic limit of Manuka honey on a dHL-60 neutrophil model, which was found
to be in the range of 3-5% v/v, and investigates the honey’s effect on several neutrophil
inflammatory behaviors. A cytochrome C assay was used to measure Manuka honey’s effect on
superoxide release, and it was found that concentrations of 1% v/v honey and above decrease
superoxide release after 24 hours. A Boyden chamber assay was used to measure Manuka
honey’s effect on dHL-60 chemotaxis towards fMLP, and a Western blot for the NF-κB inhibitor
α (IκBα) measured the honey’s effect on the activation of the NF-κB pathway. These
experiments demonstrated that 0.5-3% v/v honey reduce chemotaxis and IκBα phosphorylation
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in a dose-dependent fashion. Together, the work contained in Chapter 3 indicates that Manuka
honey reduces several neutrophil inflammatory behaviors.
Chapter 4 contains an in-depth examination of how Manuka honey affects dHL-60
cytokine, chemokine, and matrix-degrading enzyme release in the presence of various
inflammatory stimuli. The results indicated that 0.5% honey decreased the release of the
inflammatory signals TNF-α, IL-1β, MIP-1α, MIP-1β, and IL-12 p70, the matrix-degrading
enzymes MMP-9 and MMP-1, the angiogenic growth factor FGF-13, and the anti-inflammatory
signals IL-1ra and IL-4, but increased the pro-inflammatory signals MIP-3α and IL-8, the matrixdegrading enzyme Proteinase 3, and the angiogenic growth factor VEGF. However, 3% honey
reduced the release of all measured analytes except TNF-α, which was increased. Similarly, the
work described in Chapter 5 tests the response of dHL-60 cytokine, chemokine, and matrixdegrading enzyme release to Manuka honey when in an anti-inflammatory stimulation
environment. The results of this work indicate that when under anti-inflammatory stimulation,
0.5% honey increases the release of the pro-inflammatory signals IL-8, MCP-1, MIP-1β, and
MIP-3α, the anti-inflammatory signals IL-4 and IL-1ra, and the angiogenic growth factor FGF13 while reducing the release of the matrix-degrading enzyme Proteinase 3. However, 3% honey
reduced the release of all analytes except the inflammatory signals TNF-α and IL-8, which were
increased. The results of these two chapters indicate the dramatic difference that a slight change
in the dose of Manuka honey, from 0.5% to 3%, can elicit a completely different cytokine
response in the inflammatory environment.
In Chapter 6, Manuka honey is incorporated into electrospun templates with smalldiameter (SD) and large-diameter (LD) fibers and its effect on porosity, the honey release rate,
and the effect on the NETosis response of primary human neutrophils are examined. Honey
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incorporation was found to create more restrictive pore sizes within both SD and LD templates.
SD templates were found to release honey at a higher rate compared to LD templates with
equivalent honey loads, as expected from their higher surface-area-to-volume ratio. Fluorescence
imaging and an MPO assay indicated that 0.1%-1% Manuka honey reduced neutrophil NETosis,
on the surface of both SD and LD templates while also reducing MMP-9 output. Together, these
results indicate a role for Manuka honey in the reduction of neutrophil inflammatory activity in
the area surrounding an electrospun tissue engineering template.
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CHAPTER 1
INTRODUCTION
The purpose of this work is to investigate the effect of Manuka honey on neutrophil
inflammatory behavior. While this inflammatory behavior is necessary to begin the healing
process, inordinate neutrophil inflammatory activity can trap the wound in a state of constant
inflammation, delaying healing and, in the context of tissue engineering templates, preventing
necessary tissue-template integration. The hypothesis is that Manuka honey will reduce
inflammatory neutrophil behaviors such as superoxide production, chemotaxis, activation of the
NF-κB pathway, the release of inflammatory cytokines, and NETosis on the surface of tissue
engineering templates. Testing this hypothesis will enable greater effectiveness in designing
honey-laden tissue engineering templates for the reduction of inflammation and promotion of
healing.
Neutrophils are the first-responding white blood cells which flood a wound site soon after
injury, and they play a key role in the orchestration of the inflammatory response. In addition to
their role as phagocytes, in which they engulf invading pathogens and destroy them, they release
a wide variety of factors which damage bacteria, recruit more immune cells, degrade the ECM,
stimulate angiogenesis, and either promote or impede inflammation [1]. In response to certain
signals, neutrophils can also eject their DNA in a process known as NETosis, creating
extracellular traps decorated with anti-microbial peptides that contain and kill bacteria [2, 3]. In
the course of normal wound healing, neutrophils regulate these behaviors to create a period of
acute inflammation which is resolved within several days of the initial injury. However, in cases
of repeated injury or complicating conditions such as diabetes, the wound can enter a state of
chronic inflammation which is unable to be resolved and precludes healing. Neutrophils play a
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key role in this chronic inflammation, releasing excessive levels of inflammatory signals and
MMPs which degrade the ECM faster than the fibroblasts can rebuild it [4]. This activity creates
a continuous feedback loop of uncontrolled inflammation which must be broken by a therapy
that alters the paradigm, such as debridement or the application of Manuka honey (described in
detail in Chapter 2). Given their role as orchestrators of this response, understanding and
directing neutrophil activity is key to ensuring effective wound healing. Regulating these
neutrophil inflammatory behaviors is also integral to the reduction of inflammation around a
tissue engineering template, and to the establishment of tissue ingrowth and remodeling of that
template. The implantation of a tissue template requires the creation of a wound and the
associated recruitment of neutrophils soon after implantation. As such, the ability of tissue
engineering templates to guide the behavior of these neutrophils is of utmost importance to
preventing excess inflammation and NETosis which can cause unwanted fibrosis [5].
This chapter reviews the various activities of neutrophils from their recruitment,
extravasion, and chemotaxis to a wound site, to the production of superoxide, release of
cytokines, and the process of NETosis. These behaviors will be discussed in the context of
normal wound healing, chronic wounds, and neutrophil/biomaterial interactions.
Recruitment, Extravasion, and Chemotaxis
Neutrophils begin their lifespan in the bone marrow, which creates about 1011 of these
cells per day under normal conditions and, in response to elevated levels of cytokines such as GCSF, can produce as many as 1012 neutrophils during bacterial infection. The neutrophils will
then circulate in the bloodstream, where they make up 50-70% of the leukocyte presence [6]. As
terminally-differentiated cells, neutrophils are thought to survive less than a day in the
circulation, although recent research suggests that they may persist for as long as 5 days in the
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bloodstream [7]. When an injury occurs, vascular endothelial cells of associated blood vessels
will express selectins, which are adhesion factors that bind specific ligands of neutrophils and
cause them to loosely adhere to the vessel wall and roll along it. This roll is slowed by the
adhesion of neutrophil integrins to proteins such as ICAM-1 and ICAM-2 expressed by the
endothelial cells, which bring the neutrophil to a stop. The neutrophils then undergo diapedesis,
forcing their way through loosened tricellular junctions of endothelial cells in response to
chemokines emanating from the wound site. These chemokines, which include CXCL8/IL-8,
C5a, and fMLP, guide neutrophil chemotaxis through the tissue to the site of injury via
movement up their diffusion gradient to their source [8-10]. Along the way, these neutrophils
will become activated by a host of signals emanating from the wound site. These signals will
control the behaviors expressed by the neutrophil once it reaches the site.
Phagocytosis
One of the earliest behaviors observed in neutrophils is their ability to engulf bacteria and
other extracellular objects through a process known as phagocytosis. To begin this process,
neutrophils bind to PAMPs or DAMPs on the object to be engulfed, as well as antibodies and/or
complement factors [11]. The cell membrane of the neutrophil then undergoes an invagination
which surrounds the object. This invagination becomes an intracellular compartment known as
the phagosome, completely surrounding the object and walling it off from the rest of the cell.
Membrane sections are then added from the endoplasmic reticulum and other intracellular
membrane sources to maintain the cell size [12]. Intracellular granules containing proteinases
and other antimicrobial peptides, as well as NADPH oxidase enzymes which produce
superoxide, fuse with the phagosome and begin the intracellular destruction of the engulfed
bacteria or particle [13]. Unlike the slower phagocytosis by other cells such as macrophages,
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neutrophil phagocytosis is complete within a period of 10-20 seconds, and its phagosomes rely
more on the NADPH-driven oxidative burst than on pH change to destroy the engulfed material
[14, 15].
Neutrophil phagocytosis of pathogens and other foreign particles is a crucial part of the
initial stage of wound healing. However, the receptors which trigger phagocytosis can sometimes
be activated by IgG or complement deposited along larger surfaces, such as the vascular
endothelium or implanted biomaterials [16, 17]. This binding leads to a process termed
“frustrated phagocytosis” in which the neutrophil attempts to engulf the surface but is unable due
to its size. Instead, the neutrophil releases its granule contents and produces excess reactive
oxygen species, leading to counterproductive tissue damage. This process has been implicated in
inflammatory conditions such as thrombo-hemorrhagic vasculitis, in which complement
deposited on the vascular endothelium causes frustrated neutrophil phagocytosis, leading to
excess granule release, vascular damage, and eventually breakdown of the vessel wall [18]. In
the context of biomaterials, this frustrated phagocytosis leads to unwanted prolonged
inflammation in the surrounding area, precluding tissue infiltration and initiating fibrosis [19].
Research into biomaterial coatings has shown that some mucin-coated substrates can reduce this
process, and this field of research is ongoing [20]. An alternative approach would be to use
nanofibrous porous biomaterials that mimic the native extracellular matrix and avoid presenting
the neutrophil with the type of continuous, smooth surface that triggers frustrated phagocytosis.
This approach will be discussed in greater detail later in this dissertation.
Degranulation
Neutrophils contain four different types of granules which are distinct in their contents
and the circumstances in which their release is triggered. Primary granules, also known as
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azurophilic, are defined by their MPO content, and also contain neutrophil elastase, proteinase 3,
and defensins, among other components [21-24]. These components are potent antimicrobial
agents which are responsible for the bactericidal effect of these granules. The main function of
primary granules is to release their contents into phagosomes for the destruction of phagocytosed
bacteria and other particles, but their contents can be released extracellularly during frustrated
phagocytosis or after the release of other granule types [13, 25, 26]. Secondary granules, also
known as specific granules, contain NADPH oxidase, lactoferrin, MMP-1 and MMP-8, among
other components [23, 27]. Tertiary granules contain many of the same components as secondary
granules, but also contain the additional matrix-degrading elements MMP-2 and MMP-9 [23].
NADPH oxidase is responsible for neutrophil superoxide production, while lactoferrin is another
antimicrobial element. The MMPs are crucial for clearing pathways for neutrophil movement
and angiogenesis, as well as tissue remodeling during healing, but excess levels can perpetuate
chronic inflammation. The secretory vesicles contain receptors for formylated bacterial peptides,
and also contain serum albumin, suggesting that their contents are derived from extracellular
fluid taken in during endocytosis [28]. These vesicles are released before other granule types,
and their delivery to the cell membrane of receptors for formylated peptides allows for further
activation of the neutrophil by these peptides. A complete list of granule contents and their
functions is beyond the scope of this chapter, but can be found in a 2017 publication by Selders
et al. [19].
Neutrophil degranulation is triggered by signals such as fMLP and CXCL8/IL-8, which
elicit an increase in intracellular calcium ions. As this calcium level rises, granules are recruited
in the following order: secretory vesicles, then tertiary granules, then secondary granules, then, if
the calcium level is high enough, primary granules [25, 26]. The release of these granule contents
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is vital to the destruction of invading pathogens, as individuals with deficiencies in the ability to
form specific granules are susceptible to recurring infections [29, 30]. However, elevated levels
of granule contents in chronic wounds have been implicated in the delay of healing. Specifically,
the reactive oxygen species produced by NADPH oxidase and MPO damage host cells as well as
bacteria, and have been implicated chronic inflammatory conditions [31, 32]. As mentioned
above, excess MMP levels during chronic inflammation break down the ECM faster than it can
be repaired, keeping the wound from healing, and can impede tissue-template integration in the
context of biomaterials [4, 19, 33]. As such, neutrophil degranulation in the area surrounding a
tissue engineering template must be tightly controlled.
Superoxide Production
NADPH oxidase, which is present in primary granules and on the cell membrane of
activated neutrophils, is the enzyme by which neutrophils produce superoxide. This multi-protein
electron transfer enzyme catalyzes the movement of electrons from intracellular NADPH to
molecular oxygen to O2-, which are highly reactive and can damage both bacteria and native
tissue. Activation of this response is triggered by a number of signals, including bacterial
products such as LPS and fMLP, inflammatory cytokines such as CXCL8/IL-8 and TNF-α, and
other signals such as halogenated proteins [34-36]. Superoxide anions in the extracellular space
will react with water to form hydrogen peroxide, which is then used by MPO to create
hypohalous acids such as HOCl and HOBr. These acids are potent antimicrobials, but also cause
tissue damage via halogenation and oxidation of proteins, lipids, nucelotides, and carbohydrates
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Figure 1. Feedback loop of superoxide, hydrogen
peroxide, hypohalous acid, and halogenated
macromolecule production of the inflammatory activated
neutrophil.
[37-41]. Halogenated macromolecules are themselves stimulatory signals for neutrophil
superoxide production, creating a positive feedback cycle shown in Figure 1.
Superoxide, hypohalous acids, hydroxyl anions, and hydrogen peroxide collectively fall
under the umbrella term ROS, and they all contribute to the destruction of bacteria and native
tissue during inflammation. In addition, ROS are involved in signaling mechanisms that recruit
additional inflammatory cells, and in triggering fibroblast activity involved in myofibrogenesis
[42-44]. Enzymes such as superoxide dismutase can scavenge ROS, but this protection is limited
in its capacity and can be overcome during persistent inflammation. Persistent, elevated ROS
levels around a biological implant are associated with excess collagen fibril and fibroblast
presence, leading to fibrosis [45]. In the context of tissue engineering templates, fibrosis impedes
tissue-template integration, leading to failure of the implant to induce the regeneration of
functional tissue.
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NETosis
In response to pathogenic stimuli or chemical signals such as PMA, CXCL8/IL-8, or
LPS, neutrophils release their DNA to form NETs which can trap and kill invading bacteria.
Within the neutrophil nucleus, the enzyme PAD4 modifies the arginine residues of histones,
transforming these residues into citrulline and thereby altering their charge. This charge
alteration loosens the binding of the DNA to the histones, causing the chromatin to decondense
and be expelled from the cell [46, 47]. In the process of being expelled from the cell, the
chromatin becomes coated with components of azurophilic, secondary, and tertiary granules,
including components such as NE, MPO, lactoferrin, and MMPs that damage bacteria and native
tissue. NETs have been shown to be effective at trapping and killing fungal, viral, parasitic, and
bacterial infections, although some of these organisms have developed countermeasures [48].
For instance, some bacterial strains utilize DNAses to degrade and escape NETs and can coat
themselves in a polysaccharide capsule that makes them resistant to antimicrobial peptides [49].
HIV has been shown to promote the generation of IL-10 by dendritic cells, which suppresses
NETosis in the surrounding area and thus protects the HIV from being trapped and killed [50].
NETs are a useful weapon for neutrophils against invading pathogens, but they are not 100%
effective against all attackers.
It has been demonstrated that neutrophils sense the size of invading pathogens and are
triggered to undergo NETosis when presented with large pathogens that cannot be easily
phagocytosed [51]. This is important in the context of biomaterials because they are too large to
be phagocytosed, and have been demonstrated to trigger NETosis even under sterile conditions
[52]. As the NETs contain components such as NE, MPO, and MMPs that have been implicated
in tissue damage, chronic inflammation, and fibrosis, it stands to reason that high levels of
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NETosis could impede functional tissue regeneration. In fact, it has been demonstrated that
excess NETosis on the surface of a tissue engineered template is correlated with fibrous capsule
formation around that template [5]. This template-induced NETosis can be regulated through
template architecture (fiber diameter), or through the incorporation of NETosis-inhibiting
bioactive agents such as Cl-amidine [5, 53]. Methods of regulating NETosis around a tissue
engineering template or other biomaterials are an area of ongoing research in the tissue
engineering field.
Pro-inflammatory Cytokine Release
Neutrophils which have been activated by bacterial peptides such as LPS or formylated
peptides have the ability to synthesize and secrete cytokines and chemokines which amplify the
inflammation response. In addition to the general inflammation mediators TNF-α and IL-1β,
neutrophils release signals such as CCL2/MCP-1, CCL3/MIP-1α, and CCL4/MIP-1β which
recruit and activate monocytes/macrophages, effectors such as CCL5/RANTES which recruit
and activate T-cells, and signals such as CXCL8/IL-8 which recruit and activate other
neutrophils [54]. These signals are key to the regulation of inflammation, playing a vital role in
recruiting enough immune cells to quickly and efficiently stave off infection and keep it from
spreading, and to create the acute inflammatory response that is necessary for wound healing.
However, elevated, prolonged levels of these pro-inflammatory cytokines can have a detrimental
effect on healing. It has been demonstrated that TNF-α and IL-1β increase the release of MMPs
while suppressing ECM synthesis and the secretion of TIMPs, shifting the paradigm away from
ECM synthesis and towards degradation [55-59]. Similarly, sustained release of the chemokines
CCL2/MCP-1, CCL3/MIP-1α, CCL4/MIP-1β, CCL5/RANTES, and CXCL8/IL-8 create a
prolonged presence of inflammatory cells that is correlated with delayed re-epithelialization,
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angiogenesis, and collagen synthesis [60, 61]. The regulation of pro-inflammatory
cytokine/chemokine release is thus crucial to ensuring an orderly progression from acute
inflammation to resolution and healing in the wound.
Anti-Inflammatory Behavior
Although the pro-inflammatory effects of activated neutrophils have been much more
extensively characterized, research has also indicated that neutrophils have the ability to decrease
inflammation. In response to the presence of signals such as IL-4, IL-13, and TGF-β over a 1824 hour period, neutrophils have been demonstrated to release IL-1ra, an antagonist molecule
which blocks the receptor for the pro-inflammatory IL-1β and prevents the activation of its
inflammatory pathway [62]. This antagonist action of IL-1ra imbues it with potent antiinflammatory activity, including the ability to reduce endotoxic shock and circulating levels of
TNF-α and IL-1β in a bacteria-challenged in vivo rabbit model [63, 64]. The IL-1ra release from
neutrophils in response to anti-inflammatory stimulators increases when pro-inflammatory
stimulators such as TNF-α are also present, suggesting a synergistic action of both proinflammatory and anti-inflammatory stimulation on neutrophil anti-inflammatory activity [62].
This indicates that in the context of an in vivo wound, neutrophils can respond to prolonged
inflammation by releasing IL-1ra to decrease that inflammation and prevent it from becoming
chronic. Neutrophils have also demonstrated the capacity to release IL-4, another antiinflammatory cytokine, although this release is not as well-characterized as that of IL-1ra [65].
In addition to their ability to release anti-inflammatory signals, neutrophils exhibit other
potent anti-inflammatory behaviors: their ability to reverse migrate out of a wound or die through
apoptosis and be engulfed by other phagocytes. Decreasing the number of neutrophils present at
a site of injury is crucial to resolving the period of acute inflammation before it becomes chronic
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[66]. It has recently been demonstrated that as the inflammatory state of an injury resolves, as
many as 70-90% of the recruited neutrophils reverse migrate away from the injury into the
surrounding tissue and back into the bloodstream [67, 68]. The removal of pro-inflammatory
activated neutrophils, which are continual sources of pro-inflammatory signals, thus allows the
inflammation to resolve. In addition to their ability to reverse migrate, neutrophils also clear
themselves from the wound site through the process of apoptosis. While neutrophil apoptosis can
be delayed by pro-inflammatory signals such as IL-8 or bacterial components, these signals
decrease as infection is eradicated and inflammation begins to resolve [69, 70]. As these signals
disappear, some neutrophils activate apoptosis pathways and begin the process of regulated cell
death. This process alters the cell surface, changing the lipids and proteins present in a way that
promotes the phagocytosis of the dying neutrophil by macrophages [71-73]. Not only does
macrophage phagocytosis remove the neutrophil from the wound site, it also inhibits
macrophage production of pro-inflammatory molecules such as IL-1β and TNF-α. Additionally,
this process increases macrophage production of anti-inflammatory TGF-β [74]. Neutrophil
apoptosis is thus an important trigger of subsequent downstream effects that resolve
inflammation.
From a tissue engineering standpoint, facilitating neutrophil anti-inflammatory activity
around a tissue template would be useful in reducing inflammation and promoting tissuetemplate integration. A controlled release of anti-inflammatory signals such as IL-4, IL-13, or
TGF-β, or a biomaterial additive such as Manuka honey, could trigger subsequent neutrophil
release of IL-1ra, shifting the paradigm of the wound environment towards an anti-inflammatory
state. Additionally, histological examination of a tissue engineering template over time in an in
vivo model allows monitoring of the inflammation state by visualizing the number of neutrophils
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present at the biomaterial surface. By screening tissue engineering template designs for a
prolonged neutrophil presence, researchers can identify materials and design features which are
able to avoid inducing a chronic inflammatory state in the surrounding tissue.
Growth Factor Release
In addition to their release of matrix-degrading enzymes and pro/anti-inflammatory
cytokines, neutrophils have the capacity to secrete several growth factors important to wound
healing. In response to inflammatory signals such as TNF-α or bacterial-derived signals such as
SOZ, neutrophils have been demonstrated to release VEGF. As VEGF stimulates the endothelial
cell sprouting that is key to the initiation of angiogenesis, this release indicates a role of
neutrophils in the induction of new blood vessel formation during the healing process [75]. The
fact that this release is stimulated by inflammatory signals indicates that neutrophil VEGF
release occurs during the acute inflammation stage of the wound, rather than during the
inflammation-resolution phase. Another angiogenesis-stimulating growth factor, angiopoietin-1,
is also released from neutrophils in response to pro-inflammatory signals such as PMA, fMLP, or
TNF-α. In addition to its role in blood vessel sprouting, angiopoietin-1 is important for the
maturation and survival of blood vessels after their initial growth [76]. In response to stimulation
with TNF-α and LPS, neutrophils also have the capacity to release activin A, another growth
factor important in wound healing [77]. Activin A is a member of the TGF-β family of proteins,
and it plays a key role in vivo in the proliferation of keratinocytes during wound healing,
promoting rebuilding of the epidermis [78]. HGF, a cytokine that combines both angiogenic
properties and the ability to stimulate granulation tissue formation, is also produced by
neutrophils under inflammatory stimulation by signals such as TNF-α, LPS, and fMLP. Although
HGF was first discovered as a mitogen for hepatocytes, it has subsequently been shown to
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stimulate proliferation, migration, and MMP production in keratinocytes, as well as new blood
vessel formation [79-81]. By releasing these growth factors into the wound environment during
inflammation, neutrophils initiate the process of angiogenesis and tissue repair that continues
after inflammation subsides.
In addition to their direct production of growth factors, neutrophils can also cause the
release of other growth factors from depots in the wound environment. This is mediated through
neutrophil release of matrix-degrading enzymes such as heparinase, an enzyme that degrades
heparan sulfate side chains of proteoglycans in the basement membrane [82]. This degradation
releases stores of bFGF present in this part of the ECM, causing this growth factor to activate
other cells within the wound site [82-84]. bFGF has potent angiogenesis-stimulating properties,
stimulates endothelial cell proliferation, and causes mesenchyme production [85-87]. Other
growth factors such as IGFs, TGFs, and HGF have been demonstrated to exist in similar stores
within the extracellular matrix, and are likely to be released along with bFGF when that matrix is
degraded by heparinase or MMPs [88]. However, this has yet to be experimentally confirmed.
The release of these angiogenesis-stimulating growth factors is crucial to creating tissue
ingrowth into a tissue engineering template. Because these ECM-mimicking templates have no
native vascularization, infiltrating cells are reliant on the development of new blood vessels for
the delivery of nutrients and the removal of waste. This vessel ingrowth is reliant on the presence
of pores in the template structure through which vessels can develop, and on the presence of
endothelial cells and angiogenesis-stimulating factors to facilitate the budding and maturing of
new blood vessels [89]. The release of these growth factors by neutrophils is vital to the
induction of neovascularization, and thus to the overall success of the tissue engineering
template.
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Conclusion
As the first immune cells to arrive at a wound site, neutrophils have a unique role as
orchestrators of the initial inflammatory response. Through their phagocytosis, degranulation,
superoxide production, and NETosis, they act as sentinels to fight off infection and clear the
wound of debris. By releasing pro- and anti-inflammatory cytokines, neutrophils ramp up and
then subsequently ramp down the inflammatory state of the wound, and by releasing a host of
growth factors, neutrophils stimulate angiogenesis and tissue remodeling within the wound site.
Disruption of these events through repeated injury, persistent infection, or chronic conditions
such as diabetes leads to chronic inflammation and ongoing tissue damage via excessive proinflammatory cytokine, MMP, and superoxide release. As such, it is imperative to develop
therapies that control these behaviors to reduce chronic inflammation in non-healing wounds and
promote angiogenesis.
The following work tests the suitability of Manuka honey to act as such a therapy. It was
found that Manuka honey is effective at reducing superoxide release, chemotaxis, and the
activation of the NF-κB inflammatory pathway. Low levels of Manuka honey reduce the release
of some inflammatory signals, although other inflammatory signals were increased. When
incorporated as a tissue template additive, Manuka honey reduced NETosis within a therapeutic
window, and also reduced MMP-9 production. Together, these findings demonstrate the
feasibility of Manuka honey as a tissue engineering template additive for decreasing neutrophil
inflammatory activity.
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CHAPTER 2
LITERATURE REVIEW
Honey has been used as a wound treatment by indigenous cultures around the globe for
thousands of years. Archeological findings and early written works indicate that wounds were
treated with honey by the ancient Egyptians, Greeks, and Romans, among others [90]. With the
advent of antibiotics in the 1940s, honey fell out of use as a wound treatment [91]. However,
with the increasing prevalence of antibiotic-resistant bacteria, as well as new in vitro and in vivo
data supporting honey’s effectiveness in treating wounds and as a natural broad-band antibiotic,
it has recently made a comeback in clinical medicine. Additionally, honey’s ability to aid in situ
cellularization and regeneration of implanted acellular tissue-engineered structures has the
potential to revolutionize the field of tissue engineering.
Honey is a natural product produced by a variety of honeybee species around the world.
First, the bees collect nectar from flowering foliage. This nectar is processed in an internal pouch
called the crop, where a variety of enzymes break down sugars. The resulting solution is
regurgitated by the bees into honeycomb within their hives, where it is further concentrated by
air currents created by the fanning of bee wings. The product is a highly concentrated, viscous
solution of floral sugars and proteins, enzymes, and amino acids derived from the bee crops [92].
These sugars are primarily fructose and glucose, with smaller amounts of maltose, sucrose, and
isomaltose [93, 94]. Glucose oxidase from the bee crop slowly breaks down glucose into
gluconic acid, which lowers the pH of honey, and hydrogen peroxide, which helps kill bacteria
[95]. In a wound site, the lower pH of honey (3.5-4) reduces protease activity, increases oxygen
release from hemoglobin, and stimulates the activity of macrophages and fibroblasts, while the
hydrogen peroxide content sterilizes the wound and stimulates VEGF production [95]. Invertase,
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another enzyme from the bee crop, slowly divides sucrose into glucose and fructose, increasing
the strength of the osmotic potential. In addition, flavenoids derived from the floral nectar
sources neutralize free radicals created by the hydrogen peroxide, which minimizes inflammation
and tissue damage [95].
Although some honey varieties have been shown to have beneficial effects in a wound
site, most modern research has focused on a particular variant produced in New Zealand from the
nectar of the Leptospermum Scopartum shrub, called Manuka honey. This honey contains all the
components of other honey varieties, but its unique component, methylglyoxal, acts as an
additional antibacterial agent [96-99]. Several companies collect, pool, filter, and sterilize
Manuka honey for clinical use, including ManukaGuard (located in New Zealand) and
Medihoney (a subsidiary of Derma Sciences, based in the United States). This collection and
pooling of the honey helps limit batch-to-batch variability between hive locations and times of
the year, while the filtration removes wax, dirt, and pollen particulates from the honey to reduce
the potential to cause an allergic reaction. Although honey has shown anti-bacterial properties,
these products are still sterilized via gamma irradiation or pasteurization to doubly ensure that no
live bacteria or spores are present.
Honey performs several valuable functions as a wound covering. As a viscous fluid, its
thick consistency forms a barrier between the wound and the external environment, protecting
against bacteria and keeping the wound hydrated [99]. Its high concentration of sugars and other
solutes creates a strong osmotic gradient that pulls fluid up through the subdermal tissue [100].
This fluid flow flushes bacteria, debris, slough, and necrotic tissue out of the wound, and carries
nutrients and oxygen from the deep tissue into the wound area. Additionally, the low pH of the
honey increases tissue oxygenation and the activity of macrophages and fibroblasts, while the
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flavonoids and aromatic acids scavenge free radicals, preventing tissue damage and controlling
inflammation [95, 101]. The high sugar content of honey also provides an additional source of
glucose for proliferating cellular components (i.e. fibroblasts and endothelial cells) in the area
[102].
In addition to these other functions, honey also has multiple bactericidal effects. The
osmotic potential of the honey crenates bacteria at the top of the wound, destroying them [99,
103]. As mentioned above, honey also contains hydrogen peroxide. Hydrogen peroxide easily
gives up one of its oxygens to the surrounding environment, creating a free radical that causes
oxidative damage to bacterial cell walls. Additionally, the presence of bee defensin-1 has been
shown in honey [104]. Like other defensins, bee defensin-1 permeabilizes bacteria and inhibits
their RNA, DNA, and protein synthesis [105]. As mentioned above, the glucose oxidase content
of honey lowers its pH, which can also kill some bacteria [104]. Manuka honey in particular
contains methylglyoxal, a compound which has been shown to damage bacteria flagella and thus
limit their mobility and ability to adhere to surfaces [106].The presence of these multiple
bactericidal mechanisms (osmotic potential, hydrogen peroxide, bee defensin-1, pH, and
methylglyoxal) makes Manuka honey especially useful against antibiotic-resistant bacteria [96,
107]. The many functions of Manuka honey thus not only clear wound debris, maintain
hydration, control inflammation, and stimulate healing, but also sterilize the wound.
In vitro Evidence of the Beneficial Effects of Honey in Wounds
There is a wealth of in vitro evidence demonstrating the effects of honey on different cell
types. Ranzato et al. showed low concentrations (0.1% v/v) of a variety of honey types,
including Manuka honey, increase closure rate in a keratinocyte scratch assay by 180%, and
increase fibroblast migration by 150-240% in a transwell insert chemotaxis assay (higher honey
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concentrations were not tested) [108]. Likewise, Tonks et al. tested the monocyte response to
several honey types, including Manuka honey, and observed that all honey types caused an
increase in the release of the inflammatory mediators TNF-α, IL-6, and IL-1 over a 24-hour
culture period, as seen in Figure 2 [109]. Of the three honey varieties tested (all 1% v/v in culture
medium), Manuka honey caused the lowest release of these three inflammatory cytokines, but
these levels were still significantly higher than in the non-honey controls. Specifically, Manuka
honey caused an increase of about 2000 pg/mL in TNF-α release, about 100 pg/mL in IL-1
release, and about 700 pg/mL in IL-6 release over 18 hours of culture as measured relative to
non-honey controls. This finding would seem to run counter to the evidence showing that
Manuka honey resolves inflammation in vivo [110-112]. However, it should be noted that there

Figure 2. Honeys induce monocyte inflammation response. IL-6, IL-1, and TNF release from
peripheral blood monocytes over 18 hours in the presence of artificial honey (syrup control),
Manuka honey, Pasture honey, and Jelly bush honey. Reproduced with permission from
Tonks et al., Cytokine; published by Elsevier, 2003.
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are many other inflammatory and anti-inflammatory cytokines involved in this healing response
that were not tested in this study, and this study only tested one concentration of honey rather
than the gradient of honey concentrations present in a wound. Nevertheless, it is possible that
these honeys cause a temporary increase in inflammatory cytokines in a wound site before later
resolving that inflammation, or that by increasing inflammation the honey “shocks” the wound
environment into quickly clearing infections to allow for inflammation resolution. Ultimately,
future studies examining more honey concentrations and more of the relevant cytokines will be
necessary to bridge the gap between these in vitro and in vivo findings. In addition, detailed time
courses must be examined in order to understand the difference between how honey affects the
different stages of inflammation in the wound site, especially the vast differences between the
effects on the acute and chronic phases.
In another study, Leong et al. examined the effect of 21 New Zealand honey types,
including varieties of Manuka honey, on neutrophil superoxide production. Their results indicate
that all the honey types reduced superoxide production in a dose-dependent manner, and this
decrease in superoxide production was independent of the methylglyoxal content of the honey
samples. Cytotoxicity testing revealed that at the 50% inhibitory concentrations (IC50, ranging
from 3.1 mg/mL to 44.4 mg/mL depending on the honey variety) of honey on superoxide
production, none of the honey varieties caused significant amounts of neutrophil death [97].
However, honey treatments in wounds typically involve direct application of honey to the wound
at much higher concentrations than these IC50s, throwing doubt onto the relevance of this finding
to wound treatment. This study also involved an in vivo murine test which measured the effect of
topical application of these honey varieties on neutrophil recruitment to the site of arachidonic
acid (inflammatory stimulus) application in a murine ear model. The results showed that several
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honey varieties, including Manuka honey, significantly decreased neutrophil recruitment to the
site [97]. These results indicate an overall anti-inflammatory effect of Manuka honey on
neutrophils, reducing their inflammatory superoxide production and reducing their recruitment to
a site of inflammation, and thus correlate more closely than the results of the previous study with
the clinical data showing that Manuka honey resolves inflammation [110, 112].
Some studies have examined the anti-bacterial action of Manuka honey against a variety
of pathogens. Sherlock et al. used agar plate well diffusion assays and a spectrophotometric
minimum inhibitory concentration assay to demonstrate antibacterial effects. These effects were
quantified for both Manuka honey and Ulmo honey, a strain from Chile. The results of these
experiments, shown in Table 1, demonstrated that both Manuka and Ulmo honey significantly

Table 1. Honeys inhibit bacterial growth. Zones of inhibition (diameter, in mm) of different
concentrations of Ulmo and Manuka honey against various strains of MRSA. Reproduced with
permission from Sherlock et al. Complementary and Alternative Medicine; published by BMC,
2010.
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inhibited the growth of E. coli, P. aeruginosa, and MRSA. Interestingly, the Ulmo honey was
more effective against MRSA, although slightly less effective against E. coli and P. aeruginosa
[113]. Jenkins et al. also reported that Manuka honey inhibits the growth of MRSA, and showed
that the presence of honey causes a downregulation of UspA in the MRSA, reducing its stress
stamina response [96]. In addition to its effectiveness against MRSA, Cooper et al. showed that
Manuka honey also inhibits the growth of at least seven different strains of vancomycin-resistant
enterococci [99]. Manuka honey also has been shown to be effective against Helicobacter pylori,
the cause of most stomach ulcers [114]. Research by Watanabe et al. in 2014 showed that
Manuka honey inhibits influenza viral replication, enhancing the effects of antiviral drugs [115].
This work has been replicated with varicella and rubella viruses, indicating an exciting new
avenue for the clinical use of Manuka honey [116, 117]. These studies provide a wealth of
evidence supporting the use of Manuka honey as an anti-bacterial wound sterilizing agent. As the
honey is cheaper than many antibiotics and has not yet been shown to induce resistance bacteria,
it is likely to become an essential alternative to antibiotics in the field of wound care.
An additional benefit of using honey in therapeutic products is that its natural antibiotic
properties give it an extremely long shelf life. In sealed containers, honey remains stable for
hundreds or even thousands of years, and it is often used to increase the shelf life of other food
products [118-122]. Many antibiotics have limited shelf lives even under refrigeration – for
example, penicillin in solution has a shelf life of twelve months at 10º C [123]. In contrast,
honey’s robust thermal stability allows it to go un-refrigerated and still maintain its properties
indefinitely [124]. This is a major advantage, as it eliminates the need for a “cold chain” of
constant refrigeration and therefore reduces costs substantially. The lack of need for a cold chain
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is an additional benefit in rural areas or developing countries where there is less access to
refrigeration and power interruptions can be frequent [125, 126].
In vivo Preclinical Evidence Supporting the Use of Honey in Wounds
There is a plethora of in vivo animal model evidence of honey’s usefulness as a wound
treatment. In one example, rabbit wounds were treated with topical honey (type of honey not
specified) and studied for 21 days. After 14 days, the non-honey wounds were covered by scabs
and imperfect epithelialization, while skin repair in the honey-treated rabbits was perfect and
detection of the injured area from the surrounding tissue was difficult. Samples of the healed skin
were excised and mechanically tested after 21 days, and the honey-treated rabbit skin had a
significantly higher tensile yield strength (3.3 MPa) and ultimate strength (3.4 MPa) than the
non-honey wounds (1.2 MPa and 2.3 MPa, respectively). Histological examination of the
wounds at 14 days revealed well-vascularized tissue with organized fibroblasts and collagen
fibers with few inflammatory cells still present in the honey-treated group, while the non-honey
group showed necrosis, uneven epithelialization, and a large neutrophil presence [112].
Likewise, honey treatment in a rat dorsal wound model had similar effects. Topical application
of honey to these wounds caused a 107% increase in salt-soluble collagen, a 117% increase in
acid-soluble collagen, and a 109% increase in insoluble collagen after 7 days relative to nontreated controls. Introduction of radiolabeled hydroxyproline one day before sacrifice allowed
measurement of collagen synthesis rate over a 24-hour time period, and showed a 124% increase
in acid-soluble collagen production rate and a 105% increase in insoluble collagen production
rate during this sixth day after wound creation relative to control, suggesting that the healing rate
is increased at this time point by the honey treatment. The acid-soluble collagen extracted from
honey-treated rats had a 122% increase in aldehyde content relative to that extracted from non-
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treated rats, indicating a higher degree of crosslinking in the wounds that were honey-treated.
This was confirmed by an 11% drop in the solubility of the insoluble collagen of the honeytreated rats in the presence of urea. Interestingly, experimental groups of rats with honey
administered orally and intraperitoneally showed higher degrees of collagen synthesis and
crosslinking than the topical-administration group [127]. Although the administration of honey
via the oral and intraperitoneal routes has not been widely studied, these findings suggest it may,
in fact, be more beneficial than the current topical administration model. The authors of this
study suggest that the oral administration of the honey allows for greater nutrient uptake, which
is an unsatisfactory explanation for these results as those nutrients would be processed and
dispersed systemically and thus unlikely to have a greater effect on the wound than topical
administration. More exploration of the benefits of these routes of administration, including
repeating this study, may be beneficial to confirm or disprove these potentially impactful
findings.
In a different study, Medhi et al. used a rat ulcerative colitis model to study the efficacy
of rectally-applied Manuka honey to treat ulcerative colitis. Rats were administered intra-colonic
TNBS to induce colitis and then treated with Manuka honey at 5 g/kg body weight through a
rubber tube inserted rectally. After 14 days, rats were sacrificed, and excised tissue was
morphologically assessed. Histological sections of colon tissue were graded on a scale from 0
(no inflammation) to 3 (intensive inflammation). Treatment with Manuka honey decreased the
sample scoring from approximately 1.8 (mean TNBS control score) to approximately 0.2 (mean
Manuka honey score), indicating almost no inflammation in the honey-treated samples [128].
This study indicates another promising use for Manuka honey in treating ulcerative colitis and
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other internal inflammatory diseases, and provides evidence of the general anti-inflammatory
properties of honey which make it such an effective wound treatment.
In vivo Clinical Evidence Supporting the Use of Honey in Wounds
Clinically, honey has been used in wounds to great effect. A 2010 study by Moghazy et
al. followed the treatment of 30 diabetic foot ulcers with commercial honey over a three-month
period. Ulcer size decreased in 28 of the 30 patients, with complete healing in 13 of the patients
after three months. In 27 of these patients, inflammation was significantly decreased. A number
of microorganisms were isolated from the ulcers at the beginning of the study, including
Staphylococcus aureus, E. coli, Proteus, Klebsiella, and Providencia. All of these
microorganisms were eradicated by the end of the three-month study. Staphylococcus
epidermidis, a benign pathogen commonly found on human skin and thought to provide a
reservoir of resistance genes to other infections, was isolated from 28 of the patients at the end of
the study [129, 130]. The presence of healthy S. epidermidis is thus another sign of full healing
of these wounds. While the results of this study are encouraging, it would have benefited from
non-honey treatment control group to establish an effective comparison to the current goldstandard treatments.
In another study, Efem et al. used a topical commercial honey treatment to treat 59 cases
of non-healing ulcers, and described that the honey treatment caused more rapid wound
debridement, promoted rapid epithelialization, and reduced edema, causing a faster healing rate
and reduced morbidity. The author reports that within one week, sloughs, necrotic, and
gangrenous tissues were separated from the ulcers enough to be lifted away by forceps without
pain to the patients while weeping ulcers were dehydrated and foul-smelling wounds were
rendered odorless. Swabs from 51 of the wounds before treatment showed the presence of
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Pseudomonas pyocyanea, E. coli, Staphylococcus aureus, Proteus mirabilis, Klebsiella,
Streptococcus faecalis, and Streptococcus pyogenes, while swabs performed after one week of
honey treatment cases showed the eradication of these microorganisms [131]. Unfortunately,
while the progress of the wounds is described, no objective measurements of wound size or
condition are included in this study, only general clinical observations of the wounds over time.
In addition to treatments with commercial store-bought honey, some studies have focused
specifically on treatment with medical-grade Manuka honey. Gethin et al. compared Manuka
honey treatment with a commercially available hydrogel dressing in 108 patients with sloughy
infected venous leg ulcers. MRSA was identified in 16 of the wounds, 10 of which were treated
with the honey while six were treated with the commercially available hydrogel. After four
weeks of treatment, MRSA was eradicated in seven of the ten honey-treated wounds but only
one of the six hydrogel-treated wounds [132]. Numerous case studies have corroborated these
beneficial effects of Manuka honey in infected, non-healing ulcers [133-137]. These studies
provide compelling evidence that honey is an extremely effective wound treatment.
Cautionary Evidence of Cytotoxicity
While there are many studies that have demonstrated the potential benefits of honey in
wound healing, much less attention has been given to the counterproductive cytotoxic effects of
high concentrations of honey. However, a few groups have studied these cytotoxic effects in
various cell and animal models, and their data provides a cautionary window into the dangers of
using high concentrations of honey in wounds or other therapeutic applications. An in vitro study
by Sell et al. found that honey concentrations of 5% v/v or above were cytotoxic, killing almost
100% of the cells tested in fibroblast, pulmonary microvascular endothelial, and macrophage
cultures after one day [110]. Likewise, an in vivo study in which 50% v/v Manuka honey was
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applied to chinchilla ears found that it caused severe inflammation and ototoxicity. Eight
chinchillas had the honey solution applied to the round window membrane and the cochlea of
one ear while the other ear received a sham treatment of normal saline solution. All eight
chinchillas developed a head tilt and facial paralysis on the side of the experimental ear within 048 hours of honey application, with a corresponding loss of balance and nystagmus. Extraction
of the osseous bullae and cochleae showed that the honey-exposed bullae were soft and brittle
and the cochleae were darker, compared to the control bullae and cochleae which were normal in
color and consistency. Histological examination revealed a scarcity of cells and the creation of
new vacuoles within the honey-exposed spiral ligaments, with destruction of the organ of Corti
and an excess of inflammatory cells found in the honey-exposed cochleae, whereas the salinetreated organs had normal appearance, architecture, and cellularity. SEM images showed
destruction of the spiral ganglion and cochlear hair cells in the experimental ears, with no
damage to the control ears, as shown in Figure 3 [138]. Possible causes of this damage are the
low pH of the honey and its high osmolarity, although further testing with other acidic and
hypertonic solutions will be necessary to confirm this theory. In a similar in vivo effort,
Paramasivan et al. flushed ovine frontal sinuses with methylglyoxal concentrations ranging from
0.5 to 7.2 mg/mL, or with 16.5% w/v Manuka honey enriched with methylglyoxal in the same
concentration range, twice daily for 14 days. Animals were sacrificed, and the tissue was
analyzed by histology and tested for Staphylococcus aureus biofilms which had been
intentionally developed in the ovine sinuses before the study. The results indicated both the
methylglyoxal alone and 16.5% Manuka honey enriched with methylglyoxal above 0.9 mg/mL
eradicated the Staphylococcus aureus biofilms, while honey/methylglyoxal treatment with less
than or equal to 1.8 mg/mL methylglyoxal was non-irritating to the mucosa. However,
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methylglyoxal and honey/methylglyoxal treatment with methylglyoxal levels above 1.8 mg/mL
caused cilia denudation and squamous metaplasia, indicating tissue damage [139]. These results
point to methylglyoxal as a culprit of Manuka honey’s cytotoxicity, although more testing in a
variety of cell and animal models should be done to confirm this finding. If accurate, however,
these results could indicate that other honey varieties without methylglyoxal may be optimal for
applications in which a high honey concentration would be required.
The results of these papers provide compelling evidence of the cytotoxicity of Manuka
honey at higher concentrations, and should prompt a review of the current use of Manuka honey
in wound treatment. Because most clinical honey treatment involves directly applying undiluted
honey to the wound, it is likely that honey’s beneficial effects are at least somewhat counteracted
by its cytotoxicity. Even accounting for dilution of the honey by wound exudate and excess
liquid pulled from the deeper tissue by honey’s high solute osmolarity, cells within the wound
likely encounter honey concentrations at or above the 5% v/v cytotoxic concentration found by
Sell et al. [110]. When designing tissue regeneration templates, this cytotoxicity must be

Figure 3. Undiluted honey destroys cilia. (Left) SEM of saline-exposed chinchilla cochlea, in
which normal inner and outer hair cells are seen. (Right) SEM of honey-exposed chinchilla
cochlea in which the inner and outer hair cells have been damaged. Reproduced with
permission from Aron et al., Otolaryngology – Head & Neck Surgery; published by BMC,
2012.
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accounted for to avoid killing infiltrating cells and impeding tissue ingrowth. Even in
applications where tissue ingrowth is not necessary, such as a bone screw, care must be taken to
avoid causing necrosis in the surrounding area. Thus, it is paramount that these templates and
devices that incorporate honey do so in a way that allows a low-level, controlled release to avoid
cytotoxicity while prolonging the beneficial effects of the honey.
Honey in Tissue Engineering
Given the wealth of data supporting the use of honey as a wound treatment, the logical
next step is to apply these findings to the field of tissue engineering and biomaterials. The
implantation of a biomaterial within the body necessitates the creation of a wound, and the
presence of these biomaterials provides a potential site for bacteria to deposit and fester after
implantation. The antibacterial effects of honey, especially Manuka honey, could thus
significantly reduce the rates of infection in biomaterials. Additionally, given the evidence
showing that Manuka honey reduces inflammation and promotes fibroblast migration and
collagen deposition, it is likely that it could promote tissue-material integration/regeneration and
accelerate healing of the surrounding wound site [97, 108, 110, 112, 140]. An important
consideration will be how to apply the honey to the biomaterial or incorporate it into the
biomaterial to deliver appropriate concentrations of honey and achieve these optimal effects. It is
likely that in most applications a controlled-release profile will be desirable to avoid cytotoxic
effects and prolong the presence of the honey in the region of interest/need. Thus, research has
been more focused into incorporating the honey throughout biomaterials to achieve this type of
release. In the past decade, there have been numerous studies incorporating honey into a variety
of biomaterial tissue templates for tissue regeneration.
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Electrospun Templates
One of the first attempts to incorporate Manuka honey into an electrospun template was
published in 2012 by Vadodaria et al. In this study, Manuka honey was combined with PEO into
solutions which were then electrospun. SEM images showed that increasing Manuka honey
content caused thicker, merged fibers, although these morphological changes could be somewhat
compensated for by reducing the solution feed rate and increasing the applied voltage. FTIR
showed peaks indicating the presence of both PEO and Manuka honey in the fibers, while DSC
indicated that increasing the Manuka honey content lowered the melting point of these templates
[141]. This study did not include any experiments examining biocompatibility or cell behavior
on the templates and did not include a honey release profile. Nevertheless, it established the
basic parameters necessary for electrospinning Manuka honey into nanofibrous templates for use
as delivery vehicles.
In another early study, Maleki et al. electrospun PVA templates containing various
concentrations of Iran-Tabriz honey and dexamethasone, an anti-inflammatory drug. Both honey
and dexamethasone decreased the fiber diameters of the templates in a dose-dependent fashion.
Dexamethasone release studies showed a large burst release of dexamethasone within the first 10
minutes of soak due to the swelling of the PVA fibers, with no difference between the honey and
non-honey dexamethasone templates [142]. Like the Vadodaria paper, this effort did not conduct
any cellular studies or bacterial inhibition assays, but it does indicate that honey can be
incorporated into electrospun templates along with other additives. Unfortunately, although this
paper did have release profiles of the dexamethasone from the templates, no honey release
profile was included.
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A more in-depth study of Manuka honey in electrospun templates was published by
Minden-Birkenmaier et al. in 2015. In this study, solutions of PCL, HFP, and various
concentrations of Manuka honey were electrospun into fibrous templates which were then
characterized with regards to fiber morphology, WVTR, permeability, mechanical properties,
honey release, fibroblast response, and bacterial inhibition. Templates were also created
replacing the Manuka honey with equivalent amounts of water to use as morphological controls.
By sonicating the Manuka honey in the HFP before adding the PCL, and then electrospinning the
resulting solution within 24 hours, templates were created with equivalent fiber diameters,
varying from 2 µm to 3.5 µm in diameter, up to a 20% v/v honey content. Water vapor
transmission rate after a one-hour soaking period increased with increasing honey content, as did
template permeability. Honey incorporation caused a decrease in the elastic moduli and peak
stress of the templates, but there was no significant change in these properties over a 28-day
soaking period. Glucose assays indicated that while up to 80% of the honey content of the
templates was lost during a one-hour ethanol disinfection soak, the templates retained enough
honey that they released significant amounts of honey over the following 24-hour period of
soaking, proportional to the amount incorporated into the scaffold. Fibroblast chemotaxis assays
showed no effect of honey content in inducing chemotaxis towards the templates, indicating that
the honey left in the templates to be released after the disinfection step is probably too low of an
amount to induce chemotaxis. However, the 20% honey templates caused a significant increase
in fibroblast proliferation and infiltration over PCL controls, indicating the potential of Manuka
honey to improve template-tissue integration and regeneration (Figure 4). Bacterial inhibition
studies of E. coli and S. agalactiae showed significant inhibition of both bacterial types by the
10% and 20% honey templates as expected due to the bactericidal properties discussed earlier,
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although this inhibition was much less than that of a sterile disc swabbed with pure Manuka
honey. Together, these findings indicate the potential benefit of Manuka honey in improving
cellular proliferation, cellular ingrowth, and bacterial inhibition associated with a tissue template
[143]. However, the fact that 80% of the incorporated Manuka honey was removed during
ethanol disinfection indicates that future studies may consider investigating core-shell
electrospinning to protect the honey payload from disinfection and provide for a more long-term,

Figure 4. Honey induces fibroblast infiltration. (A) Representative images of H&E stained
honey templates and water controls after 28 days of fibroblast culture. (B) Cellular infiltration
depth of the furthest 60 cells on each image. Reproduced with permission from MindenBirkenmaier et al., Journal of Engineered Fibers and Fabrics; published by INDA, 2015.
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controlled release period. Other disinfection or sterilization methods, like gamma irradiation,
should also be investigated as alternatives that may remove less of the incorporated honey.
The physical properties detailed in the Minden-Birkenmaier study also indicate that the
majority of the honey is likely sequestered to the fiber surface during the electrospinning
process, where it is easily released once rehydrated, allowing for greater template permeability
but maintaining mechanical strength due to the PCL fiber core [143]. As expected, this
morphology makes the templates hygroscopic, allowing them to soak up water but changing their
physical properties as they are exposed to ambient humidity or liquid water (as demonstrated by
the water vapor transmission rate data discussed above). It will be important to take this
hygroscopidity and the associated processing issues into account when producing and packaging
honey-laden templates for clinical use. For instance, production and packaging in a low-humidity
environment may be necessary to improve the shelf-life of future commercial honey-laden
templates.
In a more recent effort, Balaji et al. combined Malaysian Tualang honey and PA (also
reported to have antimicrobial and anti-inflammatory properties [144, 145]) into a DMF solution
along with PU, which was then electrospun into templates. Fiber diameter measurements showed
that the honey and papaya extract reduced template fiber diameter, from a mean diameter of 434
nm for PU controls down to 190 nm for the PA/honey templates; however, porosity only
experienced a minor decrease. FTIR confirmed the presence of both the honey and the PA along
with the PU in the fibers. Water absorption tests showed that the presence of both honey and PA
in the templates caused a three-fold increase in water uptake, indicating a potential benefit of
these hydrophilic substances in absorbing wound exudate. Hemocompatibility studies indicated
that the PA/honey templates had significantly greater adsorption of albumin but significantly less
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adsorption of fibrinogen relative to PU controls, indicating a resistance to clotting. APTT and PT
assays likewise indicated that the PA/honey templates took longer to activate thromboplastin and
prothrombin than the PU controls, 180 seconds (honey) versus 152 seconds (control) for APTT
and 45 seconds (honey) versus 37 seconds (control) for PT. The PA/honey templates also had a
decrease in the hemolytic percentage from the PU controls (2.7% for PU control and 0.9% for
the honey template) indicating a reduction in red blood cell lysis. This hemocompatibility
indicates a possible use of the template in vascular tissue engineering [146]. While the results of
this study are impressive, particularly with regards to hemocompatibility, it would have been
beneficial for separate templates containing different amounts of honey or PA to be tested, as the
effects of the honey and the PA on hemocompatibility could have been isolated from each other.
This separation of honey and PA would have allowed for a more robust study to indicate the true
hemocompatibility potential of the honey and the PA alone.
Several studies have investigated combinations of silk fibroin and honey in electrospun
templates. Kadakia et al. electrospun silk fibroin templates from HFP containing either P407, a
hydrophilic polymer used to improve cell adhesion, or Manuka honey. Fiber diameter
measurements taken from SEM images showed that the incorporation of P407 at either a 1:1 or
3:1 silk:P407 ratio (total polymer concentration of 10% w/v) significantly decreased fiber
diameters (from 2.2 μm down to 1.8 μm), while 1% honey increased fiber diameters (from 4.4
μm up to 5.8 μm) and 5% honey decreased fiber diameters (down to 3.6 μm). Mechanical testing
indicated that increasing P407 and honey concentrations decreased the elastic moduli of the
templates relative to silk control templates when dry. However, when the templates were
hydrated, the honey templates had elastic moduli in the range of 5-9 MPa, above the 2-3 MPa
range of the silk controls, indicating that the honey increased elasticity. While no difference was
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seen in the swelling of the silk/P407 templates and pure silk controls, the honey templates
swelled to a significantly higher degree, with a swelling ratio of about 350% after four hours
while the silk fibroin control had a swelling ratio of approximately 240%. Water vapor
transmission rate was observed to decrease from approximately 1750 g/m2/day for the silk
control template to approximately 1550 g/m2/day with the incorporation of 1% honey and
approximately 1400 g/m2/day with the incorporation of 5% honey. Water contact angle
measurements showed that the incorporation of p407 decreased water contact angle from about
70º to about 45º for 3:1 silk:P407 and about 11º for 1:1 silk:P407. Surprisingly, the incorporation
of honey increased water contact angle from around 61º to approximately 67º for 1% honey and
approximately 78º for 5% honey. Fibroblast experiments showed no increase in proliferation in
the 1% honey templates, and impeded proliferation on the 5% honey templates, indicating a
degree of cytotoxicity of the honey as discussed earlier in this review. However, fibroblasts
infiltrated fully into all template types after 28 days, with no differences between groups, and no
significant difference in hydroxyproline production was observed between the groups [147]. This
study would have benefited from a glucose release study to ascertain the amount of honey
released during disinfection and subsequent culture. Given the cytotoxicity seen in the fibroblast
culture experiments, it is speculated that templates with lower amounts of loaded honey, or a
lower, persistent release of honey over time would have performed better in the cellular studies.
In a similar effort, Yang et al. electrospun solutions of silk fibroin and PEO with
concentrations of 0%, 10%, 30%, 50%, and 70% wt/v Manuka honey into nanofibrous templates.
FTIR showed the presence of the Manuka honey in the fibers, and SEM images showed an
increasing fiber diameter with honey concentration, from an average of 484 nm without honey to
an average of 2229 nm with 70% wt/v honey, as seen in Figure 5. Bacterial inhibition tests using
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E. coli, S. aureus, P. aeruginosa, and MRSA indicated that the templates retained the
antimicrobial effects of the Manuka honey. Specifically, bacterial inhibition over 24 hours of all
four bacterial strains was approximately zero for the non-honey template, but increased to around
50% inhibition of E. coli, about 28% inhibition of S. aureus, about 57% inhibition of P.
aeruginosa, and about 40% inhibition of MRSA for the 70% wt/v honey template. Templates
were also used to treat a mouse dorsal wound model over a 12-day period, and saw complete
healing of the wounds treated with the 70% honey template, whereas wounds treated with a nonhoney silk template or a commercial AquacelAg wound dressing had only around a 90%
reduction in wound size over this timeframe [148]. The most novel part of this study was the use
of deionized water and hydrophilic polymers in the electrospinning process, as opposed to the
organic solvents used in the previously described studies. This water-based solution could
potentially eliminate the sequestering of the honey to the outside of the fibers, reducing the
mechanical strength of the template but delaying the release of the honey over time. As such, this
study would have benefited from a glucose release experiment showing the release profile of
honey from the template to indicate if this delayed, controlled release is present.
Cryogels
Cryogels, fabricated by freezing a crosslinked polymer solution, have been investigated
as templates for bone tissue engineering due to their porosity, elasticity, and ability to retain their
three-dimensional architecture. As bone fractures or defects are often sites of biofilm formation
and bacterial infection due to their open nature, the eradication of bacteria is of utmost
importance. Thus, research has focused on incorporating honey into cryogels as an antimicrobial
agent. In a 2017 study, Hixon et al. incorporated Manuka honey into cryogels formed from either
gelatin or silk fibroin. While the silk cryogels had larger pores (average pore diameter 25-40 μm)

35

than the gelatin cryogels (average pore diameter 17-20 μm), the incorporation of Manuka honey
significantly decreased these pore diameters in the silk cryogels but not in the gelatin cryogels.
Honey decreased the swelling ratios of the gelatin cryogels, but not the silk ones. Ultimate
compression testing indicated that honey significantly decreased the average peak stress in both
cryogel types, and decreased the modulus of the gelatin cryogels, which could make the honeyincorporated cryogels less feasible in load-bearing bone tissue applications. Manuka honey
incorporation had no significant effect on the proliferation of seeded MG-63 osteosarcoma cells,
but increased cellular infiltration in the highest (10% v/v) honey concentration silk cryogel
samples. Similar to the results seen in the electrospun honey templates discussed above, glucose
release tests showed the bulk of the incorporated honey was released within the first hour of
hydration, however, after this bulk release there was a consistent release of 0.03 mg/mL glucose
per day throughout the 14-day soak period for both the gelatin and silk cryogels. The peracetic
acid sterilization procedure also was shown to remove most of the incorporated honey from both
polymer types. Thus, it may be beneficial to use other sterilization methods such as gamma
radiation in the future to avoid leaching out the honey from these structures. Bacterial clearance
tests showed that the incorporation of honey significantly increased bacterial clearance of both E.
coli and S. agalactiae, and bacterial broth clearance and bacterial adhesion assays confirmed this
trend. Honey incorporation did not alter mineralization of the cryogels by the MG-63 cells over a
28-day culture period [149]. While the mechanical testing data indicates that the presence of
honey weakens these cryogels and makes them more brittle, their ability to inhibit bacterial
growth and induce cellular infiltration indicates their potential in bone tissue engineering. This
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tradeoff of mechanical stability should be accounted for when designing future honey cryogelbased therapies. Efforts should focus on protecting the honey content from washing out during

Figure 5. Honey increases fiber diameter. SEM images and histograms of fiber diameters of
silk/PEO nanofibrous matrices spun with (a and a’) no Manuka honey, (b and b’) 10% w/v
Manuka honey, (c and c’) 30% w/v Manuka honey, (d and d’) 50% w/v Manuka honey, and
(e and e’) 70% w/v Manuka honey. Reproduced with permission from Yang et al.,
Materials & Design; published by Elsevier, 2017.
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sterilization or as an initial bulk release, creating a more long-term, sustained release greater than
one-to-two hours. Additionally, the utilization of other polymers should be explored as means to
maintain mechanical strength and elasticity even with the incorporation of honey.
Although not addressed in this study, it has been shown that lowering the pH in the area
around bone tissue can stimulate increased bone resorption and reduce mineral deposition by
osteoclasts [150, 151]. This effect is switched off at or above a pH of 7.4 but is near-maximal at
pH of 7 [151]. Thus, there is a danger that the low pH of honey could impede bone regeneration
rather than stimulate it. The study by Hixon et al. showed no effect of the honey on MG-63
osteosarcoma cell mineralization in vitro, but additional testing with non-cancerous osteoblasts
and osteoclasts should be done. Given these well-documented effects of lowering the pH on bone
resorption, it is speculated that honey-incorporated cryogels are unlikely to be a useful bonerepair therapy.
In a subsequent study by Hixon et al., Manuka honey with various UMFs (a general
quantification of bacterial inhibition) was incorporated into cryogels and electrospun templates,
both fabricated from silk fibroin. The amount of honey in all constructs was kept constant at 5%
v/v, while the UMF was varied by utilizing commercially available honeys rated with UMFs of
5+, 10+, 12+, 15+, and 20+. In general, UMF had no effect on the morphology of the cryogels or
electrospun templates or on their ability to inhibit E. coli or S. aureus, and the electrospun
templates had greater bacterial clearance (0.5-1 cm) than the cryogels (approximately 0.16 cm).
The glucose release profiles from the cryogels and the electrospun templates were not
statistically different, with the bulk of the glucose released within the first four days of soak
maintaining a level of 0.4-0.6 mg/mL glucose in the surrounding solution [152]. Thus, it is
unknown why the electrospun templates were more effective at clearing both types of bacteria.
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One explanation could be that different bactericidal components of the honey, such as the
methylglyoxal, hydrogen peroxide, or the gluconic acid, are released at different rates or profiles
than the glucose, and these rates may be different between the cryogels and the electrospun
templates. Assays for these other components may be necessary to fully explain the dramatic
difference in bacterial inhibition between these template types. Likewise, it is curious that the
UMF of the honey used in these templates did not affect their bacterial clearance. Part of the
problem may be that the exact UMF of each honey obtained was not listed, only that it was
above the listed level (5+ means that it has a UMF of at least 5, not exactly 5). Thus, it is
possible that the actual UMFs of the honeys did not vary as much as was thought based on their
labels. It would be beneficial for future studies testing different UMFs to test the UMF in-house,
rather than relying on the UMF rating of the commercial vendor. Thus, it is still unknown
whether the UMF of the Manuka honey used affects bacterial clearance or other properties when
incorporated into tissue templates.
Hydrogels
Hydrogels, highly absorbent networks of hydrophilic polymer chains, are often used as
templates and drug delivery devices in tissue engineering due to their polymeric structure and the
ability to control characteristics such as pore size, water content, and degradation profile. Several
groups have explored incorporating honey into hydrogels for use as wound coverings. In a 2012
study, Wang et al. incorporated Chinese sunflower honey at 10% or 20% v/v into hydrogel
sheets fabricated from chitosan and bovine gelatin. Swelling studies indicated that the presence
of honey reduced the ability of the hydrogel to absorb fluid, with the 20% honey hydrogels
swelling only around 250% as compared to the 700% swelling of the non-honey control.
Compression testing indicated that honey content also reduced the modulus of the hydrogel
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sheets from around 110 kPa to around 60-70 kPa for the 20% honey hydrogel and approximately
58 kPa for the 10% honey hydrogel. Antibacterial assays showed that the presence of honey
significantly increased the inhibition of S. aureus and E. coli growth, with the 20% honey
hydrogel causing almost 100% inhibition while the non-honey hydrogel caused approximately
20% inhibition of both bacterial types. In vivo oral toxicity tests were performed in mice, and
dermal irritation and burn wound healing tests were performed in rabbits. As expected, the mice
toxicology tests showed no toxic symptoms. After eight days of treatment in rabbit wounds, the
honey hydrogel group averaged about 80% wound closure, while the ointment group had about
60% wound closure and the non-treated group had about 45% wound closure, as shown in Figure
6. Histological examination of the wounds after 12 days revealed that the untreated wounds were
infected, contained a high amount of inflammatory cells, and had no hair follicles. The ointmenttreated group had smaller ulcers than the non-treated group, but still contained acute
inflammatory infiltrate that collected in small cysts underneath the regenerated epidermis. Both

Figure 6. Honey hydrogel induces wound closure. Wound closure rates in rabbit wounds that
were untreated, treated with a commercial wound ointment (MEBO), or treated with a honeyinfused chitosan/gelatin hydrogel (HS) at 4, 8, or 12 days after beginning of treatment.
Reproduced with permission from Wang et al., Carbohydrate Polymers, published by
Elsevier, 2012.
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the ointment group and the honey hydrogel group showed epidermal healing, but the honey
hydrogel group had less inflammatory infiltrate and also had proliferating hair follicles on the
surface [153]. Although this study thoroughly characterized the in vitro and in vivo aspects of the
honey hydrogel, the lack of a control non-honey hydrogel group in the animal studies call into
question whether the honey improved the in vivo performance of the hydrogel. Additionally, the
lack of a topical honey treatment group in these studies made it impossible to ascertain whether
incorporation of the honey into a hydrogel improved healing over the current clinical method of
treatment. Thus, the only conclusion that can be drawn from this section of the study is that this
honey-containing hydrogel improves healing relative to an ointment treatment. A glucose release
study would also improve this paper by showing whether the honey is released in a burst or
released in a controlled fashion over days or weeks after implantation.
More recently, Sasikala et al. incorporated Manuka honey into chitosan hydrogel films,
also for use as wound dressings. Chitosan solutions containing 8% w/v Manuka honey were cast
in Petri dishes and dried at 40 °C for 24 hours. Honey increased the folding endurance of the
samples with the honey samples surviving a mean of 289 folds, whereas the non-honey films
survived a mean of 143 folds. This finding indicates greater flexibility of the honey hydrogels
which is likely a function of the hygroscopic effect of the honey. However, no effect of the
honey was seen on the water vapor transmission rate of these films, which was curious given the
results seen in electrospun scaffolds as detailed earlier in this review. As observed in the study
discussed above, honey decreased the swelling ratios of the hydrogel films and increased the
inhibition of S. aureus and E. coli growth. When these films were placed in a rat dorsal wound
model, increased wound closure was observed in the honey samples relative to non-honey
control films and cipladin ointment controls. Specifically, after 12 days of treatment, the honey
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hydrogel wound was 94% closed, the non-honey hydrogel wound was 78% closed, the ointmenttreated wound was 86% closed, and the non-treated control wound was 64% closed [154]. The
use of non-honey control hydrogel films in this animal study show the benefit of the honey to the
wound healing process, which is an improvement over the Wang et al. study discussed above.
However, many of the studies described in this paper seem to have been undertaken with a
sample size of n=1, as there are no standard deviations or standard errors reported. Although the
methods section says that an ANOVA was performed on the wound closure data, it does not
report which specific sample groups were significant from each other, casting doubt as to the
scientific veracity of these findings. This study would benefit from being repeated more
thoroughly so that its findings can be scientifically corroborated.
In 2008, Gethin et al. published a study in which 20 patients with chronic, non-healing
leg ulcers were treated with Apinate, a commercially available Manuka honey hydrogel dressing
made by Derma Sciences. This study focused on the effect of the Manuka honey hydrogel in
lowering the wound pH, and the corresponding effect on wound size reduction. The Apinate
dressing itself had a pH of 4.0, due to the acidity of the honey. After a 2-week period, wounds
treated with Apinate had a mean pH drop of 0.46, with a mean wound size reduction of 1 cm2. A
linear regression model was developed using the experimental data, showing a significant
relationship between drop in pH and a reduction in wound size over the 2-week period, with 1
unit reduction in pH being associated with a decrease of 81% of wound size [92]. It is unknown
how much of the healing effect was a function of the honey’s pH, as opposed to its osmotic
effects, bactericidal effects, or other properties detailed earlier in this review, or whether the pH
is an effect of wound healing instead of a cause. However, a decrease in pH has been shown to
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increase oxygen saturation, reduce elastase activity, and kill certain bacteria, which all aid wound
healing [155-157].
Giusto et al. have conducted preliminary research incorporating Manuka honey into
pectin-based hydrogels. In a conference poster, they report that honey-containing pectin
hydrogels have superior bacterial clearance of S. aureus and E. coli, and demonstrate no
cytotoxicity to fibroblasts [158]. However, these results have yet to be published in a peerreviewed journal, so a full review of their findings is not currently possible. More thorough
research was conducted by Zhodi et al. in which Gelam honey, a honey produced in Malaysia,
was incorporated into hydrogels made from PVP and PEG. Honey content significantly
decreased the pH value of the hydrogels (from 5.3 to 4.3) and increased the swelling of the
hydrogels by a factor of five relative to non-honey controls. A large-scale burn wound study was
undertaken using 96 rats, six rats per experimental group. Wounds treated with the honeycontaining hydrogels significantly decreased in size relative to non-honey hydrogel controls by
days 21 and 28, with the honey-treated wounds averaging a 91% reduction in size compared to
the 72% reduction in size of the control hydrogel wounds. Histological examination showed
decreased inflammatory exudate by day seven and increased dermal repair and reepithelialization
by day 21 in the honey-containing hydrogel wounds. These wounds also showed an increase in
granulation tissue and capillary formation as well as collagen synthesis. RNA extracted from the
wound site showed that the honey-containing hydrogel treatment caused a significant decrease in
IL-1α, IL-1β, and IL-6 expression relative to control hydrogels, a commercial Opsite film wound
dressing, or non-treatment groups. Specifically, the honey hydrogel caused a drop from around
3.5 % expression to 0.5% of IL-1α and IL-1β, and from about 3.5 % expression to 0.1%
expression of IL-6 mRNA after seven days, normalizing expression to a β actin control, as
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shown in Figure 7 [159]. This animal study is the most in-depth look at the in vivo effect of
honey-containing hydrogels and demonstrates that the honey content reduces inflammatory
cytokine output, reduces inflammatory exudate, increases the formation of granulation tissue,
and increases the wound closure rate. Ideally, future studies of this type will also look at a
greater number of relevant cytokines, such as TNF-α, IL-8, MIP-1α, MIP-3α, VEGF, MMP-1,
MMP-9, and Proteinase 3, among others. In this way, a more complete understanding of the
wound environment could be ascertained.
Commercialization
Currently, several companies sell products which contain Manuka honey for wound care.
Derma Sciences, a tissue regeneration company based in Princeton, New Jersey, sells a line of

Figure 7. Honey reduces inflammatory cytokine expression. mRNA expression of IL-1α, IL1β, and IL-6 in a rat burn wound model treated with a control hydrogel, a commercial Opsite
film dressing, the honey hydrogel, or non-treated (-Ve) control, normalized to β-actin.
Reproduced with permission from Zohdi et al., Evidence-based Complementary and
Alternative Medicine; published by Hindawi, 2012.
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Manuka honey products under the brand Medihoney®. In addition to pastes and gels combining
Manuka honey with gelling agents to increase viscosity, this company also sells several variants
of an alginate-based hydrogel sheet containing Manuka honey for use as wound coverings,
including the Apinate dressing discussed earlier in the hydrogel section [160]. Several in vitro
studies have confirmed the antibacterial effects of these products [161, 162]. Furthermore,
randomized controlled trials and case studies have demonstrated the antibacterial and wound
healing effects of these products in the clinical setting [136, 163-167]. Simon et al. detailed the
treatment of various surgical wounds and drainage sites in pediatric oncology patients with a
Medihoney alginate wound covering and reported that the honey reduced irritation and cleared
infections. One acute lymphatic leukemia patient with a high level of immune suppression had a
persistent deep surgical site infection that healed completely once treated with the Medihoney
[136]. Johnson et al. conducted a randomized controlled trial of topical Medihoney application
versus mupirocin in preventing catheter-associated infections and found that while the honey was
comparable to the mupirocin in preventing infection, 2% of staphylococcal isolates were
mupirocin-resistant. Thus, they concluded that honey represented a good alternative to the goldstandard antibiotic [163]. A wound-focused randomized controlled trial conducted by Robson et
al. using topical Medihoney observed about a 10% increase in healing rate in the honey-treated
wounds as opposed to conventionally-treated wounds, which was statistically significant [164].
A prospective observational study by Biglari et al. using Medihoney focused specifically on
chronic pressure ulcers and found that the honey eradicated bacterial growth in all 20 ulcers
treated, with 90% of patients showing complete wound healing after four weeks [166]. Likewise,
Smith et al. published a case series of topical Medihoney-treated recalcitrant venous leg wounds
that had failed to respond to four-layer compression, topical silver, nonadherent dressings, and
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antibiotic therapy. All 11 wounds treated had 100% closure by six weeks, with an average
wound healing velocity of 0.25 cm2/day [167]. Another company, the New Zealand-based
Manuka Health, manufactures a similar glycerine-based honey-containing hydrogel sheet for
wound covering [168]. In addition to proving the efficacy of the Medihoney product line
specifically, these trials and case studies lend additional weight to the general benefits of
Manuka honey on wounds.
Besides the Medihoney line by Derma Sciences, there are a few other companies that sell
Manuka honey-based therapeutic products. Another New Zealand-based company, ManukaMed
Ltd., sells a number of variations of gauze-based, honey-impregnated fiber pad wound coverings
[169]. The United Kingdom-based Advances Medical makes several types of Manuka honeyimpregnated wound coverings including cellulose-based net dressings (Actilite and Activone
Tulle) and alginate hydrogels (Algivon, Algivon Plus) [170]. Additionally, a Memphis,
Tennessee-based company, SweetBio Inc., is developing a resorbable membrane for oral
surgery, with manufactured prototypes currently undergoing testing [171]. Of these products, the
only ones extensively studied in peer-reviewed literature are the Medihoney® coverings. Except
the Sweetbio membrane, all of these products are designed as temporary wound coverings that
must be physically replaced. While no company has published release profiles of the honey from
their products, given the described methods of application it is likely that the honey is delivered
at high concentrations as a bolus. As high concentrations of Manuka honey have been observed
to be cytotoxic in vitro, there may be a potential to improve the healing outcomes of wounds
treated with these products by diluting the honey or by attenuating the release to lower levels for
prolonged amounts of time [97]. However, attenuating the honey concentration may diminish the
antibacterial effects of the dressings. Thus, higher concentrations of honey should be used
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initially in infected wounds to ensure destruction of the invading bacteria. A two-step process
may be optimal, in which heavily infected wounds are first treated by topical application of
undiluted Manuka honey to eradicate the infection, and then the honey is removed and replaced
by a controlled-release template to aid in tissue regeneration. Alternatively, delivery of lower
levels of honey alongside an antibiotic could enable the eradication of bacteria and stimulation of
healing without the undesirable cytotoxic effects of the honey.
The Future of Honey in Tissue Engineering
The greatest hurdles to be overcome in the development of honey-containing tissue
engineering templates are the cytotoxicity of high amounts of honey and the lack of prolonged,
consistent release rates of the honey over time. In templates which rely on cellular infiltration
and tissue ingrowth, cells may encounter higher concentrations of honey as they infiltrate into
the honey-containing template than they would outside or adjacent to that template. Such
templates will be surrounded by a honey gradient radiating away from them into the surrounding
tissue, and migrating cells will encounter higher and higher honey levels as they move towards
and into the template. Thus, it will be important to monitor honey levels not only in the template
releasate, but within the template environment itself during in vitro honey release studies. While
some of the studies discussed above did not see honey cytotoxicity as an impediment to cellular
proliferation and infiltration, these studies used liquid ethanol disinfection or peracetic acid
sterilization steps that washed away the majority of the honey from the templates before cell
seeding [143]. In applications where templates are disinfected via ultraviolet or gamma radiation,
or ethylene oxide sterilization, no honey will be removed before cell seeding or template
implantation. Thus, cytotoxicity could impede cell infiltration and proliferation. The templates
studied thus far tend to release their honey content in a bolus during the first day of soak or
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implantation. While this type of release may be acceptable for a wound covering that can be
removed and replaced, templates that are surgically implanted and resorbed into the body must
contain the entire honey payload necessary for the application. Thus, it is important that methods
be developed to attenuate and delay the release of honey over a period of days to weeks. In
electrospun fibers, this may be accomplished by the use of core-shell electrospinning, in which
fibers are created with a core of one polymer type and a shell of another [172, 173]. By
encapsulating honey within the fiber cores, its release could be delayed over time, with either
diffusion or polymer degradation controlling its release rate. Templates created via this method
should be subjected to rigorous mechanical testing to ensure that incorporating a honey core does
not cause the fibers to weaken or become too brittle for their intended use. As of yet, there are no
published studies using core-shell electrospinning with honey. However, this technology is likely
a next step for the field.
As there is no equivalent to core-shell electrospinning in the field of hydrogel and cryogel
fabrication, other methods must be used to attenuate the honey release. Possible techniques
include increasing polymer molecular weight and concentration and increasing crosslinking
density to reduce liquid diffusion through the templates – however, this will likely decrease the
swelling ratio of the templates which may be undesirable. These effects will likely have to be
balanced to achieve the optimal honey release rate, water vapor transmission rate, and
absorbance of these hydrogels and cryogels. Additionally, due to the reported decrease in
compressive modulus and strength of these constructs with honey incorporation, care will have
to be taken to make sure that their mechanical properties are not compromised for their intended
application [149, 153, 174].
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More study is also needed on the effects of honey on immune cells such as neutrophils
and monocytes/macrophages. While Tonks et al. showed that Manuka honey causes an increase
in the output of TNF-α, IL-1, and IL-6 by monocytes over a 24-hour period, it would be
informative to ascertain the effect on levels of other inflammatory, anti-inflammatory, and
angiogenic signals such as IL-8, VEGF, IL-4, IL-1ra, MIP-1α, MIP-3α, etc. Additionally, similar
testing of neutrophil cytokine output would be helpful, as their inflammatory and antiinflammatory effects as first responders in wounds are being viewed with increased importance
[175-177]. Further testing of the effects of honey on neutrophil superoxide output, chemotaxis,
and NF-kB activation in the presence of different inflammatory and anti-inflammatory
stimulators is needed to fully understand how honey affects the regulation of the wound
environment by neutrophils.
Conclusions
There is a wealth of in vitro and in vivo evidence showing that honey, particularly
Manuka honey, eliminates bacteria, resolves chronic inflammation, and promotes faster wound
healing. Its potency against antibiotic-resistant bacteria such as MRSA make it a particularly
invaluable tool in an age where more and more strains of resistant bacteria are developing. As
such, honey is a valuable addition to many tissue engineering templates in eliminating bacterial
infection, aiding in inflammation resolution, and improving tissue integration with the template.
Future research should focus on attenuating and prolonging the release of honey from the
templates to avoid cytotoxicity and prolong the beneficial effects of the honey within the site.
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CHAPTER 3
MANUKA HONEY MODULATES THE INFLAMMATORY BEHAVIOR OF A dHL-60
NEUTROPHIL MODEL UNDER THE CYTOTOXIC LIMIT
Introduction
Studies have demonstrated that topical application of honey to wounds promotes wound
closure, induces an osmotic gradient which cleanses the wound via fluid movement, reduces
wound inflammation, and inhibits the growth of a range of bacteria varieties [92, 97, 99, 178].
The high concentration of sugars in the honey creates an osmotic gradient that pulls fluid from
the subcutaneous tissue up through the wound area, flushing necrotic debris from the wound site
and carrying nutrients and oxygen from the surrounding area into the damaged tissue [102].
Additionally, this gradient helps to remove excess fluid from the wound environment, which has
been shown to impede bacterial growth [179]. Flavonoids within the honey scavenge free oxygen
radicals, reducing inflammation and minimizing tissue damage [180-182]. Previous work by
Alvarez-Suarez et al. has analyzed the phenolic content of Manuka honey via HPLC-MS, and it
is theorized that these components improve the intracellular antioxidant response [183]. In
addition, honey’s hydrogen peroxide content acts as an antiseptic against many types of bacteria
[184-186]. These properties and others have been reviewed in detail in previously published
literature [95, 100-103, 187-189].
The anti-inflammation and pro-healing properties of Manuka honey have led some
groups to incorporate it as an additive within biomaterials such as tissue engineering templates
[147-149, 152, 190]. As the implantation of these templates requires the creation of a wound site
and the associated increase in neutrophil presence, the effect of Manuka honey on neutrophil
activity is relevant to this line of research. Excessive neutrophil inflammatory activity has been
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implicated in the initiation of fibrosis, which can impede tissue-biomaterial integration [19]. The
ability of Manuka honey to modulate such neutrophil inflammatory activity would increase its
usefulness as a template additive. Of particular importance to this research are potential cytotoxic
effects of the honey, which could inhibit cell infiltration and proliferation within these templates.
As such, it is necessary to determine the concentration at which honey becomes cytotoxic to
neutrophils, and to investigate a range of honey concentrations to determine the optimum loading
and release levels for tissue engineering templates.
In this study, a specific variety of honey termed Manuka honey is used. In addition to the
effects described above, Manuka honey contains a methylglyoxal component which imbues it
with additional antimicrobial activity [96, 97]. This methylglyoxal component is primarily
responsible for the UMF, a term used by the industry to describe the heightened antimicrobial
activity of Manuka honey. After Manuka honey is collected, it is subject to a bacterial inhibition
test, and the UMF is defined as the concentration of phenol necessary to achieve the bacterial
inhibition of that Manuka honey sample (for instance, Manuka honey with a UMF of 15 would
exhibit the same bacterial inhibition as 15% phenol) [191]. This test is standardized and used
across the industry to compare the antimicrobial effects of various Manuka honey products [152,
192, 193]. As the properties of Manuka honey can vary slightly based on area of collection and
processing parameters, this test allows for a standardized measurement of the honey’s bacterial
inhibition properties.
Although the role of neutrophils has been classically considered to be primarily
phagocytic, recent research has demonstrated the ability of these cells to regulate wound healing
through the release of growth factors, chemo/cytokines, and proteases [194]. These cells arrive
through the bloodstream, travel via chemotaxis to the wound site soon after the occurrence of
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injury, and begin fighting bacterial invasion via phagocytosis, superoxide release, and the
extrusion of NETs [195]. Additionally, they release a wide variety of factors that recruit more
neutrophils, macrophages, and other inflammatory cells, and also amplify the overall
inflammatory response [196]. While this pro-inflammatory neutrophil activity is effective at
fighting bacterial invasion, the factors released by these cells can damage native tissue, impairing
wound healing [197]. However, in addition to this pro-inflammatory behavior, neutrophils also
have the ability to exhibit anti-inflammatory, pro-resolution behaviors [198, 199]. These
behaviors include inhibiting additional neutrophil recruitment to the wound site, downregulating
the degranulation of mast cells, releasing anti-inflammatory IL-10, promoting angiogenesis, and
inhibiting T-cell activation [197, 198, 200, 201]. The balance of these neutrophil behaviors is
important both in promoting acute inflammation and transitioning the wound from inflammation
to resolution and healing, and thus avoiding chronic inflammation [195, 198]. Given the
importance of neutrophils in controlling wound inflammation, as well as the growing clinical use
of Manuka honey as a wound additive with demonstrated anti-inflammatory properties, the effect
of Manuka honey on neutrophil behavior is of scientific interest [202].
One important indicator of the activation of the inflammatory response of the neutrophil is
the phosphorylation of IκBα, a regulatory protein which inhibits the inflammatory nuclear
transcription factor NF-κB by trapping it in the cytoplasm. NF-κB is a transducer for many
inflammatory pathways [203-206]. Upstream signal cascades trigger the phosphorylation of
IκBα, which is bound to NF-κB. As IκBα is phosphorylated, it releases NFκB, allowing it to
enter the nucleus and bind to response elements within the promoter regions in the DNA. By
binding to these regions, NF-κB upregulates the transcription of proinflammatory genes [207209].
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In this study, the human leukemia HL-60 cell line was differentiated and used as a model
of the neutrophil. This neutrophil model has been extensively characterized [210-212]. Certain
behaviors of primary neutrophils can vary substantially from donor to donor, including substrate
adherence, chemotaxis, cytokine release, and damage to surrounding cells/tissues [213-215].
Utilizing the dHL-60 model eliminates this variability and provides a reliable standard that can
be used by others in the field. These differentiated cells were polarized with LPS and fMLP as
inflammatory stimuli or TGF-β as an anti-inflammatory stimulus. These cells were cultured in a
range of concentrations of Manuka honey, and their behavior was characterized with regards to
cytotoxicity, superoxide release, chemotaxis and IκBα phosphorylation.
The hypothesis of this study is that Manuka honey reduces neutrophil inflammatory
behavior, specifically superoxide release, chemotaxis to the bacterial signal fMLP, and IκBα
phosphorylation, when present under the cytotoxic limit.

Materials and Methods

HL-60 culture and differentiation
HL-60s were purchased from ATCC (CCL 240, Manasses, VA, USA) and cultured at a
cell density range of 2 x 105 to 1 x 106 cells per mL in culture media consisting of RPMI
(Hyclone, Logan, UT, USA) with 10% v/v non-heat-inactivated FBS (Hyclone), 1% v/v
penicillin/streptomycin (Pen/Strep) (Corning, NY, USA) and 1% L-glutamine (Gibco, Billings,
MT, USA) (referred to as culture medium). Cells were incubated at 37°C in a 5% CO2
environment in T-25 and T-75 culture flasks (Thermo Scientific, Rochester, NY, USA). Medium
was changed every 3-4 days and cells were passaged when cell density reached 5 x 105 cells/mL.
Cells were used for passage numbers up to 30. These cells were differentiated to a neutrophil-
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like phenotype by adding 1.25% DMSO (Fisher Scientific, Hampton, NH, USA) to the culture
medium for six days, replenishing the medium/DMSO on the third day. This procedure has been
validated in previous studies [27, 28].
Confirmation of differentiation
Differentiation was confirmed morphologically by permeabilizing with 0.17 mM Triton
X-100 (Fisher Scientific) for 5 minutes, then fixing in 4% buffered paraformaldehyde (Fisher
Scientific) and staining with DAPI (NucBlue Fixed Cell Stain ReadyProbes reagent) for 5
minutes at stock concentration and phalloidin-conjugated Alexa Fluor 488 (ActinGreen 488
Ready Probes reagent) (both from Invitrogen, Carlsbad, CA, USA) for 30 minutes also at stock
concentration according to the manufacturer’s protocols. Cells were imaged with an Olympus
microscope (model BX34F) with an attached Olympus DP73 digital color camera and Olympus
U-HGLGPS fluorescent light source (Olympus, Shinjuku, Tokyo, Japan). The percentage of
differentiated cells (kidney-shaped nucleus) was calculated to be 69%, comparable to the
percentage reported in literature (see Supplemental section 1) [210, 216].
Cell stimulation
dHL-60s were incubated for each experiment in the presence of inflammatory and antiinflammatory stimuli at the cell densities described below in each procedure. Pro-inflammatory
responses were elicited by incubating dHL-60s with 1 µg/mL LPS (Invivogen, San Diego, CA,
USA) for 90 minutes, then adding 10-7 M fMLP (Sigma Aldrich, St. Louis, MO, USA)
immediately prior to use. Work by Nath et al. has previously shown these concentrations of LPS
and fMLP with a 90 minute polarization step to effectively stimulate superoxide release in
neutrophils [217]. Anti-inflammatory responses were elicited by incubating dHL-60s with 2
ng/mL TGF-β1 (Gibco) for 24 hours prior to use. While TGF-β levels on the order of pg/mL
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have been shown to elicit neutrophil migration, levels on the order of 2 ng/mL have been shown
to exist within the healing wound environment during peak neutrophil recruitment [218, 219].
Un-stimulated dHL-60s were used as an additional experimental control.
Mitochondrial activity assay
To begin this assay, 400,000 of non-stimulated (NS), inflammatory stimulated (LPS +
fMLP), and anti-inflammatory stimulated (TGF-β) dHL-60s were seeded in 150 µL culture
media in a 96 well plate containing 0, 0.1, 0.5, 1, 3, 5, 10, and 20% v/v concentrations of
Manuka honey/culture medium (UMF 12+, Manuka Guard, Monterey, CA, USA, density of 1.51
g/mL) alongside honey/medium blanks containing no cells. At 0, 3, and 24 hours, 30 µL of MTS
solution (CellTiter 96 Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI,
USA) was added to each well including the honey/medium blanks. After incubation at 37 °C for
1 hour, the absorbances of the samples were read at 490 nm using a SpectraMax i3x Multi-Mode
Detection plate reader (Molecular Devices, Sunnyvale, CA, USA). The absorbances of the
honey/medium blanks were subtracted from the corresponding samples, and the results were
expressed as relative mitochondrial activity. Statistical significance was measured via a two-way
ANOVA with a Holm-Sidak post hoc (α=0.05).
Trypan-exclusion assay
To conduct this assay, 400,000 of NS, LPS + fMLP-stimulated, and TGF-β-stimulated
dHL-60s were seeded in 150 µL in a 96 well in 0, 0.1, 0.5, 1, 3, 5, 10, and 20% v/v of Manuka
honey/medium for 3 and 24 hours. After culturing for their respective time periods, the liquid
and cells from each well were pipetted into microcentrifuge tubes. Then, 30 µL of trypsin
(Gibco) was pipetted into each well and incubated for 5 minutes at 37 °C to remove any
remaining adherent cells. After the incubation period, the trypsin was pipetted out of each well
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and added to the corresponding microcentrifuge tube, which was centrifuged at 200 X G for 10
minutes. Supernatants were discarded, and cells were resuspended in 75 µL culture media with
75 µL trypan blue (Gibco). The numbers of viable and non-viable cells in each sample were
counted with a Countess II FL Automated Cell Counter (Invitrogen). A two-way ANOVA with a
Holm-Sidak post hoc was performed to test for statistical significance between groups (α=0.05).
Superoxide production assay
For this study, 150,000 NS, LPS + fMLP-stimulated, and TGF-β-stimulated dHL-60s
were seeded in 150 µL culture media in 96 well plates in 0, 0.1, 0.5, 1,3,5,10, and 20% v/v of
honey with 100 µM ferricytochrome C (Sigma Aldrich) in accordance with a previously defined
procedure [217, 220, 221]. After 1, 3, and 24 hours of culture, the absorbance at 550 nm was
measured using the Spectramax plate reader. Honey/medium blanks of each honey concentration
were run alongside the cell samples, and the absorbances of these blanks were subtracted from
the cell samples to get the absorbance due to ferricytochrome C reduction. The results were
displayed as relative superoxide production. Statistical significance was measured via a two-way
ANOVA with a Holm-Sidak post hoc (α=0.05).
Chemotaxis assay
Polystyrene transwell inserts with a 6.5 mm diameter polyester membrane perforated by
3.0 µm diameter pores (Costar, Kennebunk, ME, USA) were used to measure chemotaxis via an
adaptation of a previously defined method [222]. Briefly, 500,000 NS dHL-60s were seeded in
the top inserts in 100 µL of culture medium, and 650 µL of culture medium with 50 nM fMLP
and 0, 0.5, 3, and 20% honey was placed in the bottom chamber (fluid levels were the same
height when the top inserts were placed onto the bottom chambers to avoid net fluid flow from
one chamber to another). One additional control was run of NS cells seeded in top inserts above

56

chambers containing medium with no honey or fMLP to establish the amount of cell movement
that happens in the absence of a chemokine. Samples were incubated for 3 hours. At the end of
the incubation period, the top inserts were removed from the bottom chambers. The contents of
each top and bottom chamber were pipetted out into microcentrifuge tubes. 30 µL of trypsin was
added to each top chamber, and 650 µL of trypsin was added to each bottom chamber, and then
the plates were incubated at 37° C for 5 minutes. Trypsin was then removed from each top and
bottom chamber and added to the respective microcentrifuge tubes, which were then centrifuged
at 200 x G for 10 minutes. Supernatants were removed and discarded, and each sample was
resuspended in 75 µL of RPMI and 75 µL of trypan blue. The numbers of viable and non-viable
cells in each sample were then counted with a Countess II FL Automated Cell Counter
(Invitrogen). Statistical significance was measured via a two-way ANOVA with a Holm-Sidak
post hoc (α=0.05).
IKBα phosphorylation Western blot
Preliminary experimentation indicated that peak IκBα phosphorylation occurs 38 minutes
after the addition of LPS and fMLP at the same time to the culture medium. Accordingly, in this
set of experiments the LPS was added with the fMLP at time 0, rather than 90 minutes before
time 0 as was done in the above experiments. TGF-β was still added to its group 24 hours before
time 0. NS, LPS + fMLP, and TGF-β-stimulated dHL-60s were seeded at 400,000 cells per well
in 150 µL of culture media in 96 well plates with 0, 0.5, and 3% v/v Manuka honey and
incubated for 38 minutes. Plates were then placed on ice and cells were removed and lysed in 50
µL RIPA buffer (Thermo Scientific), using trypsin to remove remaining cells. Lysates were
centrifuged at 13,000 x G at 4°C for 15 minutes to pellet the cell membrane detritus, and the
supernatant was saved. Samples were denatured with LDS sample buffer and DTT reducing
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agent (both from Invitrogen) at 70° C for 10 minutes. Proteins were subjected to gel
electrophoresis using 3-8% Tris-Acetate gels (Invitrogen) and transferred to polyvinylidene
difluoride membranes (Millipore, Burlington, MA, USA). Membranes were washed 5 times with
TBS (Thermo Scientific), blocked with TBS blocking buffer (Thermo Scientific) for an hour,
then incubated overnight at 4° C in mouse anti-human IκBα primary antibody (MAB4299, R&D
Systems, Minneapolis, MN, USA) at a 0.1 µg/mL concentration and rabbit anti-human phosphoIκBα (S32/S36) primary antibody (AF4809, R&D Systems) at a 1 µg/mL concentration in TBS
blocking buffer. Following 5 washes in TBS with 0.1% Tween 20 (Fisher Scientific), the
membrane was incubated at room temperature in IRDye 680RD Donkey anti-mouse secondary
(P/N 925-68072) and IRDye 800CW Donkey anti-rabbit secondary (P/N 925-32213) (both from
Li-Cor Biosciences, Lincoln, NE, USA) at a 1:20,000 dilution in TBS blocking buffer with 0.1%
Tween 20 and 0.01% sodium dodecyl sulfate (Fisher Scientific) for one hour. The membrane
was washed 3 times in TBS with 0.1% Tween 20, one time in TBS, and then scanned on an
Odyssey CLx infrared imaging system (Li-Cor Biosciences). The relative fluorescence of the
800 nm and 700 nm channels was calculated for the relevant bands of each sample, subtracting
out background fluorescence from the area around the bands using Image Studio™ version 5.2
software. Samples were run in groups of 3 concurrent lanes on two separate Western blots (total
of 6 samples per group). Each Western blot had 3 lanes of non-stimulated dHL-60s cultured
without honey, and the relative fluorescence ratio of all other samples was normalized to this
control. Statistical significance was measured via a two-way ANOVA with a Holm-Sidak post
hoc (α=0.05).

58

Results

MTS mitochondrial assay
Figure 8 shows the mitochondrial activity of cells of all three stimulation groups
incubated at various concentrations of honey in (a) the first hour of incubation, (b) from hours 3
to 4, and (c) from hours 24 to 25. As shown by the red asterisks, a statistically significant
decrease in mitochondrial activity begins at 3% honey and becomes more pronounced as honey
concentration increases. This effect becomes stronger at the 3-4 hour and 24-25 hour time
windows, suggesting a cytotoxic effect of the honey that begins in the range of 3-5% and
becomes more accentuated at higher honey concentrations. These data sets also show that the
mitochondrial activity of the TGF-β-stimulated cells decreases relative to the other two groups at
the 3-4 hour and 24-25 hour time windows. This finding could indicate that the antiinflammatory effect of the TGF-β stimulation decreases the overall cellular metabolism, although
further studies would be necessary to confirm this hypothesis. As shown in Figure 8c, the
mitochondrial activity of the NS group is significantly upregulated at 0.5% and 1% honey,
possibly indicating increased cellular metabolism of this phenotype at these intermediate honey
concentrations.
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Figure 8. Mitochondrial activity of NS, LPS/fMLP and TGF-β-stimulated dHL-60s at various
concentrations of honey for hours (a) 0-1, (b) 3-4, and (c) 24-25 of culture. Values are
normalized relative to the 0-1 hour NS 0% honey mitochondrial activity. * indicates statistical
significance from the respective 0% honey value of that phenotype/timepoint, and + indicates
statistical significance from the other two phenotypes at that honey concentration and
timepoint. α=0.05, measured via two-way ANOVA with Holm-Sidak post hoc.

Trypan exclusion assay
Figure 9 displays the number of viable (trypan-excluding) and non-viable (non-trypanexcluding) cells of each stimulation group after 3 and 24 hours of culture with various
concentrations of honey. At the 3-hour timepoint, there is a significant decrease in viable (a) NS,
(c) LPS + fMLP, and (e) TGF-β-stimulated cells and an increase in non-viable cells of each
group at 20% honey, with this trend beginning at 5% honey in the TGF-β group and 10% honey
in NS group, indicating cytotoxicity at these concentrations. At the 24-hour timepoint, this
significant drop off in viable (d) LPS + fMLP-stimulated cells and increase in non-viable cells is
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seen at 3% honey and up, and in (b) NS and (f) TGF-β-stimulated cells, this effect happens at 5%
honey and up. These data confirm the findings from the mitochondrial activity data that there is
weak cytotoxicity in the 3-5% honey range and strong cytotoxicity at concentrations higher than
5% honey. The counts of the TGF-β group at 3 and 24 hours also confirm that the drop in
mitochondrial activity occurred in this group at 3-4 hours and 24-25 hours is not a result of
increased cell death of this phenotype, but rather decreased mitochondrial activity of viable cells
relative to the other two phenotypes.
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Figure 9. Viable and non-viable cell counts of NS, LPS + fMLP-stimulated, and TGF-βstimulated dHL-60s cultured at each honey concentration for 3 (a, c, e) and 24 (b, d, f)
hours. * indicates a statically significant difference from the respective 0% honey control
of each cell type, viable or non-viable, at each timepoint. α=0.05, measured via one-way
ANOVA with Holm-Sidak post hoc.
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Superoxide production
Figure 10 shows the superoxide production of all three stimuli groups after 1, 3, and 24
hours of culture. As expected, the LPS + fMLP samples have significantly greater superoxide
production at 0% honey at 1 and 3 hours relative to the other two stimuli groups (positive
control). However, this difference decreases as honey concentration increases and superoxide
production increases in the NS and TGF-β groups. This trend indicates that within the first three
hours, concentrations of 3% honey and above stimulate superoxide production in equal to or in
excess of the superoxide production stimulated by LPS and fMLP in both NS and TGF-βstimulated neutrophils, and also further stimulates superoxide production in the LPS + fMLP

C

Figure 10. Superoxide production of the NS, LPS + fMLP-stimulated, and TGF-βstimulated dHL-60s cultured at each honey concentration for (a) 1, (b) 3, and (c) 24 hours.
Values are shown relative to the 0% honey NS 1-hour value. * indicates statistical
significance from the respective 0% honey value of that phenotype, and + indicates
statistical significance from the other two phenotypes. α=0.05, measured via two-way
ANOVA with Holm-Sidak post hoc.
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group. However, as shown in Figure 10c at the 24-hour timepoint, there is an opposite trend with
regards to honey concentration. At levels of 3% honey and above, superoxide levels significantly
decrease in all three groups relative to the 0% honey control. Part of this decrease is likely due to
the cytotoxic effect of these higher honey concentrations (addressed in the discussion section).
Additionally, the TGF-β group has lower superoxide production than the other groups at
intermediate honey concentrations (0.5% and 1%) at 1 and 3 hours, (significant at 0.5% honey at
the 3-hour timepoint), and has significantly less superoxide production relative to the other two
phenotypes at the 24 hour timepoint at honey concentrations of 1% and lower. However, these
cells did significantly increase their superoxide production at 3%, 5%, and 10% honey at the 1hour mark and at 5% honey at the 3-hour timepoint, relative to their 0% honey control. At the
24-hour timepoint, the total cell numbers (trypan-excluding and not trypan-excluding) at 5%
honey are lower than the seeded number. This discrepancy could be due to the destruction of
non-viable cells or the phagocytosis of the non-viable cells by the live ones. However, additional
experimentation would be required to confirm this assumption.
Chemotaxis
Figure 11 shows the results of the transwell chemotaxis assay. These results show the
total amount of cells, both viable and non-viable, present in the top and bottom wells after the 3hour incubation period. The significant decrease in migration in the no fMLP control relative to
the 0% honey sample indicates that the cells are migrating from the top wells to the bottoms in
response to the presence of fMLP throughout the 3-hour experiment. Similarly, the significant
decrease in migration in the 0.5%, 3%, and 20% honey samples indicates that Manuka honey
reduces this chemotactic response, decreasing the amount of migration to a level at or below the
random walk level seen in the no fMLP control. The 20% honey sample had a significant
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decrease in the number of cells in both the top and bottom chambers, most likely due to the
cytotoxicity of this honey concentration and the effect described above with respect to Figure 9.

Figure 11. Chemotaxis of 500,000 dHL-60s to 50 nM fMLP in various concentrations of honey.
Cell numbers in top and bottom chambers were measured using a Countess II FL automated
cell counter. * indicates a statistically significant difference in cell number from the 0% honey
sample. α=0.05, measured via one-way ANOVA with Holm-Sidak post hoc
IκBα phosphorylation
Figure 12 displays the normalized IκBα phosphorylation values for each sample type at 0,
0.5, and 3% honey. As expected, IκBα phosphorylation was significantly greater in the LPS +
fMLP samples relative to the NS samples in the absence of honey. At 0.5% honey, IκBα
phosphorylation in the LPS + fMLP group was significantly lowered from the 0% honey
samples, but still significantly greater than the NS samples. At 3% honey, IκBα phosphorylation
in the LPS + fMLP group was significantly lower than both the 0% and 0.5% samples, and not
significantly different from the NS group. These results indicate that Manuka honey lowers IκBα
phosphorylation in a dose-dependent fashion when activated via LPS and fMLP, reducing the
activity of this inflammatory signal cascade. As expected, TGF-β stimulation caused no
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significant difference in IκBα phosphorylation relative to the NS group, and the presence of
Manuka honey did not significantly affect IκBα phosphorylation in the NS or TGF-β group.

a

b

Figure 12. (a) representative Western blot bands of p~IκBα and total IκBα for each sample
type. (b) IκBα phosphorylation expressed as the ratio of p~IκBα to total IκBα, normalized
to NS 0% honey control. * indicates a statistically significant difference from the NS
control at that respective honey level. + indicates a statistically significant difference from
the other concentrations of honey for that stimulus group. α=0.05, measured via two-way
ANOVA with Holm-Sidak post hoc.
Discussion
The results of this study confirm the hypothesis that Manuka honey reduces neutrophil
superoxide release, chemotaxis to fMLP, and the activation of the NF-κB pathway (IκBα
phosphorylation) when present in concentrations under the cytotoxic limit. The MTS
mitochondrial assay and the trypan-exclusion assay establish a cytotoxic limit of Manuka honey
beginning between 3-5% v/v and increasing in cell death with increased honey concentration and
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time (Figures 8-9). Figure 10a indicates that concentrations of 3% honey and above cause an
increase in superoxide release during the first hour of culture, suggesting that honey could
amplify the initial acute inflammation response. However, Figure 10c demonstrates that after 24
hours of culture, concentrations of 1% honey and above significantly reduce superoxide levels.
From Figures 8-9, we know that concentrations of 5% honey and above cause cytotoxicity,
which is likely the major contributor to the decrease in superoxide release at these honey levels.
Figure 3c indicates a significant drop in superoxide release at the 1% honey level, which did not
cause any cytotoxicity. Therefore, this drop at 1-3% honey is likely due to honey reducing the
superoxide output of the cells via anti-inflammatory effects, rather than cytotoxicity. The
chemotaxis and IκBα results also indicate that Manuka honey significantly reduces cell
migration and IκBα phosphorylation in a dose-dependent manner (Figures 4-5). Together, these
experimental results indicate that Manuka honey has a significant anti-inflammatory effect on
this in vitro neutrophil model.
These results agree with findings that have been previously published. Sell et al.
conducted cytotoxicity testing using human dermal fibroblasts, human pulmonary microvascular
endothelial cells, and human peripheral blood macrophages, and observed a cytotoxic limit at 5%
v/v Manuka honey and above for all cell types, in line with our results [110]. Leong et al. tested
the effect of several varieties of Manuka honeys on human neutrophil superoxide production and
found superoxide inhibition IC50 values to range from 4.2-37.9 mg/mL when stimulated by 0.2
µg/mL PMA. As neither the density of their Manuka honey varieties nor the time duration of the
assay was reported, a direct comparison between their results and ours cannot be made. Knowing
the density would allow the reported weight percent values to be converted to volume percent,
enabling a direct comparison of their honey range to ours. However, both sets of results indicate
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a general trend of honey decreasing superoxide release. The Leong et al. study also involved the
topical application of these honey samples to a murine arachidonic acid ear wound model, and
observed decreased neutrophil infiltration into the wound over a 4-hour period post-application
[97]. This finding concurs with our chemotaxis assay results. A 2018 publication by Gasparrini
et al. tested the effect of Manuka honey on NF-κB expression and IκBα phosphorylation in LPSstimulated RAW 264.7 macrophages, and found that the honey reduced IκBα phosphorylation
and NF-κB expression in these cells in a dose-dependent manner [223]. This study agrees with
our IκBα results, indicating that honey acts through the NF-κB pathway via IκBα to reduce
inflammatory behavior. Our results in this study thus broadly concur with the results of
previously published literature.
The mechanisms through which Manuka honey affects the dHL-60 neutrophil model are
unknown, and possibly involve a combination of processes initiated by different Manuka honey
components. Alvarez-Suarez et al. have theorized that polyphenolic components of the honey,
such as pinocembrin or pinobanksin, cross the cellular membrane to scavenge intracellular free
radicals and trigger AMPK phosphorylation, increasing antioxidant enzyme expression [183].
Evidence gathered by Gasparrini et al. demonstrates that Manuka honey increases the
intracellular expression of antioxidant enzymes such as glutathione peroxidase, glutathione
reductase, and glutathione s-transferase in macrophages, supporting the Alvarez-Suarez theory
[223]. Ultimately, more work is necessary to fully elucidate the mechanisms of action of Manuka
honey on neutrophils and other relevant cell types.
Despite the fact that these studies were conducted in vitro, certain inferences can be made
regarding the role Manuka honey plays in the wound site. When Manuka honey is used clinically
as a wound treatment, it is typically either daubed directly onto the wound and covered with a
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bandage, soaked into a cloth dressing which is then covered with a secondary dry dressing to
fasten the honey dressing to the wound, or incorporated into a hydrogel dressing [224]. These
methods of application cause the surface of the wound to experience a high concentration of
Manuka honey, potentially in excess of the 20% v/v honey concentration used as the highest end
of the honey concentration range in this study. Given the cytotoxicity results reported in this
study, it is likely that the surface of the wound experiences a “zone of death”, where the
bactericidal and osmotic effects combine to kill not only foreign bacteria, but also native human
cells, including large numbers of neutrophils which arrive in the wound soon after injury [110].
As the honey diffuses down into the wound environment and becomes more dilute, it is possible
that the deeper wound environment encounters honey concentrations closer to the 0.5% and 3%
concentrations investigated in this study. The exact concentrations of the honey at relevant
penetration depths within the wound is speculative, and has yet to be measured in vitro.
However, according to this study, such honey concentrations would initially promote the
neutrophils in the wound to release superoxide, amplifying the acute response within the first
hour of application. However, as time continues, this trend reverses, causing the neutrophils to
attenuate their superoxide release in the presence of the honey. Meanwhile, the honey’s osmotic
potential starts a slow net flow of exudate from the deep tissue through the wound bed and out to
the wound surface, washing debris and bacteria from the wound site. It is possible that this flow
also carries the neutrophils in the wound up to the cytotoxic “zone of death”, and as they are
killed they are initially replaced by naïve neutrophils through the bloodstream. However, as
shown by the chemotaxis results in this study, the presence of honey decreases neutrophil
chemotaxis in response to the fMLP. Additionally, the IκBα phosphorylation results indicate that
the honey will begin down-regulating the NF-κB pathway, reducing the expression of
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inflammatory behaviors in neutrophils in the presence of inflammatory stimuli like LPS and
fMLP. Thus, in a honey-treated wound, the time of the acute inflammation phase is likely
shortened, with fewer and fewer neutrophils chemotaxing to the wound site over time and a
reduced inflammation response in the cells encountering inflammatory stimuli.
In addition to their role in wound inflammation, neutrophils also play a part in several
inflammation-related pathologies [19, 225]. Excessive neutrophil activity contributes to the
formation of atherosclerotic plaque [225], tissue damage associated with chronic obstructive
pulmonary disorder [226], tumor formation [227], and inflammatory bowel disease [228-230],
among other conditions. The ability of Manuka honey to decrease neutrophil recruitment and
inflammatory behavior represents a potential therapeutic opportunity for these pathologies. In
particular, a 2008 study by Prakash et al. demonstrated that oral administration of Manuka honey
significantly reduced colonic inflammation in a rat inflammatory bowel disease model [231].
Although this specific application has yet to be replicated in humans, this study demonstrates the
promise of Manuka honey-based therapies in treating inflammation-related pathologies.
The results detailed in this paper demonstrate in vitro the specific effects of Manuka honey
that enable it to shorten and resolve wound inflammation in vivo. They also point towards possible
advantages of a lower level, longer term controlled release delivery of the honey to avoid
counterproductive cytotoxic effects. As these results show, the inflammation-resolving effects of
Manuka honey are present at and below the 3% v/v level. As such, a controlled release of 3% v/v
or below Manuka honey from an implanted tissue engineering template would minimize
inflammation around the template, allowing faster and more complete healing and tissue-template
integration. This effect makes Manuka honey a useful addition to templates for a wide variety of
tissue regeneration applications.
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Future research will involve examining the effect of Manuka honey on the release of
molecular signals (pro-inflammatory, anti-inflammatory, chemokines, matrix-degrading, and proangiogenic) from this neutrophil model. Additionally, Manuka honey will be incorporated into
electrospun tissue templates to examine the effect of honey incorporation on neutrophil NETosis.
These experiments will create a better understanding of how honey affects the orchestration of the
inflammatory, angiogenic, and inflammation-resolving processes within the wound. As the degree
of NETosis has been demonstrated to correlate with fibrous capsule formation and rejection of
implanted templates in vivo, the NETosis experiments will also inform our understanding of the
potential of Manuka honey to improve tissue-template integration and reduce capsule formation.
Future research should also include investigation into the effects of other honey varieties on
neutrophil inflammatory behaviors. While Manuka honey is the current focus of this paper due to
its prevalence in the would healing field, it is possible that other honey varieties may be as or even
more effective at reducing neutrophil inflammatory behaviors. An in vivo wound healing model
should also be used to confirm the effects described in this paper and measure the honey
concentration gradient within the wound.
Conclusion
In this study, the effect of various concentrations of Manuka honey on NS, LPS + fMLP,
and TGF-β-stimulated dHL-60 neutrophil models was observed in several ways. First, a
moderate cytotoxic effect was found to begin at 3-5% honey and become stronger as honey
concentration increased. Concentrations of Manuka honey at 3% and above were found to
amplify superoxide production in the first 1-3 hours of culture, but then suppress superoxide by
24 hours of culture. Furthermore, concentrations of 0.5% and above were found to significantly
suppress chemotaxis to fMLP and reduce IκBα phosphorylation. These results suggest that
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Manuka honey has an anti-inflammatory effect on neutrophils, reducing their recruitment to the
wound site, their superoxide production, and their intracellular inflammatory signaling.
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CHAPTER 4
THE EFFECT OF MANUKA HONEY ON dHL-60 CYTOKINE, CHEMOKINE, AND
MATRIX-DEGRADING ENZYME RELEASE UNDER INFLAMMATORY
CONDITIONS
Introduction
Neutrophils, the first-responding leukocytes which enter a wound site soon after injury,
orchestrate the initiation, amplification, and resolution of the inflammatory response. In addition
to their role as phagocytes, in which they engulf and destroy invading bacteria, neutrophils
release a host of molecular agents which affect the inflammatory state of the wound. In the
presence of bacterial signals such as LPS and fMLP or native inflammatory signals such as IFNγ or GM-CSF, neutrophils become pro-inflammatory, releasing superoxide and proteases which
degrade bacteria and native ECM, recruiting more immune cells, and perpetuating the cycle of
inflammation [232-235]. In the presence of anti-inflammatory signals such as TGF-α or IL-4,
neutrophils attenuate their superoxide and protease release and instead release
immunosuppressive agents such as IL-1ra [54, 62, 236, 237]. An initial proinflammatory
response is beneficial in that it kills bacteria, frees vascular endothelial cells for angiogenesis,
and recruits a host of T-cells, eosinophils, basophils, monocytes, and NK cells to continue
fighting infection [54, 234, 238, 239]. However, persistent, non-resolving inflammatory
neutrophil activity has been implicated in chronic inflammation that impedes wound healing and
causes sepsis [240-242]. Additionally, this activity has been linked to inflammatory diseases
such as rheumatoid arthritis and atherosclerosis [243-245]. It is necessary to develop and
optimize treatments to shift neutrophils from this inflammatory state to an anti-inflammatory
state to resolve such pathological inflammation.
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Manuka honey, a variety of honey produced from the nectar of the New Zealand shrub
Leptospermum scoparium, has demonstrated remarkable wound healing properties. The high
sugar concentration of Manuka honey creates an osmotic gradient when placed on a wound,
drawing fluid and nutrients from deeper tissue up through the wound and flushing bacteria and
debris from the site [246, 247]. Flavonoids derived from the honey’s floral sources scavenge free
radicals, reducing tissue damage, while the low pH of the honey increases fibroblast and
macrophage activity and helps oxygenate the wound [101, 183, 246]. Previous work by AlvarezSuarez et al. has quantified this phenolic content of Manuka honey via HPLC-MS, and the
authors theorized that these components improve the intracellular antioxidant response [183].
The honey also protects the wound site, creating a viscous layer at the top which impedes
additional bacterial deposition and keeps the wound hydrated, and the high sugar content
provides a glucose source for proliferating fibroblasts and endothelial cells in the area [247].
Manuka honey kills bacteria via its osmotic potential and the presence of methylglyoxal [99,
104-106, 248]. In vitro testing has indicated the effectiveness of Manuka honey against a variety
of bacteria, including antibiotic-resistant bacteria such as MRSA [99, 249-251]. These protective
and pro-healing effects of Manuka honey in wounds have been demonstrated both in animal
models and clinical trials [127, 131, 133, 135, 252-256]. However, some animal models and in
vitro testing have indicated that high concentrations of Manuka honey can have a deleterious
cytotoxic effect [110, 138, 257]. These findings indicate that research should focus on
concentrations of Manuka honey that are low enough to avoid this cytotoxic effect.
In this study, a dHL-60 model of a neutrophil is used. The HL-60 cell line can be
differentiated to a neutrophil-like phenotype using DMSO in a procedure that has been welloptimized [212]. Because neutrophil cytokine release can vary from donor to donor, it was
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decided to use this standardized cell model for greater reproducibility [214]. Release levels have
been compared between dHL-60s and human peripheral blood neutrophils of several cytokines
and chemokines, including TNF-α, IL-1β, IL-6, IL-12, CXCL8/IL-8, CCL2/MCP-1, CCL3/MIP1α, CCL4/MIP-1β, and CCL5/RANTES. Release was compared under control and LPSstimulated conditions, and the study found that although minor quantitative differences existed in
the levels of some of these cytokines, the overall cytokine response was qualitatively similar
between the two cell types at each condition [54]. This differentiated cell line model has become
a useful tool to study neutrophil cytokine/chemokine release [258, 259].
We have previously reported several effects of Manuka honey on this dHL-60 model,
including reducing superoxide release, chemotaxis, and activation of the inflammatory
transcription factor NF-κB. Additionally, we found that levels of Manuka honey at 5% v/v or
above were cytotoxic to the dHL-60s, in line with what previous studies have reported in other
cell types [110, 260]. As such, in this effort, we focus on concentrations of honey below this
cytotoxic limit.
This study investigates the effect of Manuka honey on cytokine, chemokine, and matrixdegrading enzyme release of the dHL-60 model under pro-inflammatory stimuli. Four different
stimulating factors (2 exogenous and 2 endogenous) were used. The bacterial product fMLP acts
on a GCPR to initiate the β-arrestin pathway, the PLC β 2/3 pathway, and the PI3-kinase
pathway to induce actin reorganization, NADPH oxidase activity, and granule release [261, 262].
LPS, a bacterial outer membrane component, acts on the Toll-like receptor 4 to initiate the
MYD88 pathway, increasing production of a variety of inflammatory cytokines for release [263].
GM-CSF binds a cytokine receptor and acts through the JAK/STAT pathway, PI3K pathway,
and SHC pathways to prime neutrophil oxidative metabolism and cytokine expression [264-266].
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IFN-γ similarly binds its cytokine receptor and acts through the JAK/STAT pathway to increase
inflammatory cytokine expression [267, 268]. The dHL-60s were cultured in the presence of
these stimulators by themselves and in combination for 3 or 24 hours, and their supernatant was
assayed for the proinflammatory signals TNF-α, IL-1β, CCL5/RANTES, and IL-12 p70, the antiinflammatory signals IL-1ra and IL-4, the matrix reorganization enzymes MMP-1, MMP-9, and
Proteinase 3, the growth factors FGF-13 and VEGF, and the chemoattractants CXCL8/IL-8,
CCL3/ MIP-1α, CCL4/MIP-1β, CCL2/MCP-1, and CCL20/MIP-3α. The experiments were
repeated in the presence of 0.5% v/v and 3% v/v Manuka honey to ascertain the effect of
Manuka honey on cytokine, chemokine, and matrix-degrading enzyme release. These
experiments will inform the greater understanding of how Manuka honey affects neutrophils
within a wound site, and how those effects can be harnessed as a biomaterial additive.
Materials and Methods
HL-60 culture and differentiation
HL-60 cells purchased from ATCC (CCL240) (Manasses, VA, USA) were cultured at a
cell density range of 2 x 105 to 1 x 106 cells per mL in RPMI (Hyclone, Logan, UT, USA) with
10% v/v non-heat-inactivated FBS, 1% v/v Pen/Strep, and 1% L-glutamine (hereafter referred to
as culture medium), all purchased from Hyclone (Logan, UT, USA). Cells were grown at 37°C
in a 5% CO2 incubator in T-25 and T-75 culture flasks (Thermo Scientific, Rochester, NY,
USA). During culture, medium was changed every 3-4 days and cells were passaged when cell
density reached 5 x 105 cells/mL. Cells were used for passage numbers up to 30. Differentiation
to a neutrophil-like phenotype was accomplished using a procedure validated in previous studies
[210, 269]. Briefly, cells were differentiated by adding 1.25% DMSO (Sigma Aldrich, St. Louis,
MO, USA) to the culture medium for six days, replenishing medium/DMSO on the third day.
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Differentiation was confirmed morphologically by permeabilizing with 0.17 mM Triton X-100
(Fisher Scientific, Hampton, NH, USA) for 5 minutes, then fixing in 10% buffered formalin
(Fisher Scientific, Hampton, NH, USA) and staining with DAPI (NucBlue Fixed Cell Stain
ReadyProbes reagent) for 5 minutes at stock concentration and phalloidin-conjugated Alexa
Fluor 488 (ActinGreen 488 Ready Probes reagent) (both from Invitrogen, Carlsbad, CA, USA)
for 30 minutes also at stock concentration according to the manufacturer’s protocols. Cells were
imaged with an Olympus microscope (model BX34F) with an attached Olympus DP73 digital
color camera and Olympus U-HGLGPS fluorescent light source (Olympus, Shinjuku, Tokyo,
Japan). The percentage of differentiated cells (kidney-shaped nucleus) was calculated to be 69%,
comparable to the percentage reported in literature [210, 270].
Cytokine release experiment
To initiate the experiments, dHL-60s were seeded in a 96 well plate at 400,000 cells per
well (8 million cells/mL) in 150 µL of culture media with either no additives (control), 1 µg/mL
LPS, 10-7 M fMLP, 100 U/mL GM-CSF, 100 U/mL IFN-γ, both 1 µg/mL LPS and 10-7 M fMLP,
both 1 µg/mL LPS and 100 U/mL IFN-γ, or all four of 1 µg/mL LPS, 10-7 M fMLP, 100 U/mL
GM-CSF, and 100 U/mL IFN-γ (LPS from InvivoGen, San Diego, CA, USA, fMLP from Sigma
Aldrich, St. Louis, MO, USA IFN-γ and GM-CSF from R&D Systems, Minneapolis, MN, USA).
Concentrations of these analytes used are based on prior studies. 100 U/mL GM-CSF has been
demonstrated to optimize TLR2 and CD14 expression and IL-8 release in neutrophils [265].
Similarly, 100 U/mL IFN-γ has been demonstrated to maximize MIP-1α and MIP-1β release
when used in conjunction with LPS [271]. The combination of 1 µg/mL LPS and 10-7 M fMLP
maximizes neutrophil superoxide output [272]. Cells were cultured for 3 or 24 hours, and then
centrifuged to remove and save supernatant. This supernatant was analyzed using a multiplexed
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magnetic bead immunoassay (R&D Systems, Minneapolis, MN, USA) on a MAGPIX® reader
(Luminex, Austin, TX, USA). These results were analyzed to determine the stimuli and
combinations which elicited the greatest overall release response. Based on these results, it was
decided to focus on the groups stimulated with LPS, LPS and fMLP, and all-four stimuli (LPS,
fMLP, IFN-γ, and GM-CSF). The experiment was then repeated with these stimulation groups in
the presence of 0.5% and 3% Manuka honey (UMF 12+, Manuka Guard, Monterey, CA, USA)
alongside honey/media blanks which contained no cells. Honey was added at the same time as
the stimulus (timepoint 0). These supernatants were assayed using the MAGPIX® immunoassay.
Additionally, a control group and an LPS-stimulated group without honey were run again for 24
hours and their values were compared against the values from the first kit run to determine
reproducibility. All supernatant samples were initially run using a dilution factor of 2 in assay
diluent, and select samples whose readings were above the Max LOD were re-run using a
dilution factor of 200 in assay diluent.
Statistical Analysis
Non-parametric methods were used for comparisons due to the data distributions. The
results of the control group and LPS-stimulated group measured in two subsequent assay runs
were compared using a non-parametric alternative to the two-sample t-test, called the Wilcoxon
rank sum test, for each analyte. Using an α=0.05 value, no significant differences were found
between the assay runs, indicating reproducibility and allowing comparisons to be made between
the assay runs. Comparisons between stimulation groups at each honey level (0, 0.5, and 3%)
and between honey levels within stimulation groups were analyzed using the Kruskal Wallis test.
The Bonferroni p-value adjustment was used to account for multiple comparisons (α=0.05).
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Differences between timepoints within stimulation groups at each honey level were also tested
using the Wilcoxon rank sum test (α=0.05).
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Results

Figure 13. Released levels of various cytokines, chemokines, and matrix-degrading enzymes
at 3 and 24 hours in pg/mL: Scale bars are mean ± standard deviation. * indicates a
statistically significant difference from the nonstimulated control cells at that respective
timepoint. No statistically significant differences were found between timepoints within
treatment groups. Brackets with + indicate particular stimulation groups that are statistically
significant from each other. A Kruskal-Wallis test was used with a Bonferroni adjustment for
multiple comparisons, while a Wilcoxon rank sum test was used to establish significant
differences between timepoints for each stimulation type (α=0.05). Analytes are grouped by
trend (A-E). N=3.
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The released levels of each analyte at 3 and 24 hours in the absence of honey are
displayed in Figure 13. These figures are grouped by trend, and all individual p values for the
comparisons shown in this paper are given in the supplementary material. The differences
mentioned in this Results section are statistically significant unless noted otherwise. The TNF-α
data, grouped alone in Figure 13A, illustrates that TNF-α release is increased by LPS with a
synergistic effect contributed by fMLP. TNF-α levels had a non-significant decreasing trend
from 3 to 24 hours for the groups stimulated with LPS, IFN-γ and LPS, and LPS and fMLP. The
results displayed in Figure 13B indicate that IL-1β release occurs only in the presence of all-four
stimuli (LPS, fMLP, IFN-γ and GM-CSF) and occurs after the first 3 hours post-stimulation.
Figure 13C contains the release results for MMP-1, CCL5/RANTES, CCL20/MIP-3α, MMP-9,
IL-12 p70, and VEGF. These analytes had minimal release at the 3-hour timepoint and an
increasing trend from the LPS group to the LPS, fMLP group to the all-four stimuli group (nonstatistically significant in CCL20/MIP-3α and IL-12 p70). The MMP-1 and VEGF data indicate
an increase in release in the GM-CSF-stimulated group relative to non-stimulated control,
although this group is much lower than the LPS-stimulated group in the MMP-1 results.
Together, these results suggest that of the stimuli used in this study, LPS is the most effective
driver of release for these analytes, with fMLP providing a synergistic effect and the
combination of all-four stimuli providing an additional synergistic increase.
Figure 13D contains the CCL3/MIP-1α, CCL4/MIP-1β, and FGF-13 release data. These
results indicate release at both 3 and 24 hours in the groups stimulated with LPS, IFN-γ and LPS,
LPS and fMLP, and all-four stimuli, with a non-significant increasing trend from 3 to 24 hours.
CCL3/MIP-1α had an increase between the LPS and LPS, fMLP group at 3 hours, but a nonsignificant decrease between these groups at 24 hours. In contrast, the CCL4/MIP-1β results

81

indicate an increasing trend between the LPS and LPS, fMLP groups at both 3 and 24 hours (not
statistically significant at 3 hours). The FGF-13 results also reveal an increasing trend at 24 hours
between the groups stimulated with LPS, LPS and fMLP, and all-four stimuli (non-statistically
significant). Similar to the results displayed in Figure 1A and 1C, these results suggest that LPS
is the most effective of the stimuli at causing release of these analytes, with the addition of fMLP
causing a synergistic response (not present at 24 hours in CCL3/MIP-1α). The use of all-four
stimuli caused an additional non-significant synergistic increase in FGF-13 release, but did not
affect CCL3/MIP-1α release and caused a non-significant decreasing trend at 3 hours in
CCL4/MIP-1β release.
Figure 13E contains the release results for IL-1ra, CCL2/MCP-1, Proteinase 3,
CXCL8/IL-8, and IL-4. The IL-1ra, and IL-4 results indicate an increase in release at 24 hours in
the GM-CSF group, less than the LPS-stimulated group for IL-1ra and for IL-4 at 3 hours but
near the LPS group at 24 hours in IL-4. The release of IL-4 was greater in the LPS, fMLP and
all-four stimuli groups than the LPS group alone at 24 hours, while IL-1ra release was near to or
exceeded the maximum level of detection (Max LOD) in all groups with LPS at both 3 and 24
hours. MCP-1 release exceeded the Max LOD in all groups except the culture media control,
control cells, and fMLP at 24 hours, but at 3 hours had a non-significant increase in all LPSstimulated groups relative to non-LPS groups. Proteinase 3 release likewise was close to or
exceeded the Max LOD for all groups except LPS, fMLP and culture media at 24 hours, but at 3
hours had no apparent increase in any of the stimulation groups. IL-8 release approached or
exceeded Max LOD for all groups except the IFN-γ group, culture media, control cells, fMLP at
24 hours, and GM-CSF at 3 hours. These results indicate that all stimuli except IFN-γ increase
IL-8 release. Together, these results suggest that LPS is the most effective stimulus at causing
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IL-1ra, IL-4, and MCP-1 release, but has no effect on Proteinase 3 release and may not be more
effective than fMLP or GM-CSF at causing IL-8 release.

Figure 14. Released levels at 3 hours in the absence of honey or presence of 0.5, and 3%
Manuka honey. Scale bars are mean ± standard deviation. * indicates a statistically significant
difference from the non-stimulated control at that respective honey level, ^ indicates a
statistically significant difference from the non-honey group of that stimulation type, and ^
indicates a statistically significant difference from the 0.5% honey group of that stimulation
type. A Kruskal-Wallis test was used with a Bonferroni adjustment for multiple comparisons
to establish significant differences between stimulation types at each honey level and between
honey levels at each stimulation type (α=0.05). Analytes are grouped by trend (A-D). N=3.
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Figure 14 contains the release data at 3 hours in the presence of 0.5% and 3% Manuka
honey, grouped by trend. Figure 14A displays the TNF-α release data and indicates that TNF-α
release was increased in the presence of 3% honey relative to 0 and 0.5%. Release at all
concentrations of honey was maximal in the LPS, fMLP group. TNF-α was the only analyte
measured whose release was increased by 3% honey.
Figure 14B contains the release results for IL-1β, CCL20/MIP-3α, CCL5/RANTES,
CXCL8/IL-8, Proteinase 3, MMP-1, and VEGF. These analytes had their release increased in all
or most stimulation groups in the presence of 0.5% honey. The LPS, fMLP group had the highest
release of IL-1β, CCL20/MIP-3α, and MMP-1 in both the absence and the presence of honey,
while 0.5% honey reduced the release of CCL5/RANTES and VEGF in this group. Release of
CXCL8/IL-8 was above the Max LOD in most groups, making it difficult to discern trends for
this analyte. However, CXCL8/IL-8 release was increased in the control cells in the presence of
0.5% honey. Proteinase 3 release was above the Max LOD for all 0.5% honey samples, and was
higher than the 0% honey samples in all stimulation groups except LPS, in which this difference
was not statistically significant. 3% honey caused release of IL-1β, CCL20/MIP-3α,
CCL5/RANTES, MMP-1, and VEGF to be minimal, but caused no change from the non-honey
sample in Proteinase 3 release. IL-8 release increased in the presence of 3% honey in the control
cells, but had a non-significant decreasing trend in the LPS-treated cells relative to the nonhoney samples. In general, these results reveal that 0.5% honey increased release while 3%
honey decreased release for the analytes in Figure 2B.
The release data for FGF-13, IL-1ra, CCL4/MIP-1α, CCL2/MCP-1, CCL3/MIP-1α, and
IL-4 are displayed in Figure 14C. In general, 0.5% honey either had no effect or caused a
decrease in the release of these analytes relative to the non-honey samples, and 3% honey caused
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release to become negligible. The LPS, fMLP group had the highest release of CCL4/MIP-1α
and CCL3/MIP-1α at 0 and 0.5% honey, and also caused release of IL-1ra above Max LOD. In
contrast, the FGF-13, CCL2/MCP-1, and IL-4 release data indicate no discernable trend between
stimulation groups, but had a general decrease in release as honey concentration increases.
Figure 14D indicates that there was no release above the Min LOD for MMP-9 or IL-12 p70 at
this 3-hour timepoint.
Figure 15 displays the 24-hour release data for each stimulation group at 0, 0.5, and 3%
honey. Similar to the results shown in the 3-hour data, the TNF-α results are grouped by
themselves in Figure 15A and show an increase in all stimulation groups in the presence of 3%
honey. The greatest release was observed in the LPS, fMLP group, which exceeded the Max
LOD. As in the 3-hour results, TNF-α was the only analyte whose release was increased in the
presence of 3% honey in all stimulation groups.
Figure 15B contains the release data for IL-1β, FGF-13, CCL5/RANTES, CCL3/MIP-1α,
CCL4/MIP-1β, IL-12 p70, CCL2/MCP-1, MMP-9, MMP-1, IL-1ra, and IL-4. These analytes did
not increase in most or all stimulation groups at the 0.5% honey level, and many were decreased
by this concentration of honey. There was a trend of increasing release between the control cells
and the groups stimulated with LPS, LPS and fMLP, and all-four stimuli in the IL-1β, FGF-13,
CCL5/RANTES, IL-12 p70, MMP-9, and MMP-1 results at 0% honey. However, 0.5% honey
obscured this trend for all of these analytes. 3% honey reduced release of these analytes to
minimal with only a few exceptions: the all-four stimuli group in the CCL2/MCP-1 results, the
LPS, fMLP and all four-stimuli group in the IL-1ra results, and the all four-stimuli group in the
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IL-4 results. Even in these few exception groups, however, release at 3% honey was lower than
the release at the 0 and 0.5% honey levels.

Figure 15. Released levels at 24 hours in the absence of honey or presence of 0.5, and 3%
Manuka honey. Scale bars are mean ± standard deviation. * indicates a statistically
significant difference from the non-stimulated control at that respective honey level, ^
indicates a statistically significant difference from the non-honey group of that stimulation
type, and ^ indicates a statistically significant difference from the 0.5% honey group of that
stimulation type. A Kruskal-Wallis test was used with a Bonferroni adjustment for multiple
comparisons to establish significant differences between stimulation types at each honey
level and between honey levels at each stimulation type (α=0.05). Analytes are grouped by
trend (A-C). N=3.
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In Figure 15C, the release results for CCL20/MIP-3α, CXCL8/IL-8, Proteinase 3, and
VEGF are displayed. These analytes had release results in one or more groups that were
increased in the presence of 0.5% honey relative to the 0% honey release levels. 0.5% honey
increased the release of CCL20/MIP-3α in the control cells and all stimulation groups. In the
CXCL8/IL-8 release results, almost all of the readings were above the Max LOD, making it
difficult to draw conclusions about the effect of honey on the release of this analyte. However, it
can be observed that release was increased by both 0.5 and 3% honey in the control cells group.
Proteinase 3 and VEGF release were increased by 0.5% honey in all groups except the LPS,
fMLP group, where release was attenuated by this honey concentration. It is unknown why this
trend of increasing release at 0.5% honey would be reversed in the LPS, fMLP group, and this
effect is deserving of further study. Release of CCL20/MIP-3α, Proteinase 3, and VEGF was
attenuated in the presence of 3% honey in all groups. However, release of CXCL8/IL-8 was
increased by 3% honey in the control cells. As CXCL8/IL-8 release at all honey concentrations
exceeds the Max LOD in the non-control groups, this trend cannot be confirmed or refuted in
these groups.
Figure 16 contains four analytes whose concentrations were above their respective Max
LOD values of the assay when originally measured using a dilution factor of 2. This figure
displays the values of select 24-hour samples measured utilizing a dilution factor of 200 to
extend the range of the assay. The CXCL8/IL-8 results shown in Figure 16A indicate that 0.5%
honey increases release in the LPS, fMLP group and causes a non-significant increasing trend in
the all four-stimuli groups. 3% honey had no effect on release in the LPS group, caused a
decrease in the release of the LPS, fMLP group, and appeared to non-significantly increase
release in the all-four stimuli group although this result had a high degree of variance. Figure
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Figure 16. Released levels of CXCL8/IL-8, IL-1ra, CCL2/MCP-1, and Proteinase 3 at 24
hours in the absence of honey or presence of 0.5, and 3% Manuka honey, measured using a
dilution factor of 200 to assay levels above the Max LOD of the earlier assay. Values are
expressed as mean ± standard deviation. * indicates a statistically significant difference from
the non-stimulated control at that respective honey level, ^ indicates a statistically significant
difference from the non-honey group of that stimulation type, and ^ indicates a statistically
significant difference from the 0.5% honey group of that stimulation type. A Kruskal-Wallis
test was used with a Bonferroni adjustment for multiple comparisons to establish significant
differences between stimulation types at each honey level and between honey levels at each
stimulation type (α=0.05). N=3.
16B indicates that 0.5% honey caused a non-significant increase in IL-1ra release in the LPS,
fMLP group but lowered release in the LPS and all four-stimuli groups below the Min LOD. 3%
honey lowered IL-1ra release in all groups. In Figure 16C, CCL2/MCP-1 release was nonsignificantly increased in the LPS, fMLP group by 0.5% honey, while release in the other two
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groups was decreased by 0.5% honey. 3% honey caused IL-1ra release to be minimal in all
stimulation groups. Figure 16D displays the Proteinase 3 release data, indicating that release had
a non-significant increasing trend caused by 0.5% honey in the groups stimulated by LPS and
all-four stimuli, but minimal release in all groups in the presence of 3% honey.
It should be noted that the non-honey results in Figure 16D are below the Proteinase 3
release levels displayed for the non-diluted samples in Figure 15, indicating a discrepancy in the
values measured between these two experimental runs. This discrepancy could be due to the
degradation of the supernatant samples, as they went through a freeze/thaw cycle between the
two assay runs. However, it can be seen in the LPS group that the relationship between the 0.5%
honey and the non-honey groups is the same, that is, the 0.5% honey group is higher than the
non-honey group on both data sets. The results of all parts of this figure have a high degree of
variability, which is likely due to the large dilution factor. Nevertheless, the results suggest a
trend of greater release of IL-8, IL-1ra, and MCP-1 in the LPS, fMLP group relative to the LPS
and LPS, fMLP, IFN-γ, GM-CSF groups. This trend is increased in the presence of 0.5% honey.
In contrast, Proteinase 3 trended towards much higher levels in the LPS and LPS, fMLP, IFN-γ,
GM-CSF groups with 0.5% honey than in the other stimulation groups. The presence of 3%
honey caused a non-significant decreasing trend of IL-1ra and MCP-1 release in all groups.
Although the Proteinase 3 release values of the 3% honey samples are below the Min LOD in
this figure, Figure 15 indicates that 3% honey decreases Proteinase 3 release in all groups. As
observed in Figure 15, however, 3% honey has no significant effect on IL-8 release in any group.
Discussion
The clinical usage of Manuka honey typically involves the topical application of non-diluted
Manuka honey to the wound site [131, 133, 135, 255, 273, 274]. While variations of this method
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have demonstrated effectiveness for in vivo wound healing, in vitro testing has indicated that
Manuka honey concentrations of 5% v/v or above are cytotoxic [110, 260]. This cytotoxic effect
has been verified in vivo in chinchilla ears and ovine frontal sinuses [257, 275]. It is likely that
when applied to a wound, Manuka honey creates a “zone of death” at the surface which kills
bacteria and native human cells alike. As the honey diffuses deeper into the wound environment,
it becomes more dilute. However, the majority of implanted tissue engineering devices will not be
open to the surface and will not be able to slough off dead cells and excess honey. As such, tissue
engineering efforts have focused on incorporating Manuka honey into templates that can release
it into the template interior or surrounding tissue at levels below the cytotoxic limit [153, 174, 187,
274-278]. The 0.5% and 3% v/v levels of honey used in this study are similar to the levels of honey
likely to be encountered by a neutrophil entering a wound bed or interacting with a honey-laden
tissue template. As the implantation of such a template necessitates the creation of a wound,
infiltrating neutrophils will encounter an inflammatory environment which has been modeled in
this study using LPS, fMLP, IFN-γ, GM-CSF, and various combinations of these stimuli. The
effect of Manuka honey on neutrophils within inflammatory environments is highly relevant to the
modulation of tissue-template interactions and the desired resolution of inflammation and
induction of healing and regeneration.
The cytokine release results indicate that of the stimuli tested, LPS is the main driver of the
release of the majority of the analytes tested, including both inflammatory and anti-inflammatory
signals. When combined with LPS, fMLP had synergistic effects on release for most analytes. In
contrast, the IFN-γ, LPS group only caused a non-statistically-significant increase in the release
of CCL3/MIP-1α, CCL4/MIP-1β, CCL20/MIP-3α, MMP-1, and VEGF at 24 hours relative to
LPS alone. For some analytes, release was decreased by the combination of all-four stimuli
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relative to the other stimulation groups. These analytes include TNF-α (24-hour timepoint),
CCL3/MIP-1α (3-hour timepoint), CCL4/MIP-1β (3-hour timepoint), and CCL20/MIP-3α (3hour timepoint). For other analytes, though, release was increased by the combination of all-four
stimuli. These groups include IL-1β (24-hour timepoint), CCL5/RANTES (24-hour timepoint),
IL-12 p70 (24-hour timepoint), MMP-9, MMP-1, Proteinase 3 (24-hour timepoint), VEGF (24hour timepoint), and IL-4 (24-hour timepoint). These results are to be expected given that
different signaling receptors and pathways are activated by LPS, fMLP, IFN-γ, and GM-CSF as
discussed in the introduction section. The activation of these mechanisms causes release to be
increased over the levels observed when only one or two of these mechanisms are activated.
The introduction of Manuka honey into this system caused a change in release that was
highly dependent upon the concentration of honey present. 0.5% honey caused a decrease in all
or most stimulation groups in the release of most analytes. In contrast, the release of IL-1β,
CCL20/MIP-3α, CCL5/RANTES, Proteinase 3, VEGF, CXCL8/IL-8, and CCL2/MCP-1 was
increased at one or both timepoints by the presence of 0.5% honey. 3% honey caused a decrease
in the release of all analytes at all timepoints except TNF-α and CXCL8/IL-8. As TNF-α and
CXCL8/IL-8 are pro-inflammatory signals, these results suggest that 3% honey has a proinflammatory effect in this model.
A similar study by Tonks et al. corroborates this pro-inflammatory effect in vitro in
monocytes. In this study, the culture media of an MM6 cell line monocyte model and human
peripheral blood monocytes was supplemented with 1% v/v of several honey types, including
Manuka honey, and the release of IL-1, IL-6, and TNF-α was measured over 24 hours. All honey
types tested, including Manuka honey, caused a significant increase in IL-6, IL-1, and TNF-α
release in both the MM6 cells and the peripheral blood monocytes over control cells with no
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honey or artificial sugar syrup [109]. The increase in the release of these cytokines (particularly
the ~8-fold increase in the pro-inflammatory TNF-α) suggests a pro-inflammatory effect of the
honey similar to that suggested by the results of 3% honey in this study. However, the results
from multiple in vivo models indicate an opposite, anti-inflammatory effect of Manuka honey
[252, 253, 279]. In particular, a study by Zhodi et al. utilized a Gelam honey-loaded (Gelam is a
variety of honey similar to Manuka) PVP/PEG hydrogel in a rat burn wound model, and found
that the honey hydrogels caused a significant reduction in the expression of IL-1α, IL-1β, and IL6 expression within the wound site [280]. This expression was measured from total RNA taken
from the wound, so it is unknown how much of this RNA is from neutrophils, macrophages,
fibroblasts, etc., but nevertheless these results point to a general inflammation-reducing effect of
the honey in vivo. Unfortunately, TNF-α expression in the wound was not measured, so it is
unknown whether the honey increases its in vivo expression. The release of honey from the
hydrogel was not quantified, so it is also unknown what the level of honey is in the wound at
each timepoint. Nevertheless, this study is currently the best measure of honey’s in vivo effect on
cytokine production within a wound. In a 2014 review paper, Majtan theorized that honey’s
pro/anti-inflammatory effects are dependent on the state of the wound environment, upregulating
inflammation in acute wounds while downregulating inflammation in chronically-inflamed
wounds. While there is some evidence to suggest this effect, as detailed in the review, more
investigation is needed to fully explore and verify this claim [281].
Another factor to consider is the number of neutrophils that arrive at the wound site. A 2011
study by Leong et al. used arachidonic acid to create inflammation in a mouse model, and found
that the topical application of Manuka honey reduced the infiltration of neutrophils into the
wound site by around a factor of 2 [97]. We have also previously reported that Manuka honey

92

reduces dHL-60 chemotaxis to fMLP [260]. As such, while our results indicate that 3% honey
increases TNF-α release at both 3 and 24 hours, it is possible that the overall drop in neutrophil
number, coupled with the decrease in release of all other factors measured in this study except
IL-8, causes the inflammation decrease observed in vivo. The results at 0.5% honey are more
confounding, with no clear pattern between the effect of the analyte (e.g. pro-inflammatory,
ECM-degrading, angiogenic, or anti-inflammatory) and its change in release levels relative to
non-honey controls. Although TNF-α, CCL3/MIP-1α, and CCL4/MIP-1β were decreased at both
timepoints in most or all samples, CCL20/MIP-3α, CCL5/RANTES, and CXCL8/IL-8 all were
increased in one or more sample groups by this concentration of honey. Thus, no definitive
conclusion can be drawn from these results regarding the effect of 0.5% honey on the regulation
of inflammation by neutrophils. As shown above, both concentrations of Manuka honey
decreased MMP-9 and MMP-1 production at the 24-hour timepoint. As excessive amounts of
MMPs have been implicated in ongoing tissue damage during chronic inflammation, this MMP
regulating effect of the honey may be a key component to the reduction of tissue damage [4,
241]. Ultimately, an in vivo study in which different concentrations of honey are applied to a
wound model will be necessary to ascertain the effect of low (below 1% v/v) honey
concentrations on the resolution of inflammation and activation of the healing response.
Although the mechanisms by which Manuka honey causes these cellular effects are not
fully known, it is theorized that the phenolic components of honey, which include known
bioactive molecules like pinobanksin and pinocembrin, can cross the cellular membrane [262,
282-284]. Under this theory, these phenolic molecules neutralize free radicals within the cell and
trigger AMPK phosphorylation, increasing the expression of antioxidant enzymes and modifying
numerous intracellular pathways [183, 285]. While this proposed mechanism of action is
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plausible, more work is required to fully validate it and elucidate other possible methods by
which Manuka honey modifies neutrophil behavior. It should be noted that Manuka honey has
previously been shown to contain trace amounts of LPS, although these levels are below the
minimum needed to stimulate most neutrophil inflammatory behaviors [109, 286]. Nevertheless,
this LPS content may play a role in the cytokine profiles reported in this paper, as one bioactive
component among many. As Manuka honey is a natural product, there is no practical way to
eliminate this LPS component, nor is it necessary. The clinical and in vitro evidence described in
the introduction demonstrates that Manuka honey has valuable pro-healing effects in spite of its
trace LPS content.
Conclusion
The results of this study indicate that Manuka honey drastically changes the release of
cytokines, chemokines, and matrix-degrading enzymes from the dHL-60 neutrophil model. This
change is highly dependent on the concentration of honey present and the inflammatory
preconditioning of the cells. These findings suggest that honey-releasing tissue engineering
templates could elicit a variety of effects with regards to neutrophil behavior and inflammation
resolution depending on the release profile of the honey from the template. Future work will
focus on the effect of honey on dHL-60s under anti-inflammatory conditions (i.e. TGF-α, IL-4,
IL-13) and the in vivo modulation of inflammation by honey-containing templates with different
honey loads and release profiles.
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CHAPTER 5
MANUKA HONEY MODULATES THE RELEASE PROFILE OF A dHL-60
NEUTROPHIL MODEL UNDER ANTI-INFLAMMATORY STIMULATION
Introduction
Manuka honey, a variety of honey indigenous to New Zealand, has been widely
researched as a wound treatment due to its extraordinary wound-healing properties [183, 187,
247, 274]. These properties include reducing bacterial infection, an effect attributed to its
methylglyoxal and hydrogen peroxide content, as well as accelerating wound closure [99, 127,
183, 189, 247, 287, 288]. Manuka honey’s high sugar concentration creates an osmotic effect
within the wound, causing a flow of liquid and nutrients from the deeper subcutaneous tissue into
the wound and flushing debris and bacteria out of the wound bed [246, 247]. This high sugar
concentration also gives the honey a viscous quality, creating a protective covering over the
wound which hydrates the area and prevents additional bacterial deposition [247]. The sugars
also provide a nutrient source for proliferating cells such as endothelial cells and fibroblasts
[247]. Manuka honey’s acidic pH increases wound oxygenation as well as fibroblast and
macrophage activity [101, 246]. The flavonoids within the honey react with free radicals,
reducing tissue damage within the wound [101, 246]. These flavonoids have been quantified via
HPLC-MS analysis, and are also theorized to improve the antioxidant response of cells within
the wound [183]. These properties have been corroborated in several animal models and clinical
trials [92, 127, 135, 252, 253, 255]. A few analyses, however, have demonstrated that high
concentrations of Manuka honey can have a counterproductive cytotoxic effect [110, 257, 289].
We have previously reported a cytotoxic limit of 5% v/v Manuka honey, and as such, use
concentrations below this limit in this current work [260].
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Within a period of minutes to hours after the occurrence of injury, neutrophils swarm the
wound site and begin orchestrating the inflammatory response within the wound [19, 290]. These
cells kill bacteria through phagocytosis and reactive oxygen species release and produce a
variety of cytokines, chemokines, and matrix-degrading enzymes. These mediators recruit more
neutrophils and other immune cells, activate inflammatory pathways within those newly
recruited cells, and break down the ECM within the wound site to clear debris and free vascular
endothelial cells for angiogenesis [232, 234, 291]. This initial acute inflammatory phase is
necessary for the destruction of bacteria and removal of dead cells and damaged ECM from the
wound. However, if this inflammation persists and becomes chronic, it can prevent the wound
from healing [240-242]. In addition to their pro-inflammatory role, however, neutrophils also
have the capability to release anti-inflammatory mediators, decreasing inflammatory behaviors in
the surrounding immune cells, reducing further immune cell recruitment, and promoting wound
healing [292-294]. This anti-inflammatory activity contributes to the resolution of acute
inflammation within the wound, preventing the wound from being stuck in a phase of chronic
inflammation and allowing it to heal.
In this study, the effect of Manuka honey on neutrophil anti-inflammatory activity is
investigated using a dHL-60 model of a neutrophil. The HL-60 cell line is a promyelocytic
progenitor that can be differentiated to a neutrophil-like phenotype using DMSO [212, 269, 295,
296]. The use of this model eliminates the donor-to-donor variability found in the primary
neutrophil cytokine response, and it has been previously validated as a model of neutrophil
cytokine release [54, 214]. We have investigated the effects of Manuka honey on this model, and
reported reduced superoxide release, chemotaxis, and activation of the inflammatory
transcription factor NF-κB in the presence of Manuka honey concentrations below the cytotoxic
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limit of 5% v/v [260]. In addition, we have investigated Manuka honey’s effect on the dHL-60
cytokine release profile in the presence of several inflammatory stimulators, and found a dosedependent effect of reducing several inflammatory mediators and ECM-degrading components
[297].
This study investigates the dHL-60 release of cytokine, chemokine, and matrix-degrading
enzymes under anti-inflammatory stimuli in the presence of Manuka honey. Three antiinflammatory stimuli were used: TGF-β, IL-4, and the combination of IL-4 and IL-13. TGF-β
activates the SMAD/RSMAD pathway, while IL-4 activates the Akt/PKB pathway, and, in
concert with IL-13, the Jak/STAT pathway [298-300]. These signals have been demonstrated to
reduce neutrophil superoxide production and activate neutrophil release of the anti-inflammatory
factor IL-1ra [62, 237]. The dHL-60s were preconditioned with these stimulators (TGF-β, IL-4,
and IL-4 + IL-13) for 72 hours prior to the addition of Manuka honey to allow for the activation
of their respective pathways, and then cultured with both their respective stimulators in the
absence of honey or the presence of 0.5% or 3% v/v Manuka honey for 3 or 24 hours. The
supernatant of these cultures was then assayed for several pro-inflammatory signals, antiinflammatory signals, matrix degrading enzymes, angiogenic growth factors, and
chemoattractants. To validate these findings, primary human neutrophils were cultured with 0,
10, 100, or 1000 ng/mL IL-4 in the absence of honey or presence of 0.5% or 3% v/v Manuka
honey for 3 or 24 hours. Supernatant collected from these samples was assayed for MMP-9,
VEGF, and IL-1ra, and these results were compared to the cytokine production of the dHL-60
neutrophil model in the absence of honey or presence of 0.5% or 3% v/v Manuka honey. These
experiments reveal the impact of Manuka honey on neutrophil cytokine output under antiinflammatory stimulation, informing future honey-based therapies and biomaterials.
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Materials and Methods
HL-60 culture and differentiation
The HL-60 cells were obtained from ATCC (CCL240) (Manasses, VA, USA) and
cultured in RPMI 1640 with 10% v/v non-heat-inactivated FBS, 1% v/v penicillin/streptomycin,
and 1% L-glutamine (hereafter referred to as culture media), all obtained from Hyclone (Logan,
UT, USA). Cells were cultured at a density ranging from 2 x 105 to 5 x 105 cells per mL. These
cells were maintained at 37 °C in a 5% CO2 incubator. Throughout the culture period, medium
was changed every 3-4 days and cells were passaged at a cell density of 5 x 105 cells/mL. Cells
were discarded after reaching a passage number of 30. HL-60s were differentiated to a
neutrophil-like phenotype using a previously validated procedure, adding 1.25% DMSO (Sigma
Aldrich, St. Louis, MO, USA) to the culture medium for 6 days and replenishing medium/DMSO
on the third day [210, 212]. The morphology of these differentiated cells was observed by
permeabilizing the cells with 0.17 mM Triton X-100 (Fisher Scientific, Hampton, NH, USA) for
5 minutes, then fixing in 10% buffered formalin (Fisher Scientific, Hampton, NH, USA) and
staining with DAPI (NucBlue Fixed Cell Stain ReadyProbes reagent) for 5 minutes at stock
concentration and phalloidin-conjugated Alexa Fluor 488 (ActinGreen 488 Ready Probes
reagent) (both from Invitrogen, Carlsbad, CA, USA) for 30 minutes also at stock concentration
according to the manufacturer’s protocols. Imaging was conducted using an Olympus
microscope (model BX34F) with attached Olympus DP73 digital color camera and Olympus UHGLGPS fluorescent light source (Olympus, Shinjuku, Tokyo, Japan). The percentage of
differentiated cells (kidney-shaped nucleus) was calculated to be 69%, comparable to the
percentage range of 60-90% reported in literature [210, 270, 301].
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Cytokine release experiment
First, dHL-60s were pre-conditioned for 72 hours with their respective stimuli. Cells were
maintained in T-75 culture flasks (Thermo Scientific, Rochester, NY, USA) and either not
stimulated (control) or stimulated with 2 ng/mL TGF-β, 10 ng/mL IL-4, or both 10 ng/mL IL-4
and 10 ng/mL IL-13. Concentrations of these analytes were taken from prior published studies
[62, 260]. After the 72-hour pre-conditioning period, the dHL-60s were seeded in a 96-well
culture plate at 400,000 cells per well (2.67 million cells per mL) in 150 µL of culture media
with their respective stimuli and in the presence of 0%, 0.5%, and 3% Manuka honey (UMF 12+,
Manuka Guard, Monterey, CA, USA) alongside honey/medium blanks which contained no cells.
Cells were cultured for 3 or 24 hours and then centrifuged, and supernatants were removed and
saved. These supernatants were analyzed using a multiplexed magnetic bead immunoassay
(R&D Systems, Minneapolis, MN, USA) on a MAGPIX® reader (Luminex, Austin, TX, USA).
Additionally, a control group cultured for 24 hours without Manuka honey was run again and its
values were compared against the values from the first kit run to determine reproducibility.
Primary human neutrophil experiments
Neutrophils were isolated from healthy donor blood obtained from Tennessee Blood
Services as specified by protocols approved by the University of Tennessee Institutional Review
Board as previously described [5]. After the neutrophils were isolated, they were resuspended in
RPMI 1640 with 1% L-glutamine, 5% penicillin/streptomycin, and 5% human serum isolated
from the same donor blood as the neutrophils (hereafter referred to as RPMI+). Neutrophils were
seeded into a 96-well culture plate at 400,000 cells per well (2.67 million cells per mL) in 150
µL of RPMI+ with the respective concentration of IL-4 and Manuka honey and cultured for 3 or
24 hours. Immediately following the culture period, plates were placed on ice for 10 minutes to
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inhibit the further stimulation of the neutrophils. Samples were pipetted into microcentrifuge
tubes and centrifuged at 300 x G for 5 minutes to separate out the cells, and the supernatants
were frozen and saved for analysis. 20 µL of trypsin (Gibco, Dublin, Ireland) was added to each
well, and the culture plates were placed back in the incubator for 5 minutes to lift any remaining
adherent cells. After the incubation period, 20 µL of RPMI+ was added to each well to inactivate
the trypsin, and then the trypsin/media was removed from each well and added to labeled
microcentrifuge tubes, which were then centrifuged at 300 x g for 5 minutes. Supernatants were
discarded, and cells were resuspended in 75 µL RPMI+ with 75 µL trypan blue (Gibco). The
numbers of viable and non-viable cells in each sample were counted with a Countess II FL
Automated Cell Counter (Invitrogen). Two unique experiments were performed with cells
isolated from two unique same-gender (male) and age-matched (between 20 and 40 years of age)
donors, and the results were pooled.
Statistical Analysis
Groups were compared using non-parametric methods due to the data distributions. The
results of the control group between the two assay runs were compared using the Wilcoxon rank
sum test for each analyte. To be conservative in our identification of statistically significant
differences, values below the Min LOD were treated as though they were equal to the Min LOD
during the statistical analysis. Using an α=0.05, there were no significant differences found
between the dHL-60 assay runs, which indicates reproducibility and allows for comparisons to
be made between the assay runs. Stimulation groups at each honey level (0%, 0.5%, and 3%)
were compared using the Kruskal Wallis test with a Bonferroni p-value adjustment to account for
multiple comparisons (α=0.05). To control the family-wise error rate, the current anti-
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inflammatory data were analyzed a priori alongside pro-inflammatory stimulation groups, results
of which have been reported in a previous publication. 50
Results
dHL-60 experiments
The release results of each analyte at each level of honey after 3 hours of culture are
displayed in Figure 17, grouped into boxes by trend. In general, 3% honey decreased the levels
of all analytes except TNF-α and IL-8, while 0.5% honey increased the release of both proinflammatory and anti-inflammatory analytes compared to the non-honey controls. Box A
contains the results for TNF-α, the only analyte which had the highest release in the presence of
3% honey in all groups except the TGF-β-stimulated group. The presence of 0.5% honey also
increased TNF-α release relative to the respective non-honey groups in the cells stimulated with
TGF-β, IL-4, and IL-4 + IL-13. These data indicate that TGF-β has a statistically-significant
suppressive effect on TNF-α release at 3% honey, but at 0.5% honey it significantly increases
TNF-α release relative to the non-stimulated control. In contrast, stimulation by IL-4 and IL-4 +
IL-13 increased TNF-α release at 0.5% honey relative to the non-stimulated cells (statistically
significant in the IL-4 + IL-13 group). However, at 3% honey there was only a non-significant
trend of increased TNF-α in the IL-4 + IL-13 group relative to the non-control cells, with no
difference in the IL-4 group from the control.
Box B contains analytes whose release was highest when in the presence of 0.5% honey.
This trend was the strongest in the CCL3/MIP-1α, CCL4/MIP-1β, and CCL20/MIP-3α results,
where release was minimal in all groups at 0.5% and 3% honey but significantly increased at
0.5% honey in all stimulated groups relative to the non-honey control. All three of these analytes
had the greatest release in the TGF-β-stimulated group at 0.5% honey. In the CCL20/MIP-3α
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data, the TGF-β-stimulated group was about six times higher than the other groups at 0.5%
honey, while in the CCL3/MIP-1α and CCL4/MIP-1β data the IL-4 and IL-4 + IL-13 groups had
a little over half of the release of the TGF-β-stimulated group at 0.5% honey. Release of
CXCL8/IL-8 and IL-1ra exceeded the Max LOD of the assay in the experimental groups cultured
in 0.5% honey. CXCL8/IL-8 release was also significantly increased by 3% honey in the control
group and IL-4 + IL-13 group relative to their non-honey release, while IL-1ra release was
minimal in all groups in the presence of 3% honey. Significant release of IL-4 and CCL2/MCP-1
in the absence of honey occurred primarily in the IL-4 and the IL-4 + IL-13 groups, with
negligible release in the TGF-β-stimulated cells. Although 0.5% honey significantly increased
release of these analytes and 3% honey significantly decreased their release relative to nonhoney controls, the trend of increased release in the IL-4 and IL-4 + IL-13 groups over the TGFβ group persisted at each honey level. Release of MMP-1, FGF-13, VEGF, and IL-1β only
exceeded the Min LOD in the presence of 0.5% honey, with the release of FGF-13 and IL-1β
relatively equivalent across all stimulated groups close to Min LOD. VEGF release was highest
in the control cells at 0.5% honey, with levels decreased in each stimulated group relative to the
control (significant in the IL-4 and IL-4 + IL-13 groups). In contrast, MMP-1 levels at 0.5%
honey were higher in each stimulated group than in the non-stimulated control cells (significant
in the TGF-β and IL-4 + IL-13 groups).
Box C displays the release of MMP-9 and IL-12 p70, neither of which were above the
Min LOD of the assay in any group. Box D contains release results for Proteinase 3 and
CCL5/RANTES, both of which had the highest release in the control cells at 0.5% honey. As the
release of both of these analytes is significantly increased by 0.5% honey in the control cells
relative to non-honey samples, but not in any of the stimulation groups, it is likely that however
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the honey is activating Proteinase 3 and CCL5/RANTES release, this mechanism is suppressed
by each of the anti-inflammatory stimulators. Because this stimulation was done for 72 hours
prior to the addition of the honey to the cells, it is likely that by the time the honey is added, the
expression mechanisms for Proteinase 3 and CCL5/RANTES are suppressed.
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Figure 17. Release levels of cytokines, chemokines, and matrix-degrading enzymes in the
absence of honey or presence of 0.5% or 3% honey at 3 hours. Bars indicate mean ± standard
deviation. * indicates a statistically significant difference from the non-stimulated control at the
respective honey level, ^ indicates a statistically significant difference from the non-honey group
at that stimulation type, and ^ indicates a statistically significant difference from the 0.5% honey
group at that stimulation type. Values below Min LOD are shown as 0. The Kruskal-Wallis test
was used with a Bonferroni multiple comparisons adjustment to establish significant differences
between stimulation types at each honey level and between honey levels at each stimulation type
(α = 0.05). Analytes are grouped by trend (A–D). Sample size = 3 independent replicates.
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Figure 18 displays the release results for each of these analytes at 24 hours, grouped by
trend. Similar to the results seen at 3 hours, 3% honey decreased the release of all analytes
except TNF-α and IL-8, which were increased relative to the non-honey samples. Likewise, the
presence of 0.5% honey increased the release of most analytes relative to non-honey samples,
including both pro-inflammatory and anti-inflammatory factors. As in Figure 1, TNF-α is
grouped by itself in Box A and had significantly higher release in the presence of 3% honey than
0.5% honey or the absence of honey. At 3% honey, release was significantly less in the TGF-βstimulated group than the control or the IL-4 and IL-4 + IL-13 groups. Similar to the results
shown in Figure 1, these results suggest that TGF-β has a significant suppressive effect on the
release of TNF-α at 3% honey, putting the cells in a state that is resistant to the secretion of TNFα. Box B contains the release results for CXCL8/IL-8. As release exceeded the Max LOD in all
groups at 0.5% and 3% honey, and in the IL-4-stimulated non-honey group, distinctions cannot
be made between these groups. However, these results do indicate that both 0.5% and 3% honey
increase CXCL8/IL-8 release relative to the non-honey groups in the control, TGF-β, and IL-4 +
IL-13 groups. IL-4 stimulation also increased IL-8 release in the non-honey group relative to the
non-stimulated control.
VEGF release results are contained within Box C. These results indicate that 0.5% honey
causes a non-statistically significant increase in VEGF release in the control cells relative to the
non-honey samples (p=0.09), but this increase is not present in any of the stimulated groups.
This trend is similar to that seen in the VEGF results in Figure 16, which suggests that the antiinflammatory stimulators have a suppressive effect on the release of VEGF at 0.5% honey. Box
D displays the release results for Proteinase 3. Although release exceeded the Max LOD for the
0.5% honey control cells and the non-honey IL-4 and IL-4 + IL-13 groups, some conclusions can
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still be drawn from these results. The presence of 0.5% honey significantly decreased release in
the IL-4 and IL-4 + IL-13 groups, while 3% honey decreased release in all groups relative to the
non-honey samples (significant in the control, IL-4, and IL-4 + IL-13 groups). These data
suggest that the anti-inflammatory stimulation reverses the effect of 0.5% honey on Proteinase 3
release, but does not change the effect of 3% honey on the release of this analyte.
Box E contains the release results for analytes which had the highest release in the
presence of 0.5% honey. The release of MMP-9, CCL5/RANTES, CCL3/MIP-1α, CCL20/MIP3α, and MIP-1β were negligible in the non-honey and 3% honey groups, but had a statistically
significant increase in release at 0.5% honey in most groups relative to the non-honey samples.
The release profiles of MIP-1β and MMP-1 were similar in that there was elevated secretion
from all three stimulation groups at 0.5% honey relative to the non-honey samples. Release of
MMP-9, MIP-1α, CCL5/RANTES, and MIP-3α was highest in the TGF-β-stimulated group,
suggesting that TGF-β enhances the effect of 0.5% honey on the release of these analytes.
Release of CCL2/MCP-1, IL-4, IL-1ra, and MMP-1 was significantly increased in the non-honey
samples by IL-4 and IL-4 + IL-13 stimulation relative to the non-stimulation controls. In
particular, the CCL2/MCP-1, IL-4, and IL-1ra release profiles were similar in that their nonstimulated groups had low release, the TGF-β-stimulated group had elevated release only in the
presence of 0.5% honey, the IL-4 and IL-4, IL-13 groups had elevated release at 0% and 0.5%
honey, and 3% honey reduced all levels close to the Min LOD. TGF-β stimulation had little
effect on IL-1ra and MMP-1 release in the absence of honey, and decreased CCL2/MCP-1, IL-4,
and MMP-9 release relative to the non-stimulated control cells. 3% honey suppressed the release
of all of the analytes in Box F, limiting CCL2/MCP-1, IL-4, and IL-1ra levels and keeping MIP-
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1β, CCL20/MIP-3α, MMP-1, CCL3/MIP-1α, CCL5/RANTES, and MMP-9 release below the
Min LOD of the assay.
Box F displays the release results of FGF-13, IL-12 p70, and IL-1β, all of which were
released at levels close to or below the Min LOD of the assay. The presence of 0.5% honey
significantly increased release of FGF-13 and IL-12 p70 in the TGF-β, IL-4, and IL-4 + IL-13
groups relative to the control cells and the non-honey groups. IL-1β release was above the Min
LOD only in the TGF-β-stimulated sample at 0.5% honey, and even this level was barely above
the Min LOD, indicating that this release is negligible. The presence of 3% honey kept the
release of IL-12 p70 and IL-1β below the Min LOD, and release of FGF-13 was only measurable
in the IL-4 and IL-4 + IL-13 groups at this honey concentration, indicating that 3% honey
suppresses the release of FGF-13, IL-12 p70, and IL-1β.
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Figure 18. Release levels of cytokines, chemokines, and matrix-degrading enzymes in the
absence of honey or presence of 0.5% or 3% honey at 24 hours. Bars indicate mean ± standard
deviation. * indicates a statistically significant difference from the non-stimulated control at the
respective honey level, ^ indicates a statistically significant difference from the non-honey group
at that stimulation type, and ^ indicates a statistically significant difference from the 0.5% honey
group at that stimulation type. Values below Min LOD are shown as 0. The Kruskal-Wallis test
was used with a Bonferroni multiple comparisons adjustment to establish significant differences
between stimulation types at each honey level and between honey levels at each stimulation type
(α = 0.05). Analytes are grouped by trend (A–F). Sample size = 3 independent replicates.
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Primary human neutrophil experiments
Figure 19 displays the results of the primary human neutrophil experiments at both 3 and
24 hours of culture. The IL-1ra release results demonstrate that primary human neutrophils
exhibit a dose-dependent release of Il-1ra in response to IL-4, which is significantly heightened
in the presence of 0.5% honey but suppressed by the presence of 3% honey at both 3 and 24
hours. The VEGF results indicate that at 3 hours, both 0.5% and 3% honey significantly increase
VEGF release in the 100 and 1000 ng/mL IL-4 groups (and in the 0 and 10 ng/mL IL-4 groups at

Figure 19. Release levels of MMP-9, VEGF, and IL-1ra in the absence of honey or presence of
0.5% or 3% honey at 3 and 24 hours under stimulation with 0, 10, 100, or 1000 ng/mL IL-4.
Bars indicate mean ± standard deviation. * indicates a statistically significant difference from
the non-honey control at the respective IL-4 level, * indicates a statistically significant
difference from the 3% honey group at that IL-4 level, and ^ indicates a statistically significant
difference from the 0 ng/mL IL-4 group at that honey level. Values below Min LOD are shown
as 0. The Kruskal-Wallis test was used with a Bonferroni multiple comparisons adjustment to
establish significant differences between stimulation types at each honey level and between
honey levels at each stimulation type (α = 0.05). Sample size = 4 independent replicates.
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0.5% honey), but this release is still relatively low. At 24 hours, 0.5% honey causes a more
substantial VEGF release (significant in the 10, 100, and 1000 ng/mL IL-4 groups), relative to
both the non-honey control and 3% honey samples. The MMP-9 release results reveal that both
0.5% and 3% honey increased MMP-9 output (significant in all groups except 10 ng/mL IL-4 at
24 hours).
Discussion
We have previously examined the effect of 0.5% and 3% Manuka honey on the cytokine
profile of the dHL-60 model in the presence of various pro-inflammatory stimulators and found
that the effect of the honey on this cytokine expression is dependent on the concentration of
Manuka honey used. The presence of 0.5% honey decreased the release of TNF-α, IL-1β, MIP1α, MIP-1β, IL-12 p70, MMP-9, MMP-1, FGF-13, IL-1ra, and IL-4, but increased MIP-3α,
Proteinase 3, VEGF, and IL-8 release by the pro-inflammatory models. However, 3% honey
increased the release of TNF-α, but decreased the release of all other analytes measured [297].
Majtan has previously theorized that the immunomodulatory effects of honey are dependent on
the inflammatory state of the wound, with inflammation being increased in acute wounds but
decreased in chronic wounds due to the presence of the honey [281]. This hypothesis would
explain some of the effects that we previously observed, such as Manuka honey decreasing
Proteinase 3 release in dHL-60s stimulated by LPS and fMLP, but would not explain the increase
in TNF-α release in this inflammatory-stimulated model at 3% honey.
A similar difference between the effects of 0.5% honey and 3% honey was observed in
results reported in this study in the anti-inflammatory-stimulated dHL-60 models. The 24-hour
release results suggest that 3% honey has a pro-inflammatory effect by significantly increasing
TNF-α and CXCL8/IL-8 output, although this honey level does significantly decrease the output
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of the pro-inflammatory signals CCL2/MCP-1, CCL4/MIP-1β, CCL20/MIP-3α, CCL3/MIP-1α,
and CCL5/RANTES, as well as the matrix-degrading enzymes MMP-1, MMP-9, and Proteinase
3. In contrast, 0.5% honey increased the release of most analytes measured, including the
inflammatory mediators CXCL8/IL-8, CCL2/MCP-1, CCL4/MIP-1β, CCL20/MIP-3α,
CCL3/MIP-1α, IL-12 p70, and CCL5/RANTES, the matrix-degrading enzymes MMP-1 and
MMP-9, and the anti-inflammatory mediators IL-4 and IL-1ra in the TGF-β-stimulated cells, the
growth factor FGF-13 in all groups, and the growth factor VEGF in the non-stimulated control
group. Although 0.5% honey decreased Proteinase 3 release in the stimulated groups, it increased
Proteinase 3 release in the non-stimulated control cells. As such, the overall effect of the 0.5%
honey concentration is to ramp up both pro-inflammatory and anti-inflammatory cytokine output.
There are several notable changes in expression profiles between the 3-hour and 24-hour
timepoints. In the TNF-α graphs, the 3% honey control, IL-4, and IL-4, IL-13 groups show a
substantial increase over time while the 0.5% honey groups remain static, indicating that 3%
honey is much more effective at driving this release. IL-8 release exceeded the Max LOD in all
3% honey groups and the IL-4 non-honey group by 24 hours, and the IL-4, IL-13 group
increased close to this level. The release of VEGF increased in the 0.5% honey non-stimulated
control group, but remained static in the 0.5% honey stimulation groups, indicating that these
signals are suppressing VEGF output. The IL-1ra graphs show a substantial increase in the nonhoney IL-4 and IL4, IL-13 groups, indicating the effectiveness of these stimuli at driving IL-1ra
release. MMP-9 had no measurable release at the 3-hour timepoint, indicating a latency in the
release of this analyte. The Proteinase 3 graphs indicate that all non-honey groups and the 0.5%
honey-stimulated groups substantially increased in Proteinase 3 release between 3 and 24 hours.
In contrast, 3% honey repressed Proteinase 3 at both timepoints. There was also a substantial
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increase in CCL5/RANTES release in the 0.5% honey TGF-β group and a smaller increase in the
0.5% honey IL-4 and IL-4, IL-13 groups between the 3-hour and 24-hour timepoints. However,
there was no change in CCL5/RANTES release in the non-honey or 3% honey groups over time,
indicating that 0.5% honey is unique among these conditions in its stimulation of
CCL5/RANTES release.
Some conclusions can be drawn about the relative impacts of TGF-β, IL-4, and IL-4 +
IL-13 on the cytokine profile of the dHL-60 model in the absence of honey. In particular, the IL4 and IL-4 + IL-13 groups had an increase in the release of CCL2/MCP-1, IL-4, Proteinase 3, IL1ra, and MMP-1 in the absence of honey relative to the control cells. In contrast, the TGF-βstimulated group had a significant decrease in CCL2/MCP-1, IL-4, Proteinase 3, MMP-1, and
MMP-9 release in the absence of honey relative to the control cells, and also had lower IL-1ra
release than the IL-4 and IL-4 + IL-13 groups. TGF-β also reduced the impact of 3% honey on
TNF-α release, with much lower release at this honey level than the control cells and the IL-4
and IL-4 + IL-13 groups. However, TGF-β increased the release of CCL20/MIP-3α, CCL3/MIP1α, CCL5/RANTES, and MMP-9 at 0.5% honey relative to the control cells and the IL-4 and IL4 + IL-13 groups. The different effects between TGF-β and the other two stimulation groups can
be partly explained by the fact that these stimulators act through different signaling pathways, as
mentioned in the Introduction section. TGF-β activates the SMAD/RSMAD pathway, with IL-4
activating the Akt/PKB pathway and, in combination with IL-13, activating the Jak/STAT
pathway. These pathways are regulated by different decoy receptors, ubiquitin-protein ligases,
inhibitory proteins, kinases, and feedback-inhibition cycles, and activate different transcription
factors which promote transcription of the relevant genes at different levels [302-304]. It is
feasible that the effect of Manuka honey may be different on these different regulation
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mechanisms and transcription proteins, leading to different downstream effects on the cytokine
release profile of these different stimulation groups.
The primary human neutrophil experiments provide a useful dataset to compare with the
dHL-60 results and extrapolate more clinically-relevant findings. In both the dHL-60s and the
primary human neutrophils, IL-4 stimulated the release of IL-1ra, and this release was increased
by 0.5% honey but decreased by 3% honey. Similarly, at 24 hours both dHL-60s and primary
human neutrophils exhibit an increase in VEGF release in response to 0.5% honey. One notable
difference between these cell types was that in the dHL-60s, IL-4 stimulation blocked the ability
of 0.5% honey to elicit an increase in VEGF release, while in the primary human neutrophils, IL4 stimulation did not block this effect. The MMP-9 release results demonstrate that in both dHL60s and primary human neutrophils, 0.5% honey caused a significant increase in MMP-9 release.
However, the MMP-9 release of the dHL-60s was suppressed in the presence of 3% honey, while
the MMP-9 release of the primary human neutrophils was stimulated by 3% honey to a level
similar to the 0.5% honey samples. These differences in the response to 3% honey suggest that
results from dHL-60 cells should be confirmed in primary human neutrophils. However, the
similarities in the findings regarding the response to 0.5% honey illustrate the clinical benefit
that a more precise fine-tuning the local honey concentration may have with regard to reducing
inflammation via IL-1ra and stimulating angiogenesis via VEGF.
The ability of 0.5% honey to increase the release of some pro-inflammatory cytokines as
well as some anti-inflammatory cytokines is similar to the effect of the IL-4 and IL-4, IL-13
groups in the absence of honey. As shown in Figure 2, these stimuli increase the release of the
pro-inflammatory signals IL-8 and CCL2/MCP-1, as well as the matrix-reorganization enzyme
MMP-1 and the anti-inflammatory signals IL-4 and IL-1ra. This partial pro-inflammatory effect
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of IL-4 has been previously observed in literature [305]. Despite this effect, IL-4 has an overall
effect of decreasing wound inflammation, and, like Manuka honey, topical application of IL-4
has been shown to increase the rate of wound closure [306]. As such, it can be inferred that the
honey-driven increase in the release of some pro-inflammatory cytokines is not problematic
within the wound site. It should also be noted that the osmotic gradient caused by the high sugar
content of the honey creates a net fluid flow from the wound bed towards the surface which
would reduce the overall level of these cytokines in the wound environment. In addition to its
direct application to a wound, Manuka honey is also being investigated as a tissue template
additive to reduce inflammation in the area around the template and promote cellular ingrowth
and tissue-template integration [187, 274, 277, 307]. In this form of use, these honey-doped
templates will be implanted within the body, with cells coming into direct contact with the honey
within the microenvironment of the template. With the implantation of these templates into the
body, the osmotic gradient will cause fluid to flow into the interior of the template, rather than to
the surface of a wound, which could cause higher levels of these honey-induced cytokines within
the template microenvironment. As such, in vivo testing of these templates should involve
assaying cytokine levels within the template interior to confirm that this microenvironment is not
overly inflammatory.
The current predominant method of use of Manuka honey in the clinic is to spread nondiluted Manuka honey onto a wound site, sometimes covering the honey with a bandage after
application [92, 131, 133, 135, 254, 255, 273]. This usage of non-diluted Manuka honey has
been shown to effectively promote healing in vivo, but in vitro testing has indicated that
concentrations above 5% v/v Manuka honey are cytotoxic [110, 260]. Corroborating experiments
have indicated that non-diluted Manuka honey can kill cells and cause tissue damage when
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applied to ovine frontal sinuses and chinchilla ears [252, 257]. We have previously theorized that
when non-diluted Manuka honey is applied to a wound site, it creates a gradient with a “zone of
death” at the top of the wound killing human cells as well as infiltrating bacteria, and lower
honey concentrations deeper into the wound environment [297]. In the context of honeycontaining tissue templates, cells will come into direct contact with the honey within the
template microenvironment. To avoid cytotoxic effects on these cells, groups fabricating these
honey-doped templates have focused on tailoring the Manuka honey content and release rate to
elicit the desired cell responses while staying below the cytotoxic limit [174, 274-276]. As such,
the concentrations of 0.5% and 3% Manuka honey which were tested in this study are in the
general range of the honey concentrations which will be encountered by a neutrophil within the
wound bed or in contact with a honey-doped tissue engineering template. The findings of this
study are thus relevant to the design of such templates and can provide a general understanding
of how these honey concentrations will affect neutrophils during the resolution of inflammation
and transition to the pro-healing, pro-angiogenesis phase of the wound.
Conclusion
Manuka honey’s effect on dHL-60 and primary human neutrophil cytokine release under
anti-inflammatory stimulation is dependent on the concentration of Manuka honey used. The
presence of 3% honey and IL-4 caused a significant increase in the release of TNF-α and
CXCL8/IL-8 while reducing the release of all other analytes measured regardless of the antiinflammatory stimulator that was used. In contrast, 0.5% honey significantly increased the
release of CXCL8/IL-8, CCL2/MCP-1, CCL4/MIP-1β, CCL20/MIP-3α, IL-4, IL-1ra, and FGF13 in at least one stimulation group while reducing the release of Proteinase 3 in the antiinflammatory-stimulated models at 24 hours. The results also indicate that at 0.5% honey at 24
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hours, TGF-β-stimulation significantly increased the release of CCL20/MIP-3α, CCL3/MIP-1α,
CCL5/RANTES, and MMP-9 relative to the other groups. Additionally, in the absence of honey,
TGF-β stimulation significantly reduced IL-4 and MMP-9 release and caused a non-significantly
decreasing trend in the release of CCL2/MCP-1 24 hours relative to the control cells and the
other anti-inflammatory stimulation groups. These results indicate the importance of tailoring the
release rate of Manuka honey from tissue templates to elicit the desired effects on the neutrophils
in the wound during the resolution of inflammation. Future work will investigate the use of
Manuka honey-releasing templates in modulating neutrophil inflammatory behavior and
NETosis to improve tissue-template integration [5].
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CHAPTER 6
MANUKA HONEY REDUCES NEUTROPHIL NETOSIS ON AN ELECTROSPUN
TEMPLATE WITHIN A THERAPEUTIC WINDOW
Introduction
The implantation of a biomaterial tissue engineering template into the body initiates an
orchestrated series of events which have important ramifications on the ultimate success or
failure of that template. Immediately, proteins in the pooled blood around the template begin to
adsorb to its surface, altering its properties [308]. Inflammatory signals released in response to
the implantation injury recruit immune cells which interact with the template and release a host
of cytokines and chemokines, recruiting more immune cells and setting the area down a path
towards either desirable tissue integration/regeneration or undesirable fibrosis [309]. The first
wave of these immune cells consists of neutrophils, fast-arriving phagocytic cells which exert
control over the inflammatory state of the wound through the release of cyto/chemokines [310].
As the first-responders, these cells play a key role in the preconditioning of the template surface
and surrounding environment that influences the ultimate fate of the tissue engineering template.
In addition to their roles as a phagocyte and a producer of cyto/chemokines, neutrophils
also have the ability to eject a mixture of DNA and bactericidal granular components to create
NETS during a cell death process known as NETosis [311]. This process is triggered by bacterial
signals such lipopolysaccharide (LPS) and formylated peptides such as fMLP, as well as
inflammatory stimuli such as IL-8. The intracellular responses to these signals increase the
production of intracellular reactive oxygen species, which then activate an enzyme known as
PAD4 to citrullinate histone H3 [312]. Citrullination of these histones causes the chromatin to
decondense, which then leads to collapse of the nuclear membrane, adsorption of granular
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components by the chromatin, rupture of the plasma membrane, and finally NET release. This
response is a key weapon against pathogens, trapping them to reduce the spread of infection and
killing them with bactericidal granule components such as NE [313]. It has also been
demonstrated that neutrophils undergo NETosis in response to large foreign particles that they
cannot phagocytose, such as urate crystals, polystyrene beads, and cholesterol crystals [314-316].
Accordingly, the effect of nanofibrous template architecture, specifically fiber diameter and
corresponding pore size, on NETosis has been recently examined [5]. It was demonstrated that
templates with small PDO fiber diameters (0.3 ± 0.1 µM) and pore sizes (1.0 ± 0.3 µM) trigger a
significant increase in NETosis relative to templates with large fiber diameters (1.9 ± 1.0 µM)
and pore sizes (8.1 ± 3.6 µM). Furthermore, the amount of NETosis on these templates was
correlated with fibrous capsule formation around the template in vivo. As such, it is of interest to
develop methods of regulating NETosis on the surface of these tissue engineering templates to
improve tissue-template integration and subsequent tissue regeneration.
One possible method of regulating NETosis is through the incorporation of Manuka
honey into electrospun nanofibrous templates. Manuka honey, a variety of honey produced in
New Zealand from the nectar of the leptospermum scoparium shrub, is a wound treatment that
has recently become the subject of investigation as a tissue engineering template additive [307,
317, 318]. The honey’s methylglyoxal content gives it potent antibacterial properties which are
effective against antibiotic-resistant bacteria [107, 255, 319, 320]. Additionally, the honey
contains flavonoids which scavenge tissue-damaging free oxygen radicals, and particular
phenolic components have been demonstrated to activate intracellular antioxidant response
pathways [180, 183]. When incorporated into a nanofibrous template, Manuka honey increases
the proliferation and infiltration of fibroblasts [274]. Recently, this author has also examined the
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effect of Manuka honey on a dHL-60 neutrophil model, demonstrating that Manuka honey
reduces chemotaxis, reduces superoxide production and the activation of the pro-inflammatory
NF-κB intracellular signaling pathway, and reduces matrix metalloproteinase production in
response to pro-inflammatory signals [260, 297]. Given its use in tissue engineering templates
and its promising ability to regulate other neutrophil inflammatory behaviors, the logical next
step is to evaluate the ability of Manuka honey-laden tissue templates to modulate neutrophil
NETosis.
In the current study, Manuka honey was incorporated into electrospun PDO tissue
engineering templates with small (0.25-0.50 µM) and large (1.4-2.1 µm) fiber diameters. These
templates were characterized with regards to morphology and honey release. Primary human
neutrophils were cultured on the templates for 3 and 6 hours, and their degree of NETosis on the
surface of these templates was characterized using fluorescence imaging and an MPO-based
MAGPIX procedure. The release of IL-8/CXCL8, IL-1β, IL-10, IL-1ra, TNF-α, and MMP-9
from these neutrophils was also quantified using a multiplexed immunoassay. We hypothesized
that Manuka honey incorporation would reduce the degree of NETosis, especially on the
NETosis-provoking SD templates, and that Manuka honey would reduce IL-8/CXCL8, IL-1β,
MMP-9, and TNF-α release while increasing IL-10 and IL-1ra release from the neutrophils.
Materials and Methods
Electrospinning
Manuka honey (UMF12+, Manuka Guard) was added to 1,1,1,3,3,3-hexafluoro-2propanol (HFP, Oakwood Products) solutions at concentrations of 0.1, 1, or 10% v/v, allowed to
dissolve at 37 °C for 5 minutes, then vortexed to disperse. PDO (Bezwada Biomedical) was then
added to the honey/HFP solutions and allowed to dissolve overnight (samples were also
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formulated from pure HFP solutions as non-honey controls). PDO concentrations were 67
mg/mL PDO for SD templates or 135-140 mg/mL PDO for LD templates. Solutions were
electrospun from 3 mL syringes (Becton, Dickinson and Company) through either an 18-gauge
blunt needle tip (LD templates) or a 26 gauge needle (SD templates) attached to a positive power
source (Spellman CXE1000R, Spellman High Voltage Electronics) using a syringe pump (Model
78-01001, Fisher Scientific). Specific polymer concentrations, flow rates, air gap distance, and
applied voltage parameters for low humidity conditions are displayed in Table 2A and for high
humidity conditions in Table 2B. Parameters for certain templates were varied due to
atmospheric humidity fluctuations to maintain a consistent fiber diameter for each template type.
Electrospun fibers were collected onto a stainless steel grounded rectangular mandrel (20 x 75 x
5 mm) horizontally translating 6.5 cm/s over a range of 13 cm and vertically rotating at 1,250
rpm. 3 mL of solution was spun for the SD templates, and 2 mL of solution was spun for the LD
templates to equalize template thickness. The templates, which ranged in thickness from 0.050.15 mm, were stored at -20 °C prior to use.
Template characterization
To characterize fiber diameters and pore sizes, samples of each template were sputter
coated with 5 nm gold-palladium under argon and imaged using SEM imaging. Images were
taken via a FEI Nova NanoSEM 650 at + 20 kV with a spot size of 3 and a 5 mm working
distance. Fiber diameters were measured via FibraQuant 1.3 software (nanoTemplate
Technologies, LLC), and mean fiber diameters and standard deviations were calculated from a
minimum of 200 semi-automated random measurements per image. Image J software (NIH)
was used to measure pore diameters from a minimum of 3 SEMs per template type, with a
minimum of 60 measurements per template type.
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Honey release
To characterize the honey release profile of each template type, 8 mm diameter circular
punches were placed in a 96-well plate with 150 µL of HBSS (GIbco) and incubated at 37 °C. At
timepoints of 15, 30, 45 minutes, 1, 2, 3, 6, 12 hours, and 1, 2, 3, 7, 14, and 21 days, HBSS was

Table 2A and 2B. Electrospinning parameters for each template type at low (A) and high (B)
humidity conditions. Due to fluctuating humidity in the laboratory throughout this study, two
sets of parameters had to be used to maintain consistent fiber diameters for each template
type.
removed from each well and saved for analysis, and 150 µL of new HBSS was added. Collected
releasate was stored at -20 °C until analysis. A serial dilution of Manuka honey was created and
its absorbance was read at 340 nm via a SpectraMax i3x Multi-Mode Microplate Reader to
establish a standard curve. The collected releasate from the experimental samples was then read
for absorbance at 340 nm, and the standard curve was used to calculate the volumetric
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percentage of Manuka honey in each sample. 4 template punches of each template type were
used.
Response of primary human peripheral blood neutrophils
8 mm circular punches of each template type were disinfected by irradiating with UV
light using a Spectroline lamp (8 watt, Part No. EN280L) at a working distance of 9.5 cm
between the lamp and the punches. UV light with a 365 nm wavelength was applied for 10
minutes on each side of each punch in a sterile laminar flow hood. Healthy donor blood was
obtained from Tennessee Blood Services following protocols which had been approved by the
University of Tennessee Institutional Review Board, and neutrophils were isolated as described
in a previous publication [5]. Once isolated, neutrophils were resuspended in HBSS without
calcium and magnesium but with sodium bicarbonate, 10 mM HEPES (Gibco) and 0.2%
autologous serum (hereafter referred to as HBSS+). The disinfected template punches were
placed in a 96-well plate with the non-mandrel-contacting surface facing up, and 40 µL HBSS+
was added to each well to hydrate the templates. Then 100,000 neutrophils were added in 100 µL
HBSS+ to each well, and 10 µL of 150 U/mL heparin (Sigma Aldrich) was added to each well
(final concentration of 10 U/mL) to dissociate NET-associated MPO for quantification of NETs
as indicated in literature [321]. Replicates of blanks and 10% honey samples were run without
the heparin added to check that non-NET-associated MPO was negligible. Templates were
cultured at 37 °C at 5% CO2 for 3 or 6 hours. Tissue culture plastic positive and negative
controls with 100 nM PMA (Sigma Aldrich) or vehicle (0.15% DMSO, Fisher Scientific) were
run in parallel with the same amount of cells. Following the incubation period, samples were
placed on ice for 10 minutes to inhibit neutrophil stimulation. Supernatants were saved and
frozen for later analysis, and templates were fixed with 10% buffered formalin (Fisher Scientific)
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for one hour at room temperature. After a 5-minute wash with PBS (Hyclone), samples were
stored in PBS at 4 °C until further use. Four template punches of each template type were used
per timepoint.
Quantifying NETosis response via fluorescent imaging
Templates were immunostained for NE. First, free aldehyde groups were quenched with
3 washes of 25 mM glycine (Fisher Scientific) in PBS for 5 minutes each. Then templates were
blocked with 5% milk in PBS for 1 hour. Then, rabbit anti-human NE antibody (Abcam,
ab21595) was reconstituted at a 1:100 dilution and incubated on the templates for an hour. After
3 washes with 0.1% tween in PBS for 5 minutes each, goat anti-rabbit IgG H&L AlexaFluor 488
(Abcam, ab15007) was reconstituted at a 1:200 dilution and incubated on the templates for an
hour. This was followed by two washes with 0.1% tween (Fisher Scientific) and one wash with
PBS, all for five minutes. All of these steps were done at room temperature with gentle agitation.
Then, extracellular DNA was stained on each template with 5 µM SO (Invitrogen, cat. no.
S34861) in deionized water for 5 minutes. Intact nuclei were then stained with DAPI (Life
Technologies, cat. no. R37606) for 5 minutes at stock concentration. After one more 5-minute
PBS wash, imaging was undertaken with an Olympus BX43F microscope with an Olympus
DP73 high-performance digital color camera and an Olympus U-HGLGPS fluorescent light
source. Three representative images at 20 x magnification were taken of each template punch,
and 4 template punches of each type were imaged per timepoint during each experiment for three
experiments with three unique donors for a total of 36 images per template type per timepoint.
The background was subtracted by defining a region of interest containing no NETs. CellSens®
Standard 1.9 Digital Imaging software (Olympus) was used to record images, and the exposure
time and fluorescence settings for SO, NE, and DAPI were held constant for all images. Using a
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custom MATLAB® program (MATLAB R2019b), the percent area covered by red pixels but
not blue was calculated (Percent Area NETs). The number of viable cells (blue/red ratio of 1:3 or
greater), number of NETosing cells (colocalization of blue, red, and green pixels), and the
number of necrotic cells (blue/red ratio of 1:3 or less) were calculated using size thresholding
and circularity to identify discrete cells. Three experiments using neutrophils from three agematched (age range 22-28 years old) and gender-matched (male) donors were performed.
MAGPIX assay
Supernatants from the neutrophil experiments were assayed using a multiplexed magnetic
bead immunoassay (R&D Systems) on a MAGPIX® reader (Luminex Corp.) for MPO, TNF-α,
MMP-9, IL-8, IL-10, IL-1β, and IL-1ra. Samples were run using a dilution factor of 50 in assay
diluent.
Statistical methods
A Shapiro-Wilk test was used to determine the normality of each data set. Where the data
was found to follow a normal distribution, a one-way or two-way ANOVA was used with a
Holm-Sidak post hoc test to determine significance (α = 0.05). Where the data was found to be
non-normal, a Kruskal-Wallis ANOVA on ranks was used with a Mann-Whitney post hoc test to
determine significance (α = 0.05). Analysis was performed in GraphPad Prism 6.
Results
Figure 20A displays SEMs of each template type, and Figure 20B contains the
FibraQuant measurements of fiber diameter and ImageJ measurements of pore diameter. As can
be seen in these images, the solutions of low and high polymer concentration created templates
of small and large fiber diameters, respectively. The honey did not adversely affect fiber
morphology, and fiber diameters were comparable between all SD and LD templates regardless
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of honey concentration. However, increasing honey concentration did decrease pore diameter
significantly in the SD templates as compared to the non-honey blank (non-significant trend in
the LD templates), suggesting that the honey caused tighter fiber packing and/or fiber melding.
All SD templates had significantly smaller pore diameters than the corresponding LD template.
Figure 21 contains histograms of the pore distributions in each template type. As displayed in the
figure, in the absence of honey, the LD templates have about 60% of their pores with diameters
greater than 10 µm, allowing for infiltration of neutrophils (8.5 µm in diameter) [322]. In
contrast, the SD templates without honey have only about 20% of their pores with diameters
greater than 10 µm. Although honey shifts the pore distribution towards smaller pores, all LD
templates with honey have at least 25% of their pores above 10 µm in diameter, while the SD
templates with honey have a negligible number of pores with diameters above 10 µm, indicating
that neutrophil infiltration would likely be slowed or blocked in these templates.
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Figure 20. Low and high polymer concentrations create SD and LD fibers. (A) SEM images
of each template type. Scale bars = 30 µm. (B) Fiber diameters and pore diameters of each
template type (mean ± standard deviation). * indicates a significant difference between the
LD and SD templates at each honey condition. # indicates a significant difference from the
non-honey blank with the corresponding fiber size (SD or LD).
Figure 22 contains the honey release results for each template type over a 21-day release
period. As shown in the graphs, most of the honey is released as a burst within the first several
hours of hydration, but there is a low-level consistent release of honey from the templates
throughout the entire 21-day period. The 10% honey SD template released significantly more
honey than the 10% honey LD template at each time point. This can be explained by the greater
surface-area-to-volume ratio of the smaller fibers, providing more surface area for honey release
than the LD fibers. The 0.1% honey SD template also had greater honey release than the 0.1%
honey LD template, although this difference was not statistically significant. In general, the
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Figure 21. Honey reduces pore size. Histograms of pore distributions in LD and SD
templates with 0, 0.1, 1, and 10% honey.
released amount of honey was proportional to the amount of honey electrospun into the template
within each template type.
Representative fluorescence images of NETosis on SD and LD templates at 3 and 6 hours
are displayed in Figure 23 (all images taken from NETosis experiment 3). Red (SO) marks the
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extracellular DNA indicative of NETosis, while blue (DAPI) indicates the intact nuclei of nonNETosing neutrophils and green indicates NE (colocalized with red-stained DNA in NETs,
appearing as yellow as the NET is released). These images demonstrate the higher degree of
NETosis found on the SD Blank templates relative to the corresponding LD Blank templates at
both 3 and 6 hours, as expected. These images also show the decrease in NETosis on the SD
0.1% honey templates relative to the SD Blank templates at 3 and 6 hours, and the increase in
NETosis on the 10% honey templates in both the LD and SD samples. Figure 24 contains the
quantified Percent Area NETs for each template type at 3 and 6 hours compiled from three
experiments with neutrophils from three unique donors. As expected, the SD Blank samples had
significantly more Percent Area NETs than the LD Blank templates at both 3 and 6 hours. The
SD 0.1% honey templates also had significantly less Percent Area NETs than the SD Blank

Figure 22. Honey release is higher for SD templates than LD templates. Percent honey v/v in
PBS incubated with each template type for 21 days. * indicates a significant difference
between the LD and SD templates of the corresponding honey concentration, and + indicates
a significant difference from all other honey concentrations and non-honey blank of the
corresponding fiber diameter (SD or LD). Note: the 1% honey LD samples are significantly
different from the LD blank from day 3 onward, the 1% honey SD samples are significantly
different from SD blank for days 14 and 21, and the 0.1% honey SD samples are significantly
different from SD blank from day 3 onward. Due to clustering of these lines on the graphs,
these differences were unable to be notated. Sample size = 4.
128

Blank

0.1% Honey

1% Honey

10% Honey

3 Hours

SD

LD

6 Hours

SD

LD

Figure 23. Representative fluorescence images of neutrophil NETosis on LD and SD
templates with 0, 0.1, 1, and 10% honey at 3 and 6 hours of culture, taken from experiment 1.
Red indicates extracellular DNA (NETs), blue indicates intact nuclei, and green NE. Scale
bar = 50 µm.
templates at both timepoints. 10% honey significantly increased Percent Area NETs in both the
LD and SD templates at 6 hours, and had a non-significant increasing trend in the LD templates
at 3 hours. Together, these results demonstrate that 0.1% honey incorporation is effective at
reducing neutrophil NETosis on the surface of SD templates, but that the incorporation of 10%
honey induces significant NETosis on the surface of both template types. Figure 25 contains the
percent NETosing and necrosing nuclei for each template type at each timepoint. As
demonstrated in the figure, there was no significant trend in the percent necrotic cells for either
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Figure 24. The incorporation of 0.1% honey significantly reduces neutrophil NETosis on SD
templates. Percent Area NETs on LD and SD templates at 3 and 6 hours are shown. *
indicates a significant difference between the indicated samples within that template type and
timepoint, while + indicates a significant difference from the respective LD template at that
timepoint and honey level. Sample size of 3 images per replicate, 4 replicates per timepoint
per experiment, with 3 unique donor experiments.
of the template types at either timepoint, indicating that the honey is not causing necrosis. There
is a significant increase in NETosing cells on the LD 10% honey samples at both timepoints,
correlating with the increase in Percent Area NETs observed in Figure 24. There are no
significant differences in NETosing cells in the SD samples at 3 hours, but at 6 hours, there is a
significant decrease in NETosing cells in the SD 0.1% honey samples and SD 10% honey
samples. The decrease at 0.1% honey correlates with a decrease in Percent Area NETs in these
samples, while the decrease at 10% honey may be due to the fact that these cells have already
progressed in their NETosis response to the extent that their nuclei are no longer identifiable.
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Figure 25. The reduction in NETosis is not caused by honey-driven necrosis. The percentage
of cell nuclei identified as NETosing or necrotic are shown for LD and SD templates at 3 and
6 hours. * indicates a significant difference from the respective LD or SD blank. Sample size
of 3 images per replicate, 4 replicates per timepoint per experiment, with 3 unique donor
experiments.
Figure 26 contains the MPO concentrations in the supernatants taken from LD and SD
templates with and without 10% honey cultured in the presence or absence of heparin. This
experiment was performed to ensure that the amount of non-NET-associated MPO was low
enough that it would not confound the ability of the MPO assay to accurately quantify NETosis.
As the amount of MPO measured in the supernatants of the non-heparin-treated samples was
negligible relative to the heparin-treated samples, this experiment determined that the vast
majority of MPO available was NET-bound heparin. Thus, the ability of the MPO assay to serve
as an accurate measurement of the NETosis response was validated.
131

pg/mL

MPO release 6 hours
heparin vs non-heparin
350000
300000
250000
200000
150000
100000
50000
0

*

*
*

Heparin
No Heparin

LD Blank LD 10% SD Blank SD 10%
honey
honey

Sample type

Figure 26. The release of non-NET-associated MPO is negligible. The concentration of MPO
in the supernatant is shown for each sample cultured with or without the presence of heparin
to free the MPO from the NETs. * indicates a significant difference between the indicated
samples. Sample size of 3 images per replicate, 4 replicates total.
The MPO measurements of each sample type at 3 and 6 hours are displayed in Figure 27,
normalized to each experiment’s 6-hour TCP 100 nM PMA positive control and expressed as the
percent of the NETosis response. The 1% honey LD template punches had a significant decrease
in the percent NETosis response at 3 hours relative to the LD blank template samples, and both
the 0.1% and 1% honey samples had significantly less percent NETosis than the LD 10%
samples at this timepoint. Similarly, the 0.1% and 1% honey LD samples had significantly less
percent NETosis than the LD 10% honey samples at 6 hours. The 0.1% honey samples also had
significantly less NETosis than the 10% honey samples in the SD templates at 3 hours, although
this difference was not significant at 6 hours. Together, these results confirm the data presented
in Figure 24 which indicated that 0.1% and 1% honey suppressed NETosis while 10% honey
exacerbated NETosis.
Although the sample supernatant was assayed for TNF-α, MMP-9, IL-8, IL-10, IL-1β,
and IL-1ra, only MMP-9 was found in non-negligible amounts. The MMP-9 levels, displayed in
Figure 28, loosely track the percent area NETs and percent NETosis response results. The 0.1%
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Figure 27. The 0.1% honey and 1% honey samples had the least NETosis response. The
percent NETosis response, calculated from MPO concentration normalized to TCP 100 nM
PMA positive controls, are shown on LD and SD templates at 3 and 6 hours. * indicates a
significant difference between the indicated samples within that template type and timepoint,
while + indicates a significant difference from the respective LD template at that timepoint
and honey level. Sample size of 4 replicates per timepoint per experiment, with 3 unique
donor experiments.
honey LD samples had significantly less MMP-9 release than the LD blank samples at 3 hours,
and at 6 hours the 0.1% honey LD samples had significantly less MMP-9 than the blank samples
while both 0.1% and 1% honey had significantly less MMP-9 than the LD 10% honey samples.
Similarly, at 3 hours both 0.1% and 1% honey SD samples had less MMP-9 than the SD 10%
honey samples, and the 0.1% honey samples had significantly less MMP-9 release than the
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Figure 28. The 0.1% honey and 1% honey samples had the least MMP-9 release. The release
of MMP-9 is shown on LD and SD templates at 3 and 6 hours. * indicates a significant
difference between the indicated samples within that template type and timepoint. Sample
size of 4 replicates per timepoint per experiment, with 3 unique donor experiments.
blanks. At 6 hours, SD 0.1% honey had significantly less MMP-9 than the 1% and 10% honey
samples. Together, these results demonstrate that 0.1% and 1% honey incorporation reduce
MMP-9 production by neutrophils in contact with LD templates, while only 0.1% honey had a
similar effect on the SD templates. The lack of TNF-α, IL-8, IL-1β, IL-10, and IL-1ra release by
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neutrophils seeded on these templates indicate that they are not activated into pro-inflammatory
or anti-inflammatory behavior.

Discussion
Because of its potent properties as a wound-healing agent, Manuka honey has become a
common additive for tissue engineering templates, including electrospun templates, cryogels,
and hydrogels [187, 274, 277, 307, 323]. Despite this predominance in the field, no one has yet
examined the effect of Manuka honey incorporation on neutrophil NETosis at the surface of the
tissue template. As neutrophils are one of the first inflammatory cell types to interact with an
implanted material, and the NETosis response is an important predictor of the degree of fibrosis
surrounding this material, assessing this response is crucial to predicting the success or failure of
honey-laden tissue engineering templates. When incorporated into electrospun templates, it has
previously been reported that the incorporation of Manuka honey reduces pore size, and the
results shown in Figures 20 and 21 confirm this finding [274]. It has been theorized that
restrictive porosities in electrospun templates increase the degree of neutrophil NETosis on the
surface by preventing neutrophils from infiltrating into the template interior, causing them to
perceive the material as an impenetrable surface rather than an extracellular matrix analogue [5].
This theory has been suggested as an explanation for why SD templates exhibit more NETosis
than their LD counterparts. Similarly, the decrease in pore size with increasing honey content
could contribute to the corresponding increase in NETosis on the 10% honey templates.
However, the 10% honey LD templates have a greater proportion of pores above 10 µm in
diameter than the SD blank templates but exhibit similar levels of NETosis. Furthermore, the
0.1% SD honey templates have a lower proportion of pores above 10 µm in diameter than the SD
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blank templates but have significantly lower percent area NETs. As such, a decrease in porosity
cannot explain the entirety of honey’s effect on neutrophil NETosis. An alternative explanation
is that the glucose content of the honey triggers NETosis when honey is present at a high enough
concentration. A Menegazzo et al. 2014 paper demonstrated that glucose could trigger NETosis
on its own and exacerbate NETosis when triggered by another agonist [324]. As glucose is a
major component of honey, it is possible that neutrophils contacting the surface of 10% honeyladen fibers encounter concentrations of glucose high enough to trigger their NETosis response
[325]. At lower concentrations of honey, such as those encountered at the surface of a 0.1% or
1% honey template, this glucose level may not be high enough to trigger the NETosis response.
As Manuka honey also contains antioxidants such as pinobanksin which have been theorized to
cross the cell membrane and scavenge ROS, it is possible that these antioxidants disrupt the
ROS-dependent mechanisms which trigger NETosis [326]. The interplay of the glucose and
antioxidant stimulatory and inhibitory mechanisms could create a therapeutic concentration
window in which NETosis is inhibited at the surface of a tissue engineering template, similar to
the phenomenon observed in Figures 24 and 27. However, more research will have to be done to
determine whether these proposed mechanisms are the cause of honey’s ability to reduce
NETosis on a tissue engineering template when incorporated at concentrations of 0.1% and 1%
but stimulate NETosis at a concentration of 10%. It has been previously reported that Manuka
honey decreases the activation of the pro-inflammatory NF-κB pathway, but the specific
components of the honey which cause this change have yet to be isolated [260, 285]. Future
work should also investigate whether Manuka honey affects intracellular signaling events which
lead to NETosis, such as PAD4 activation or histone H3 citrullination. The ability of Manuka
honey to modulate MMP-9 release in tandem with its effect on NETosis provides an intriguing
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tool for the treatment of chronic wounds. While MMP-9 is crucial to clearing debris and opening
channels for vascular endothelial cells to create new blood vessels during the healing process of
normal wounds, elevated levels of MMPs in chronically-inflamed wounds have been implicated
in a constant cycle of tissue damage that precludes healing [4]. Accordingly, the ability of 0.1%
and 1% honey-containing templates to reduce MMP-9 release in neutrophils could reduce this
tissue damage when placed on a chronic wound, thus aiding in the resolution of inflammation
and the resumption of healing activity.
Conclusions
The degree of neutrophil NETosis on a tissue engineering template is predictive of the
degree of fibrosis it will encounter in vivo, and therefore its success or failure to integrate with
the surrounding tissue and induce regeneration. This study indicates that the incorporation of
Manuka honey in the range of 0.1%-1% in a tissue engineering template decreases the NETosis
response of neutrophils encountering that template, with a corresponding decrease in the MMP-9
release of these neutrophils. The data presented in this study demonstrate the importance of
testing honey-laden biomaterials for their impact on the NETosis response. Given the widelydivergent impact on NETosis that different honey levels have, it is vital that the surface
properties and honey levels of such biomaterials be tailored to achieve the desired NETosis
response in order to have the appropriate effect in a wound site or other application. Future work
will include correlating these findings with in vivo fibrosis studies and attempting to delineate the
effect of Manuka honey itself on neutrophils from the effect of the restrictive porosities that it
creates when incorporated into electrospun templates.
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CHAPTER 7
CONCLUSION
The ability of the human body to repair itself involves a delicate balance of processes
working at counter-purposes which, if disrupted, can delay healing and cause chronic
inflammatory conditions. In particular, excessive neutrophil inflammatory activity can create an
environment of chronic inflammation, ongoing tissue damage, and fibrosis instead of tissue
remodeling and healing. To prevent this occurrence in wounds and at the tissue-template
interface, it is necessary to develop therapies which can reduce neutrophil inflammatory
behaviors and create an environment favorable to tissue remodeling and wound closure. With its
potent anti-inflammatory properties, Manuka honey represents one such potential therapy. The
work contained in this dissertation is an effort to determine the suitability of Manuka honey for
this role.
Of the neutrophil behaviors examined throughout this work, the ones on which Manuka
honey has the clearest effect are superoxide production, chemotaxis, activation of the NF-κB
inflammatory pathway, and NETosis. By reducing the number of neutrophils which arrive at the
site of inflammation, as well as their production of superoxide and overall inflammatory state,
Manuka honey has the potential to decrease the degree of tissue damage and general
inflammatory activities within the wound site. The cytokine, chemokine, and matrix-degrading
enzyme release results in Chapters 4 and 5 are less clear, as slightly different doses of honey
created markedly different effects on these release profiles which were not clearly proinflammatory or anti-inflammatory. Chapter 6 demonstrated that Manuka honey has the ability to
significantly reduce neutrophil NETosis and MMP-9 release when incorporated into tissue
engineering templates in the range of 0.1%-1%, providing a powerful tool to reduce
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inflammation. Taken together, the results of this project are favorable for the future use of
Manuka honey to reduce neutrophil inflammatory activity in wounds or in tissue engineering
templates.
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CHAPTER 8
RECOMMENDATIONS FOR FUTURE WORK
The work reported in this dissertation raises a number of questions which should be
explored in future research. I propose three broad categories of exploration to further investigate
the usefulness of Manuka honey as a template additive for the purpose of altering the neutrophil
response to the template. The first category is the further investigation of the mechanisms
underlying the findings described in Chapters 4, 5, 6, and 7. Specifically, I propose to investigate
the biological processes behind the cytotoxicity of Manuka honey, its effect on downstream
events of the respiratory burst, its effect on neutrophil chemotaxis, how it affects the upstream
components of the NF-κB signaling chain, and how it affects the processes that lead to neutrophil
NETosis. The second category of further research that I propose is the investigation of the
relative contribution of each of Manuka honey’s constituent biologically active molecules to its
cellular effects. As a natural product composed of many different biologically active components
(both known and unknown), Manuka honey’s biological effects are understood to be a result of
its gestalt composition. It would be useful to untangle the actions of each of its components so
that this composition could be monitored and tweaked in the future to optimize its performance
as a pro-healing, anti-inflammation, bactericidal treatment. The third category of research that I
propose is the in vivo research of Manuka honey-doped electrospun templates. The experiments
described in this dissertation were conducted in vitro, utilizing either an immortalized cell line or
primary cells isolated from a human donor. However, the behaviors of these cells likely vary
significantly between the tissue culture dish and the wound environment. Therefore, the results
of this work should be investigated in vivo in animal models and eventually human trials to
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confirm and build upon the findings of this dissertation. In this chapter, I will describe in detail
my proposed experiments in each of these three categories of future work.
Investigating the biological mechanisms of Manuka honey
Cytotoxicity
The cytotoxicity results in Chapter 4 determine that Manuka honey is cytotoxic at
concentrations above 3% v/v. Based on the lack of membrane blebbing in light microscopy
images of cells exposed to high concentrations of Manuka honey, as well as the lack of NETosis
visualized in these images, the method of cell death caused by the honey is most likely necrosis.
However, this finding should be confirmed via staining with annexin V, DAPI, and propidium
iodide. In this proposed experiment, either dHL-60s or primary human neutrophils will be
exposed to 0-20% v/v Manuka honey for 3 or 24 hours, and then stained with all three of these
stains according to the manufacturer’s protocol. These cells will then be visualized using a
fluorescent microscope and the number of cells fluorescing with each dye will be counted. As a
stain for phosphatidylserine, a protein which is only expressed on the outside of the cell
membrane during apoptosis, annexin V will only stain apoptotic cells. DAPI, a membranepermeant nucleic acid stain, will stain live and dead cells as long as the chromatin has not been
unraveled, enabling a count of the total cells present. In contrast, propidium iodide is a
membrane-impermeant nucleic acid stain which will only enter necrotic cells. The use of these
stains to distinguish necrosis from apoptosis is a well-accepted method in the literature [327]. As
such, the visualization of these three stains and analysis of the corresponding fluorescent images
will provide a concomitant method to the trypan-blue based protocol used in Chapter 4.
As well as confirming the method of cell death caused by Manuka honey, the relative
contributions of the honey’s osmolarity and its methylglyoxal content should be determined.
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First, the osmotic strength of undiluted Manuka honey should be quantified using an osmometer.
Then, a sugar solution of equivalent osmotic strength should be formulated and serially diluted to
the same concentrations of Manuka honey tested in Chapter 4, 0-20% v/v. These sugar solutions
should be applied to dHL-60s or primary human neutrophils as described in Chapter 4, and the
number of viable and non-viable cells should be counted at 3 and 24 hours. While the osmotic
potential of Manuka honey is a likely contributor to its cytotoxicity, the honey’s methylglyoxal
content has also been determined to cause damage to cellular structures [257]. As such, solutions
of methylglyoxal in the range of 0-2 mg/mL (approximate concentration of methylglyoxal in
Manuka honey) should also be tested for cytotoxicity as described [328]. Once the relative
cytotoxic levels of the sugar solution and methylglyoxal have been determined, the
methylglyoxal should be added to the sugar solution at 2 mg/mL and tested for cytotoxicity as a
serial dilution. If the cytotoxic level of this methylglyoxal/sugar solution is above 3% v/v, it is
likely that there is an additional cytotoxic component of Manuka honey other than its osmotic
strength and its methylglyoxal content. Further investigation will be required to determine any
potential additional cytotoxic components.
Superoxide release downstream effects
As detailed in Chapter 4, Manuka honey reduces the superoxide production of the dHL60 neutrophil model over a 24-hour period. However, as described in Chapter 1, there are
downstream events of this superoxide production which play an important role in the
inflammatory wound environment, and Manuka honey’s effect on these events should be
investigated. Specifically, MPO released through neutrophil degranulation uses the hydrogen
peroxide created by neutrophil superoxide production to create hypohalous acids, which go on to
damage bacteria and native proteins, lipids, and nucleotides. The effect of Manuka honey on
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neutrophil MPO release through degranulation should be quantified, and the enzymatic activity
of any released MPO should also be assessed. dHL-60 cells should be cultured in 0-20% v/v
Manuka honey for 1, 3 and 24 hours, and an MPO ELISA should be used to quantify the amount
of MPO released by the cells at each timepoint. Then, an MPO activity assay should be used on
these supernatants to measure the activity of this released enzyme. These experiments will enable
a more complete understanding of Manuka honey’s effects on the bactericidal and tissuedamaging events associated with superoxide production.
Chemotaxis
Chapter 3 of this dissertation demonstrates that Manuka honey significantly decreases
dHL-60 chemotaxis to fMLP. However, neutrophils respond to many other chemoattractants,
both those which are bacterially produced and those which result from the wound formation or
which are released by host cells. In the interest of establishing a more complete picture, transwell
assays should be undertaken using a host of other chemoattractants to determine how Manuka
honey affects dHL-60 chemotaxis to these other signals. For instance, IL-8 (released by
neutrophils, macrophages, epithelial cells, and other native cell types), thrombin (blood enzyme
which converts fibrinogen to fibrin during clotting), S100A8 (calcium-binding protein found at
high levels in the extracellular milieu during inflammation), leukotriene B4 (pro-inflammatory
signal released by leukocytes), and LPS are all potent neutrophil chemoattractants whose effects
should be tested in the presence of Manuka honey [329-333]. This testing could be done in a
transwell setup as described in the methods section of Chapter 4, but it could also be done in a
three-dimensional, tissue-mimicking gel to better simulate the relevant wound environment.
Methods to measure chemotaxis in collagen or fibrin gels via time-lapse video microscopy have
been published, and represent a superior model of the in vivo environment than the traditional
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transwell setup, although they are much more expensive and time-consuming [334]. In such a
setup, the gel would be formulated with a gradient of the relevant chemoattractant and with a
gradient of Manuka honey concentrations throughout its interior. Cells would be seeded on the
downstream side of the gel and their movement up the gradient would be captured with timelapse videography and quantified using a computer program. By testing a variety of
chemoattractants which act on different cellular receptors and activate different intracellular
pathways, the mechanisms by which Manuka honey interferes with chemotaxis can also begin to
be teased out.
NF-κB pathway
In Chapter 3, the effect of Manuka honey on the phosphorylation of the IκBα inhibitor of
NF-κB was measured. This is an important bottleneck step in the classical NF-κB pathway which
is indicative of the activity of the entire pathway. However, there is an alternative NF-κB
activation pathway which does not involve the phosphorylation of IκBα whose activity in the
presence of Manuka honey should be examined. This pathway involves an NF-κB-inducing
kinase, NIK, which integrates signals from upstream receptors and activates another kinase,
IKKα, which in turn activates NF-κB. This pathway should be examined via a similar protocol to
that described in the methods section of Chapter 4, but utilizing a Western blot for
phosphorylated NIK and total NIK instead of phosphorylated and total IκBα. Then, a nuclear
translocation assay should be performed to measure the movement of total NF-κB
(encompassing both canonical and non-canonical pathways) to the nucleus. As described before,
dHL-60s will be activated via fMLP and LPS in the presence of 0, 0.5, and 3% Manuka honey
for 38 minutes, and then lysed. However, in this protocol the nucleus will be separated through a
subcellular fractionation method previously established in literature [335]. A DNA mobility shift
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assay will then be used to measure the amount of NF-κB bound to DNA in each sample, and this
will be compared to a sample of non-stimulated dHL-60s cultured for the same amount of time.
This will allow for a comprehensive assessment of total NF-κB activation, both canonical and
non-canonical.
NETosis
Chapter 6 assesses the effect of Manuka honey on neutrophil NETosis, and concludes
that Manuka honey reduces NETosis when incorporated in the range of 0.1%-1% into
electrospun templates. However, the mechanisms by which Manuka honey could affect NETosis
are still unknown. To investigate these mechanisms, I propose to assess the activation of
signaling components upstream of NETosis in the presence of Manuka honey. PAD4 is an
enzyme which citrullinates histones during NETosis, loosening the DNA-histone binding and
allowing for chromatin decondensation [336]. I propose to use a commercially-available PAD4
inhibitor screening assay kit to assess whether Manuka honey interferes with the activity of
PAD4, testing a serial dilution of Manuka honey. It has also been demonstrated that upstream
activation of PKC by stimulators such as PMA leads to neutrophil NETosis, but it is not known
whether this is the pathway by which SD templates trigger NETosis. To investigate this, I
propose to use a commercially-available PKC kinase activity kit to measure the activity of PKC
in human neutrophils seeded on SD and LD templates, with and without the addition of Manuka
honey. Templates will be created as described in Chapter 7, and primary human neutrophils will
be cultured on them for 1, 2, 3, and 6 hours. At each timepoint, the cells will be lysed and the
kinase activity of the lysate will be measured according to the manufacturer’s protocol. This
experiment will indicate whether the PKC pathway is the method by which SD templates trigger
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NETosis, and it will also indicate whether Manuka honey affects this pathway or whether the
honey acts through some other unknown pathway to reduce neutrophil NETosis.
Investigation of the constituent parts of Manuka honey
As a natural product derived from nectar which is enzymatically processed in the bee
crop, Manuka honey consists of a wide array of bioactive compounds, not all of which may be
known. However, several groups have identified the major constituents believed to be
responsible for Manuka honey’s bioactive properties (Table 3). It should be noted that the
amount of water, fructose, glucose, and gluconic acid present in Manuka honey have not been
reported, and therefore the values given in Table 3 for these components are reported ranges for
several U.S. honeys. The first objective of this line of future work will therefore be to quantify
these components of Manuka honey.
To quantify the water content of Manuka honey, a known mass of honey should be
lyophilized, and then the dry mass should be re-measured, with the difference between the wet
mass and dry mass yielding the water content. Both the fructose and glucose content can be
measured with commercially available assay kits. However, the gluconic acid content is more
difficult to measure, necessitating the use of ion exchange chromatography, gas chromatography,
or high performance liquid chromatography [337]. After quantifying the level of these
components in Manuka honey, solutions of each individual component listed in Table 3 should
be tested at the concentration listed according to the methods described in Chapters 4, 5, 6, and 7
to determine their contributions to honey’s effect on superoxide release, chemotaxis, IκBα
phosphorylation, cytokine release in the presence of pro- and anti-inflammatory stimulation, and
NETosis. These solutions of individual components should also be tested for their effect on proinflammatory intracellular signaling pathways other than the NF-κB pathway,
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Table 3| Select bioactive components of Manuka honey. *Note: the reported ranges of water,
fructose, and glucose were measured in a range of U.S. honeys. No peer-reviewed report of the
amount of these components in Manuka honey currently exists.
Component

Amount

Properties

Water

15-20% [338]*

Hydration

Fructose

30-45% [338]*

Causes osmotic gradient

Glucose

24-40% [338]*

Causes osmotic gradient,
energy source

Gluconic acid

0.5% [338]*

Gives honey a pH 3.5-4

Pinobanksin

0.27 mg/100 g honey

Scavenges free oxygen radicals

[339]
Pinocembrin

0.17 mg/100 g honey

Scavenges free oxygen radicals

[339]
Luteolin

0.14 mg/100 g honey

Scavenges free oxygen radicals

[339]
Chrysin

0.13 mg/100 g honey

Scavenges free oxygen radicals

[339]
Methyl syringate

50 mg/100 g honey [340]

Inhibits myeloperoxidase
activity

Leptosin

Methylglyoxal

9.24-55.4 mg/100 g honey

Inhibits myeloperoxidase

[340]

activity

3.8-76.1 mg/100 g honey

Antibacterial agent

[341]
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including the Jak/STAT pathway (phosphorylation of STAT1, STAT5), the TRAM/IFR3
pathway (phosphorylation of IFR3), and the MAP3K/JNK pathway (translocation of JNK to the
nucleus) [342-345]. The effect of honey on the activation of these pathways can be accomplished
through Western blotting experiments similar to the procedure described for measuring IκBα
phosphorylation in Chapter 4. The experiments described earlier in this chapter investigating the
effect of whole Manuka honey on various NETosis markers and mechanisms should also be
undertaken with these solutions of honey constituent parts to determine their relative contribution
to honey’s effect on biomaterial-induced NETosis.
Once these experiments have identified the relative contributions of each of these honey
constituent components to neutrophil inflammatory processes and intracellular signaling
mechanisms, the next step is to combine two or more of these components together and repeat
the experiments. As intracellular signaling mechanisms are often interrelated with multiple
“cross-talk” points, the effect of individual honey components is likely quite different than the
effect of two or more components applied simultaneously. When whole honey is applied to an
area of inflammation, individual components may be acting synergistically, antagonistically, or
some combination of the two with each other. As a biological product composed of many
individual components, Manuka honey is a complex system containing many parts with no
overall organizing principle (i.e. not engineered). Untangling the interplay of these bioactive
components will require painstaking experimentation into many combinations of honey
constituents, building up in number from two, to three, to four components, etc. until the
emergent properties of whole Manuka honey are reproduced. Such work will likely require
decades of research, but it has the potential to dramatically improve the understanding of
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Manuka honey’s effect on inflammation and create a corresponding dramatic benefit to the
clinical use of Manuka honey-based therapies.
Animal studies of honey-based electrospun templates
In vivo cell infiltration, NETosis, and fibrotic capsule formation around a honey-based
template
This set of experiments is designed to investigate the in vivo effect of honey-based
electrospun templates on cell infiltration, NETosis, and fibrosis within the implantation site.
Following the procedure used by Fetz et al. in a 2017 study, 10 mm diameter discs of SD and LD
templates spun from solutions of 0, 0.1, 1, and 10% v/v Manuka honey will be implanted in rat
dorsa subcutaneous pockets [5]. Animals will be euthanized 24 hours or 7 days after
implantation, and templates will be formalin-fixed and cryosectioned. Sections of each sample
will be stained with DAPI and SO to visualize cellular infiltration into the templates and
extracellular DNA on the template surface (indicator of NETosis). Sections will also be stained
with H&E and qualitatively evaluated for cell infiltration and overall inflammatory response
scoring (i.e. the amount of fibrosis). An infrared on-cell Western blot for template-bound
citrullinated histone H3 will be performed as a concomitant measure of NETosis on the surface
of each template. By comparing the honey-laden templates with the non-honey blanks within
each set of SD and LD templates, the effect of honey on in vivo NETosis and fibrosis will be
measured. These experiments will confirm or deny whether the in vitro effects of honey-laden
templates on NETosis extend to the in vivo environment, with the intent of informing the use of
these templates in future tissue engineering therapies.
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In vivo imaging of neutrophil chemotaxis towards an implanted honey-based template
To confirm and build upon the previous work demonstrating honey’s effect on neutrophil
chemotaxis, as described in Chapter 4, I propose to visually track neutrophil chemotaxis towards
honey-based templates in vivo. This experiment will involve utilizing neutrophils from
MacGreen mice which express GFP, enabling them to be tracked visually through the tissue.
Following a procedure described in a 2011 study by Ng et al., neutrophils isolated from the bone
marrow of these MacGreen mice will be transferred to albino C57BL/6 mice who lack the
dermal pigments that would otherwise interfere with fluorescent imaging [290]. First, 10 mm
discs of SD and LD templates electrospun from solutions of 0, 0.1, 1, or 10% Manuka honey will
be implanted into a mouse subcutaneous pocket within the C57BL/6 mice as described earlier in
this chapter. Then, GFP+ neutrophils will be transferred to the C57BL/6 mice, and their
movement in the patch of skin immediately surrounding the subcutaneous pocket will be tracked
using a multi-photon imaging system similar to the LaVision Biotec TrimsScope system used by
Ng et al. [290]. The number of neutrophils per mm2 moving towards each subcutaneous pocket
will be tracked as well as their movement velocity, and these metrics will be used to compare the
honey-laden templates to the non-honey SD and LD blanks. The resulting data will determine
whether the in vitro effect of Manuka honey on neutrophil chemotaxis extends to the in vivo
environment surrounding an implanted tissue engineering template.
In vivo measurement of inflammatory cytokine levels around a honey-based template
This set of experiments aims to ascertain the effect of implanted honey-based templates
on the production of cytokines within the inflammatory wound environment following
implantation, building upon the in vitro work described in Chapters 5 and 6. SD and LD
templates electrospun from solutions of 0, 0.1, 1, or 10% honey will be implanted in a rat
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subcutaneous pocket as previously described in this chapter. At timepoints of 3, 24, and 72 hours
after implantation, a syringe will be inserted directly into the implantation site and 100 µL of
fluid will be taken from the tissue at the edge of the template. This fluid will be assayed using the
Luminex MagPix system as described in Chapters 5 and 6, measuring the same list of cytokines
as was measured in those chapters. By comparing the cytokine levels present in vivo between the
honey-laden templates and SD and LD blanks, these experiments will ascertain whether the
effect of Manuka honey on neutrophil cytokine expression in vitro detailed in Chapters 5 and 6
will translate to the in vivo environment. Although the cells present in the in vivo wound at these
timepoints will not be exclusively neutrophils, it is well-documented that neutrophils
predominate within the wound site at these early timepoints, and so the cytokine levels in these
wounds should be mostly a result of neutrophil activity [33]. These results will provide a wealth
of information regarding the ability of Manuka honey to modulate inflammatory cytokine
production within an in vivo wound site.
Conclusion
The work contained in this dissertation raises several questions with regards to the use of
Manuka honey as a tissue engineering template additive. Most of these questions fall into three
main categories: (1) what are the biological mechanisms behind the effects of Manuka honey on
neutrophil behavior? (2) what are the relative contributions of the individual components of
Manuka honey to its biological effects? (3) how do the observed in vitro effects of Manuka
honey on neutrophil behavior translate to the in vivo environment? The future work proposed in
this section is an ambitious plan towards answering these questions, with the ultimate goal of
improving clinical Manuka honey-based therapies for wound healing and inflammation
resolution.
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